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ABSTRACT 
Angiogenesis is a fundamental process in which new blood vessels are formed from pre-
existing vessels. It is important in growth and development and plays a critical role in 
postnatal physiological processes such as wound healing and in tissue neovascularisation 
in response to ischaemia such as that following a myocardial infarction. Despite the 
importance of angiogenesis for survival, an imbalance in the regulation of angiogenesis 
causes inflammatory-driven pathological angiogenesis. This leads to the exacerbation of 
diseases such as cancer to increase tumour growth, or atherosclerosis where neovessels 
accelerate plaque growth causing instability and plaque rupture. Diseases associated with 
angiogenesis are highly prevalent globally, with cardiovascular-related disorders and 
cancer being the leading causes of mortality worldwide. Furthermore, with the increasing 
incidence of diabetes and the advancing aging populace, the impact of vascular 
complications associated with impaired angiogenesis are also on the rise, with peripheral 
vascular disease and impaired wound healing being key contributors to disease 
complications. Current anti-angiogenic therapies for the treatment of these diseases inhibit 
both pathological and physiological angiogenesis and cause side effects such as 
hypertension, bleeding, severe weight loss, diarrhoea and nausea in a large percentage of 
patients. Thus an alternate therapy which specifically targets the inflammatory-driven 
angiogenesis whilst preserving hypoxia-mediated angiogenesis may be beneficial to treat 
these pathologies whilst causing fewer side effects. 
One potential target as an alternate therapy are chemokines, small (8 – 10 kDa) 
chemotactic cytokines that regulate the migration of cells to sites of inflammation or 
injury. There are four sub-classes: CC, CXC, CX3C, and XC, with CC-chemokines being 
the largest class with almost 30 ligands and 10 receptors. Increasing evidence suggests CC-
chemokines play a key role in inflammatory-driven pathologies associated with 
angiogenesis. For example a host of CC-chemokines (CCL1, CCL2, CCL3, CCL5, 
CCL11, CCL13, CCL18, and CCL19) are found in human atherosclerotic plaques, and 
ApoE
-/-
 mice have reduced plaques in CC-chemokine receptor and deletion studies. 
Additionally, CC-chemokines CCL2 and CCL5 are increased in breast and prostate cancer, 
and CCL19 and CCL20 have been shown to promote tumour metastasis. CC-chemokines 
are thought to promote angiogenesis through two pathways. The first, a direct pathway in 
which CC-chemokines attach to CC-chemokine receptors on the surface of endothelial 
cells, this stimulates the PI3K/Akt pathway and increase angiogenesis. For example, CCL2 
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stimulates the phosphorylation of cytoskeletal proteins, which are essential for endothelial 
cell migration and neovessel formation. Tubulogenesis in vitro is also increased following 
incubation with CCL2, CCL11 and CCL16. Secondly, CC-chemokines promote 
angiogenesis through an indirect pathway. CC-chemokines attach to glycosaminoglycans 
(GAGs) on the surface of endothelial cells. This causes a chemokine gradient to recruit 
inflammatory cells that release pro-angiogenic cytokines and growth factors such as VEGF 
to the inflamed site promoting angiogenesis. In contrast, CC-chemokines have no reported 
implications in hypoxia-mediated physiological angiogenesis. Thus targeting the CC-
chemokine class may represent as an alternate therapy to inhibit inflammatory-driven 
angiogenesis whilst preserving hypoxia-mediated angiogenesis. Single CC-chemokine 
inhibition studies have previously been conducted in a mouse model of sponge-induced 
inflammatory angiogenesis, indicating inhibition of CCL3 or CCL5 reduced macrophage 
infiltration but did not affect angiogenesis. Furthermore, knock-out of CCL2 in mice did 
not affect monocyte recruitment. Redundancies in CC-chemokines signalling may explain 
the lack of change in these studies that have targeted only a single CC-chemokine/CC-
chemokine receptor. Thus broad-spectrum CC-chemokine inhibition may be an alternate 
therapeutic approach. 
A 35 kDa soluble protein from the Vaccinia virus called „35K‟ uniquely inhibits the whole 
CC-chemokine class while having no effect on chemokines from other classes. It has high 
affinity binding to CC-chemokines preventing them from binding to their cognate 
receptors. It does this by binding to common structural sites found on every CC-
chemokine, promoting broad-spectrum inhibition of the entire class. Previous studies with 
35K highlight its ability to inhibit a number of disease pathologies associated with 
inflammation including acute peritonitis, hepatitis, liver fibrosis and vein graft accelerated 
atherosclerosis. Similarly, ApoE knock-out mice overexpressing 35K have reduced plaque 
area and macrophage infiltration in both long and short term studies. However, its role in 
the regulation of angiogenesis across all pathophysiological contexts is unknown. 
The main objectives of the present studies were to determine and compare the role of CC-
chemokines in both inflammatory-driven and ischaemia-mediated angiogenesis. To do this, 
in vitro studies were conducted to elucidate the effect of the broad-spectrum CC-
chemokine inhibitor 35K on functional angiogenic assays and key angiogenic mediators. 
Furthermore, the effects of 35K on neovascularisation were explored in four in vivo animal 
models that represent disease pathologies where angiogenesis is important. This includes 
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the (1) peri-arterial femoral cuff model and (2) hindlimb ischaemia model that represent 
pathological and physiological angiogenesis respectively, (3) the Lewis lung tumour 
neovascularisation model and (4) the murine model of wound healing.  
Our in vitro studies conducted with isolated 35K protein evaluated the differential effects 
of CC-chemokine inhibition in inflammation and hypoxia on human coronary artery 
endothelial cells (HCAECs). The key functional angiogenic assays of proliferation, 
migration, and tubule formation were used. These represent the steps of angiogenesis in 
which activated endothelial cells increase proliferation and migration to sites of injury, and 
then assemble into tubular structures to form new blood vessels. The global inhibition of 
CC-chemokines by 35K significantly attenuated endothelial cell proliferation, migration, 
and tubule formation in response to inflammation. However under hypoxia, 35K had 
minimal effects on proliferation, migration and tubule formation in vitro. 
To elucidate the mechanistic action of 35K in vitro, the expression of two key pro-
angiogenic markers HIF-1α and VEGF were determined. We show that 35K conditionally 
regulates VEGF expression, suppressing VEGF protein levels in inflammation but, in 
contrast, had no effect in hypoxia. Interestingly, we found that 35K suppressed HIF-1α 
protein levels in both inflammation and hypoxia, although this effect was less pronounced 
in hypoxia. Given that HIF-1α is post-translationally modulated by prolyl hydroxylases 
(PHDs) in hypoxia, we determined the effects of 35K on PHDs and found, however that 
35K had no effect on PHD1-3 in hypoxia. This suggests that inhibition of HIF-1α in 
hypoxia by 35K is through an alternate pathway and not through the post-translational 
modulation of HIF-1α. Overall, the in vitro studies demonstrate that broad-spectrum CC-
chemokine inhibition by 35K conditionally regulates in vitro angiogenesis, such that 
inflammatory-driven angiogenesis is suppressed while minimal to no effects are found on 
hypoxia-mediated angiogenesis.  
To determine if the differential effects of 35K on angiogenesis also occurred in vivo, the 
peri-arterial cuff model of inflammatory adventitial angiogenesis and the hind limb 
ischemia models were used. An adenoviral approach was used to systemically overexpress 
35K protein. The adenovirus overexpressing 35K (Ad35K) was infused via the tail vein 
three days prior to surgeries. Adenovirus overexpressing GFP (AdGFP) and PBS were also 
injected three days prior to surgery as adenoviral and vehicle controls. In the peri-arterial 
femoral cuff model, mice injected with Ad35K had significantly less adventitial neovessels 
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and arterioles. Whilst there was a trend for a reduction in adventitial macrophages and 
CD68 mRNA levels, 35K did not have a significant inhibitory effect on macrophage 
recruitment, suggesting that the inhibitory effect of 35K on neovascularisation in 
inflammation is via 35K directly suppressing endothelial cell angiogenesis, rather than the 
indirect effect via the initial recruitment of macrophages. In contrast, in the hindlimb 
ischaemia model, blood flow perfusion and capillary density were not affected by CC-
chemokine inhibition, indicating that ischaemia-induced angiogenesis was preserved. 
Furthermore, gene analysis showed conditional regulation of VEGF by 35K in vivo in the 
two models.  
As in previous studies of CC-chemokine inhibition using 35K, chemokine activity was 
suppressed in the 35K treated mice for both models. Despite the inhibition of chemokine 
activity, CCL2 and CCL5 plasma levels were increased. Interestingly, we found that 35K 
induced significant reductions in CCL2 and CCL5 in the femoral artery and hindlimb 
tissues. Taken together, our CC-chemokine expression data suggests that 35K is binding to 
CC-chemokines in the tissues of the mice and then sequestering them into the circulation. 
Alternatively, circulating CC-chemokine levels increase to compensate for the reduced 
activity, however 35K continues to bind to new CC-chemokines preventing increases in 
activity leading to increases in circulating (although inactive) CC-chemokines. 
The Lewis lung tumour neovascularisation model was used to observe the effect of CC-
chemokine inhibition in a system where both inflammation and hypoxia both play a 
driving role in the exacerbation of tumour formation. As with the previous in vivo study, 
the mice were injected with Ad35K or controls 3 days prior to injection of Lewis Lung 
Carcinoma (LLC) cells. Twelve days after LLC injection at the end of the study the tumour 
was excised to study the effect of CC-chemokine inhibition on tumour angiogenesis and 
progression. The study did not show any significant changes to tumour growth, or tumour 
neovascularisation, however we observed slight trends to reduction in tumour size and 
arterioles formed in the tumours of Ad35K injected mice compared to controls. 
Furthermore, despite no changes to the expression of CCL2, inflammatory marker (p65), 
and trending increases in proliferation (Ki-67, c-Jun) and cell invasion markers (MMP2, 
MMP9), we observed a promising trend of increased expression of key apoptosis markers 
(p53, caspase 3, caspase 8, and caspase 9). Although these changes were not significant 
they are promising. Further studies will need to be conducted in a less aggressive tumour 
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model or with alternate delivery strategies of 35K to determine the effects of broad-
spectrum CC-chemokine inhibition in the context of cancer. 
Wound healing is a multi-step process requiring strict coordination between inflammation 
and cell growth in the wound. Angiogenesis plays a critical role in the early stages of 
wound healing, recruiting inflammatory cells to the wound site and providing a 
microvascular network to maintain new tissue formation. However, increased 
inflammation leads to prolonged wound healing and excessive scar formation, with 
impaired wound healing often resulting in unfavourable outcomes such as amputation. CC-
chemokines play an important role in inflammation and angiogenesis, two key wound 
healing processes. In our final animal model, we sought to examine the effect of broad-
spectrum CC-chemokine inhibition in a murine model that mimics the human process of 
wound healing. Topical application of 35K protein enhanced blood flow recovery and 
wound closure at the early-mid stages of wound healing. 35K promoted neovascularisation 
at the critical early stages of wound healing, where angiogenesis is important. 35K-treated 
wounds also had significantly lower expression of the active p65 subunit of NF-κB, the 
key transcription factor involved in inflammation. Finally, 35K-treated wounds had 
reduced collagen content indicative of less scar formation. These findings show that broad-
spectrum CC-chemokine inhibition may be beneficial in chronic wounds where 
inflammation is in excess, in order to promote wound healing and neovascularisation and 
reduce scar formation.  
In summary, the studies presented in this thesis demonstrate for the first time that broad-
spectrum CC-chemokine inhibition by 35K attenuates inflammatory-driven pathological 
angiogenesis whilst preserving ischaemia-mediated neovascularisation in vitro and in vivo. 
Mechanistically, we found that the key pro-angiogenic growth factor VEGF was 
conditionally regulated by 35K such that VEGF protein levels were suppressed in 
inflammatory conditions, but were unchanged in response to hypoxia. While the results 
were inconclusive in our tumour neovascularisation model, we observed a trend for a 
reduction in tumour weight, suggesting that further exploration is required. Finally, we 
found that 35K increased wound neovascularisation and wound closure, and reduced 
collagen formation in dermal wounds. Overall, 35K may present as an alternate therapy to 
specifically inhibit inflammatory-driven pathological diseases in which angiogenesis plays 
a key role and have distinct advantages over current anti-angiogenic therapies that inhibit 
angiogenesis in all pathophysiological contexts. 
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1.1. Introduction 
Angiogenesis is the formation of new blood vessels from pre-existing blood 
vessels. It is an essential process in development, growth and repair. Under postnatal 
physiological conditions, angiogenesis is important in tissue neovascularisation in response 
to ischaemia (such as that following a myocardial infarction and in peripheral vascular 
disease) and wound healing. However, uncontrolled regulation of angiogenesis can lead to 
the exacerbation of inflammatory-driven angiogenesis associated diseases such as 
atherosclerosis and cancer. In these conditions the effects of angiogenesis become 
pathological, where new blood vessels supply the diseased tissue with growth factors and 
cytokines promoting growth and accelerating the progression of disease states. 
Angiogenesis associated diseases are highly prevalent globally, with 
cardiovascular-related disorders and cancer being the leading causes of mortality 
worldwide. Current anti-angiogenic therapies suppress angiogenesis in all 
pathophysiological conditions and while many are successful in suppressing tumour 
progression, these are often accompanied by severe side effects, thus highlighting the need 
for novel therapeutic targets that can inhibit inflammatory-driven angiogenesis while 
having no effect on ischaemia-mediated angiogenesis.  
Key regulators of angiogenesis are small inflammatory proteins known as 
chemokines. They are divided into four classes: CC-chemokines, CXC-chemokines, 
CX3C-chemokines and XC-chemokines. Emerging evidence suggests that the CC-
chemokine class promote inflammatory-driven pathological angiogenesis, however there is 
little reported evidence for their role in ischaemia-mediated physiological angiogenesis. 
Therefore, we propose that broad-spectrum inhibition of the CC-chemokine class may 
specifically suppress pathological inflammatory-driven angiogenesis, whilst preserving 
important physiological ischaemia-mediated angiogenic processes. This approach may 
have advantages over current anti-angiogenic therapies. 
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1.2. Angiogenesis in pathophysiological states 
The regulation of angiogenesis in various pathophysiological contexts involves a 
number of critical growth factors, cytokines, signalling cascades and cellular processes that 
are triggered in response to either an inflammatory or ischaemic response and is regulated 
via two distinctly different yet overlapping pathways (Carmeliet 2000). The pathological 
angiogenesis pathway seen in tumour and atherosclerotic plaque progression is driven by 
inflammation. Conversely, the physiological angiogenesis required in response to tissue 
ischaemia or wound healing is mediated by ischaemia/hypoxia. 
 
1.2.1. Inflammatory-driven pathological angiogenesis 
Inflammatory-driven pathological angiogenesis accelerates a number of disease 
processes, in particular atherosclerosis and cancer (Carmeliet 2000; Moulton et al. 1999; 
Moulton et al. 2003). Pathological angiogenesis is induced at sites of vascular 
inflammation that have increased recruitment of monocytes/macrophages.  Neovessel 
formation is stimulated by macrophages through the release of pro-angiogenic  factors, 
including VEGF, bFGF, TNF-, IFN-, that then stimulate excessive neovessel formation 
(Mantovani et al. 2008). For example, plaque neovessels allow the increased transportation 
of cells, cytokines and growth factors to the plaque which exacerbate the disease process 
(Carmeliet & Jain 2000b; Moulton et al. 1999; Moulton et al. 2003). This makes plaque 
neovessels particularly undesirable. Furthermore, they are also thin walled and prone to 
haemorrhage making the plaque unstable and prone to rupture (Moreno et al. 2004). 
Elevated levels of inflammation also have direct effects on endothelial cells and will 
stimulate neovascularisation. Under inflammatory conditions vessels form dense and 
highly disorganised networks (Nagy et al. 2009). These new vessels develop from existing 
vessels in which endothelial cells are recruited from sites adjacent to the injury (Chung & 
Ferrara 2011). These recruited endothelial cells accelerate angiogenesis either by forming 
part of the new vessel or by stimulating vessel growth. For example in tumours, fibroblasts 
aid in the remodelling of the extracellular matrix (ECM) to make way for new vessels and 
have also been shown to have pro-angiogenic properties (Bhowmick, Neilson & Moses 
2004; Kalluri & Zeisberg 2006). Due to the imbalance between the pro- and anti-
angiogenic switch, pathological angiogenesis persists and exacerbates the disease, 
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preventing its resolution. Inflammatory-driven angiogenesis is implicated in several 
inflammatory diseases such as atherosclerosis, cancer and rheumatoid arthritis. 
 
1.2.2. Ischaemia-mediated physiological angiogenesis 
Vascular supply of oxygen is critical to human growth and development. During 
embryonic growth the cardiovascular system is established early, reflecting on the 
importance of oxygen supply via the vasculature (Carmeliet 2003). As an adult, postnatal 
physiological angiogenesis is critical for growth and repair, wound healing, menstrual 
cycle, and pregnancy to supply oxygen and nutrients to the embryo. During angiogenesis, 
early vessels are formed by endothelial cells, however as blood flow is established 
remodelling may occur and involve additional cell types such as endothelial progenitor 
cells (EPCs) derived from the bone marrow, or smooth muscle cells from surrounding 
tissue. These vessels form a smooth muscle layer to cope/respond to increased blood flow 
in the area (Chung & Ferrara 2011). Physiological angiogenesis is primarily triggered 
when there is a chronic imbalance in tissue oxygen supply versus demand following injury 
or vessel occlusions, which restrict the supply of blood. The ensuing hypoxic environment 
induces neovascularisation of the ischaemic tissue. In athero-occlusive diseases this 
response is crucial for the formation of a coronary collateral circulation (Ware & Simons 
1997), which is a critical factor for survival following a myocardial infarction (Sabia et al. 
1992) and is associated with improved prognosis in the context of stable chronic coronary 
disease (Billinger et al. 2002). When sufficient vasculature is achieved, angiogenesis 
resolves and a balance between pro- and anti-angiogenic factors is re-established. 
Physiological angiogenesis is therefore an essential regenerative process, which is 
important in ischaemia-related cardiovascular disease. Additionally, peripheral vascular 
disease is on the rise due to decreased activity and increased consumption of fatty foods. 
Peripheral vascular disease is the narrowing of the vessel wall in arteries outside of the 
cardiac system. It is largely due to atherosclerosis, but can also occur as occlusions in the 
vein, by thrombosis or insufficient blood flow to the peripheral limbs. This has significant 
health impact on sufferers of this disease, often resulting in lower limb amputation and has 
great economic impact.  
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1.2.3. Angiogenesis is critical for tumour growth and development 
Tumour growth depends implicitly on neovascularisation, as tumour cells become 
distant from nearby vessels (Carmeliet 2000). Furthermore, tumour neovessels accelerate 
tumour growth by allowing the passage of inflammatory cells that secrete pro-angiogenic 
factors (Mantovani et al. 2008). Rapid tumour expansion, through neovascularisation, 
increases the likelihood of metastasis as tumours have poorly developed lymphatics so 
secreted tumour cells are shunted to the peripheral lymph nodes (Carmeliet & Jain 2000b). 
Hypoxia is a common characteristic of locally advanced solid tumours and has been linked 
with a diminished therapeutic response and malignant progression (Vaupel 2004). As the 
tumours grow, it rapidly outgrows the available blood supply, resulting in portions of the 
tumour with hypoxic regions. Cancer cells in these hypoxic microenvironments in solid 
tumours have been reported to alter their metabolism in order to maintain continuous 
growth and proliferation. 
 
1.2.4. Angiogenesis is critical for postnatal wound healing 
Wound healing is a complex multistep process comprised of 3 overlapping but 
distinct phases: (1) inflammation, (2) proliferation, (3) remodelling as outlined in Figure 
1.1. The inflammation phase occurs early (24 – 48 hours) after wound injury. A fibrin clot 
forms to prevent blood loss, and debris removal occurs through the recruitment of 
neutrophils and macrophages to the wound site. Macrophages appear in the later part of 
this stage to transition to the second wound healing phase, proliferation. Proliferation 
occurs between 2 – 10 days after wound injury. It is characterised by re-epithelialisation to 
bring the wound to a close. This is aided by angiogenesis which helps recruit macrophages 
to stimulate healing, and EPCs, keratinocytes, and fibroblasts to form new tissue at the 
wound site. During this proliferation stage granulation tissue begins scar formation. 
Remodelling is the final step of wound healing and can last for up to one year. In this 
phase, inflammation and angiogenesis ceases and new blood vessels disintegrate allowing 
the fibroblasts to reorganise the collagen matrix, forming a closed wound  (Gurtner et al. 
2008). Angiogenesis is important during both the inflammation and proliferation phases. 
Primarily angiogenesis initiates the formation of angiogenic capillary sprouts that allow for 
recruitment of inflammatory cells to the wound for debris removal. Additionally 
angiogenesis allows for the  invasion of the fibrin/fibronectin-rich wound clot, and 
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reorganisation of a microvascular network to maintain the newly formed granulation tissue 
(Tonnesen, Feng & Clark 2000). Wounds that exhibit impaired healing frequently enter a 
state of pathological inflammation, with most chronic wounds developing into ulcers and 
the incidence of these are associated with ischaemia, diabetes mellitus, venous stasis 
disease or pressure (Guo & DiPietro 2010). Chronic, non-healing wounds greatly impact a 
person‟s quality of life and when left untreated sometimes lead to amputation resulting in 
an enormous health care burden (Mathieu, Linke & Wattel 2006; Menke et al. 2007).  
 
 
 
Figure 1.1. The three main stages of wound healing.  
Wound healing is composed of three main stages: inflammation (early), proliferation (mid) 
and remodelling (late). The main objective of the inflammation stage is clot formation to 
prevent bleeding and removal of debris to prevent infection in the wound. This stage is 
dominated by neutrophils and angiogenesis begins to occur. The proliferation stage is 
directed by macrophages which maintain angiogenesis and aid in the re-epithelialisation 
of the wound area. The last stage, remodelling, is characterised by the formation of 
granulation tissue, lack of inflammation, and angiogenesis ceases at this stage. 
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1.3. Intracellular mechanisms for the regulation of angiogenesis in different 
pathophysiological conditions 
Endothelial cells (ECs) are one of the major cell types involved in angiogenesis. As 
ECs are mainly quiescent, angiogenesis needs to be triggered by a stimulating cytokine, 
such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor 
(bFGF). These cytokines bind to their cognate receptors on ECs present in pre-existing 
blood vessels (Carmeliet 2000; Karamysheva 2008). Once activated ECs then release 
extracellular proteinases such as matrix metalloproteinases (MMPs) that degrade the 
basement membrane of the existing capillary wall, forming a branch point. Surrounding 
ECs then proliferate into the adjacent matrix and form solid sprouts connecting 
neighbouring vessels (Folkman & Shing 1992). As sprouts extend toward the source of the 
angiogenic stimulus, VEGF facilitates endothelial cell detachment from the parent vessel 
and directs migration into the neighbouring stroma, using adhesion molecules called 
integrins. These sprouts then reorganise and form loops to become a full-fledged vessel 
lumen as cells migrate to the site of angiogenesis. Finally, the endothelial cells secrete 
platelet derived growth factor (PDGF), which recruits pericytes to the site in order to 
stabilise the newly formed tubules that are interconnected, forming a network.  
Angiogenesis is a multi-step process that occurs in several well defined stages and 
involves a complex orchestration of growth factors, cytokines, signalling cascades and 
cellular events. Depending on the pathophysiological context, angiogenesis is driven by 
distinctly different, although partially overlapping, pathways. The pivotal transcription 
factor for inflammatory-driven angiogenesis is nuclear factor-κB (NF-κB) while 
ischaemia-mediated angiogenesis is primarily modulated by the main hypoxic transcription 
factor, hypoxia-inducible factor-1α (HIF-1α). 
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1.3.1. Inflammatory-driven angiogenesis is modulated by NF-κB signalling pathway 
Prolonged chronic inflammation has been implicated in the pathogenesis of 
atherosclerosis and cancer. The transcription factor NF-B is a pivotal promoter of 
pathological inflammatory-driven neovascularisation (Ng et al. 2007; Ware & Simons 
1997). While there are two established NF-κB signalling pathways, namely the (a) 
canonical or classical (mediated by IκB degradation) and (b) non-canonical or alternative 
(p100 mediated) (Pomerantz & Baltimore 2002), inflammatory-driven angiogenesis is 
primarily regulated by the canonical pathway.  
A brief schematic diagram of the canonical/classical NF-κB pathway is shown in 
Figure 1.2. Under normal conditions, the NF-κB complex (p50/p65) is sequestered within 
the cytosol by the inhibitor of κB (IκB) proteins, specifically IκBα. The canonical pathway 
is activated by inflammatory stimuli, such as tumour necrosis factor-α (TNF-α), 
interleukins or lipopolysaccharides, triggering the activation of the IκB kinase (IKK) 
enzyme complex, resulting in IκBα phosphorylation (Mercurio et al. 1997). Upon 
phosphorylation, the IκB complex is targeted for ubiquitination and subsequent 
proteasomal degradation. This releases the NF-κB complex, allowing it to translocate into 
the nucleus where it binds to the NF-κB response element to initiate the transcription of 
pro-angiogenic mediators including VEGF, MMPs and cell adhesion molecules (CAMs) 
(Chen et al. 1995; Chen 2005; Tak & Firestein 2001). 
Page | 9  
 
 
Figure 1.2. Canonical/Classical NF-B signalling pathway (adapted from Viennois et al., 
2013). 
Pro-inflammatory stimuli such as TNF-α, IFN-, IL-8 or LPS triggers the phosphorylation 
of IBα by the IKK complex, causing ubiquitination and degradation of IBα. The p50/p65 
NF-B complex is released and translocates into the nucleus, binding to the NF-B 
response element to activate the production of NF-B target genes to further drive the 
inflammatory response. These targets also include pro-angiogenic mediators such as 
VEGF and MMPs. 
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Inflammatory-driven pathological angiogenesis may be triggered by direct or 
indirect stimulation. Direct stimulation involves an increase in inflammatory cytokines and 
growth factors which in turn regulate endothelial cell migration and proliferation leading to 
angiogenesis. Conversely, indirect stimulation requires the initial recruitment of 
macrophages to the inflamed site. Macrophages are potent promoters of pathological 
angiogenesis as they secrete a host of growth factors and cytokines (VEGF, bFGF, PDGF, 
TNF-α and IFN-γ) known to promote angiogenesis (Jackson et al. 1997; Sunderkotter et al. 
1994), which subsequently accelerate plaque growth and increase plaque instability/rupture 
(Moulton et al. 1999; Moulton et al. 2003). Key inflammatory mediators including TNF- 
and chemokines such as monocyte chemoattractant protein-1 (MCP-1) have all been 
shown to directly induce angiogenesis in vitro and in vivo (Charo & Ransohoff 2006; 
Galvez et al. 2005; Jackson et al. 1997; Salcedo et al. 2001; Strasly et al. 2004; Werts et al. 
2007; Weyrich et al. 1995). 
Atherosclerosis is a chronic inflammatory disease associated with the recruitment 
of circulating leukocytes into the vascular wall. Atherosclerosis develops over several 
decades and encompasses a host of cellular processes involved at various stages of disease 
from the initiation of plaque formation to plaque rupture, with NF-B shown to be the key 
transcription factor involved throughout the entire disease progression. The initial stage of 
atherosclerosis involves damage to the endothelium and the activation of endothelial cells 
via the NF-κB signalling pathway. This results in the expression of various chemokines 
and adhesion molecules such as CCL2, CCL5, MIF, and CX3CL1 (Liu & Jiang 2011; 
Morand, Leech & Bernhagen 2006; Zernecke & Weber 2010) that promote the recruitment 
of leukocytes to the vascular intima. Intimal neovascularisation is triggered by pro-
angiogenic mediators including VEGF and TNF-α. The newly formed capillaries often 
localise in areas rich with cell types that can activate angiogenesis, such as monocytes and 
macrophages (Polverini et al. 1977). Pro-angiogenic factors expressed by monocytes 
promote the proliferation of endothelial cells, and mobilisation and homing of bone 
marrow-derived endothelial progenitor cells (EPCs) (Lambert, Lopez & Lindsey 2008). In 
addition, activated macrophages generate pro-angiogenic factors including VEGF and 
FGF-2, further augmenting intimal neovascularisation (Murdoch et al. 2007), with NF-κB 
being the critical promoter of angiogenesis which induces VEGF expression (Morais et al. 
2009). Due to the close proximity of plaque neovessels to inflammatory infiltrates and 
elevated endothelial expression of cell adhesion molecules such as vascular cell adhesion 
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molecule-1 (VCAM-1), intracellular cell adhesion molecule-1 (ICAM-1) and E-selectin, 
there is additional recruitment of inflammatory cells to the lesion site (O'Brien et al. 1996). 
This creates a positive and deleterious feed-forward loop whereby inflammatory cells 
stimulate angiogenesis in the plaque and the newly formed vessels promoting further 
inflammatory cell recruitment.  
 
1.3.2. Ischaemia-mediated angiogenesis is driven by HIF-1α signalling pathway 
Physiological angiogenesis is stimulated in response to ischaemia, and is primarily 
driven by the transcription factor HIF-1α which in turn upregulates a range of pro-
angiogenic factors in particular VEGF with a 30 fold increase (Carmeliet 2003). Other 
hypoxia-responsive genes are also upregulated including nitric oxide synthase (NOS) and 
CXCL12/CXCR4 that promote angiogenesis by increasing EPC migration and 
mobilisation, and promoting cell differentiation (Cooke & Losordo 2002; Liekens, Schols 
& Hatse 2010; Zheng et al. 2007). HIF-1α is essential in physiological angiogenesis where 
inactivation of HIF-1α in mice results in abnormal vascular development and embryonic 
lethality (Iyer et al. 1998; Kotch et al. 1999; Licht et al. 2006; Ryan, Lo & Johnson 1998). 
The hypoxia-inducible factors (HIFs) are heterodimeric nuclear transcription 
factors comprised of two subunits that regulate transcription of genes mediating cellular 
homeostatic responses to changes in cellular oxygen levels. The HIF subunits (HIF-1α and 
HIF-2α) is oxygen-regulated, whereas HIF-β is constitutively expressed in the nucleus 
(Semenza 2012). The stability and transcriptional activity of HIF-1α is regulated post-
translationally within the cytosol by the prolyl hydroxylase domain protein family (PHD1-
3), which require molecular oxygen as a co-substrate (Appelhoff et al. 2004; Bruick 2003; 
Huang & Bunn 2003; Nakayama et al. 2004; Nakayama, Qi & Ronai 2009; Semenza 
2004).  
A brief schematic diagram of the post-translational modulation of HIF-1α is shown 
in Figure 1.3. Under aerobic conditions, the PHDs hydroxylate proline residues, causing 
ubiquitination and proteasomal degradation of HIF-1α subunits (Bruick & McKnight 2001; 
Epstein et al. 2001; Ivan et al. 2001; Jaakkola et al. 2001; Masson et al. 2001). Conversely, 
a decrease in intracellular [O2] triggers the activation of the PI3K/Akt signalling pathway 
resulting in the induction of gene transcription of the ubiquitin ligases Siah1 and Siah2. 
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Siahs promote the degradation of PHD enzymes, protecting HIF-1α from degradation and 
leading to HIF-1α stabilisation and accumulation (Nakayama et al. 2004). This in turn 
allows HIF-1α to translocate into the nucleus, where it complexes with the HIF-1β subunit, 
facilitating its binding to the hypoxia response element (HRE), and driving the expression 
of angiogenic mediators including VEGF, angiopoietin, bFGF, MMPs and tissue inhibitors 
of MMPs (TIMPs). In turn, these angiogenic factors drive angiogenic cellular processes 
including endothelial cell proliferation and migration, smooth muscle cell recruitment, 
extracellular matrix degradation and stabilisation and maturation of the vessel walls. 
 
 
Figure 1.3. HIF-1α signalling pathway in normoxia and hypoxia (adapted from Maes et 
al., 2012). 
Under normoxia, PHD1-3 hydroxylates HIF-1 allowing von Hippel-Lindau proteins to 
bind. This causes the ubiquitination and degradation of HIF-1α. In hypoxia, low oxygen 
levels stimulate the increase of Siahs. Siahs inhibit PHDs, preventing HIF-1α from 
ubiquitination and degradation, allowing it to translocate into the nucleus. In the nucleus 
HIF-1α complexes with HIF-1 and Cbp to bind to the hypoxia response element (HRE) 
driving angiogenic target genes such as VEGF.  
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While the role of VEGF is critical in driving ischaemia-mediated angiogenesis, 
HIF-1α also regulates angiogenesis at every step of the process through multiple signalling 
pathways and cellular processes. Firstly, activated migrating ECs degrade the extracellular 
matrix via the upregulation of MMPs including MMP2, which is a direct target of HIF-1α 
and mediates EC migration in response to hypoxia (Ben-Yosef et al. 2005). Hypoxia also 
regulates vessel branching via the modulation of Notch signalling as HIF-1α directly binds 
to the Notch intracellular domain to augment its transcriptional activity, driving vascular 
branching and morphogenesis (Gustafsson et al. 2005). Endothelial cells then begin to 
form tubes in order to extend the existing vascular network and hypoxic stimulation has 
been shown to enhance endothelial tubule formation in vitro, with these effects being 
dependent on HIF-1α levels (Tang et al. 2004).  
Another critical regulator of ischaemia-mediated angiogenesis is endothelial nitric 
oxide synthase (eNOS). In response to hypoxia eNOS stimulates nitric oxide (NO) 
production. NO controls growth factors such as VEGF, angiopoeitins, fibroblast growth 
factors and genes involved in matrix metabolism, including MMPs (Munk et al. 2006). 
Many functional processes of angiogenesis such as cell migration, proliferation and 
tubulogenesis can also be induced by hypoxia (Krishnamachary et al. 2003; Phillips, 
Birnby & Narendran 1995). Bone marrow-derived EPCs also make significant 
contributions to ischaemia-mediated neovascularisation by paracrine release of angiogenic 
factors or by direct participation in neovessel formation (Sieveking et al. 2008). Taken 
together, these studies highlight the importance of HIF-1α as a pivotal regulator of 
ischaemia-mediated angiogenesis, making it a target for therapeutic regulation.  
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1.3.3. Tumour neovascularisation is driven by both inflammation and hypoxia 
Tumour neovascularisation is critical for tumour growth as the formation of tumour 
neovessels facilitate the recruitment of inflammatory cells that will express pro-angiogenic 
mediators. This promotes the positive angiogenic feed-forward loop, similar to that of 
plaque neovessels. Tumour angiogenesis is regarded as a negative prognostic variable for 
several malignancies including breast and prostate cancer (Cavallaro & Christofori 2000; 
van Hinsbergh, Collen & Koolwijk 1999; Zachary 1998). It is well established that many 
different types of human tumours have uncontrolled regulation of NF-κB, in which NF-κB 
is constitutively active. The link between NF-κB and tumour angiogenesis was highlighted 
in an in vivo study where inhibition of the NF-κB signalling pathway suppressed the 
expression of VEGF in cultured human ovarian cancer cells implanted into an orthotropic 
nude mouse model (Huang et al. 2000). Furthermore, the suppression of VEGF directly 
correlated with decreased tumorigenicity, reduced neovascularisation of lesions and 
prolonged survival (Huang et al. 2000). The link between NF-κB, VEGF and angiogenesis 
was also confirmed in an in vitro study utilising high and low metastatic adenoid cystic 
carcinoma cell lines (Zhang & Peng 2007). 
Furthermore, as tumours expand to become solid tumours, the microenvironment 
becomes progressively hypoxic, forcing cancer cells to adapt to the environment in order to 
survive. While hypoxic effects can negatively impact tumour cell growth (Vaupel & 
Harrison 2004), they may, conversely, lead to hypoxia-mediated responses that enhance 
malignant progression and aggressiveness, ultimately resulting in increased resistance to 
therapy and poor long-term prognosis. This is induced by a series of hypoxia-mediated 
proteomic and genomic changes that facilitate cell survival (Vaupel 2004). In this instance, 
HIF-1α activation is detrimental as it results in the induction of downstream targets that 
facilitate key cellular processes that promote tumour growth such as angiogenesis (VEGF 
and inducible nitric oxide synthase, iNOS), cell proliferation and survival (EGF, IGF-2 and 
TGF-β) and metabolic adaptation (glucose transporters including glucose transporter-1, 
GLUT-1 and glycolytic enzymes) (Vaupel 2004). 
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1.3.4. Wound neovascularisation 
Angiogenesis plays a critical role in the early stages of wound healing, particularly 
during the inflammation and proliferation phases. With this in mind, both the NF-κB and 
HIF-1α signalling pathways play a role in mediating wound neovascularisation. Following 
wounding, the wound microenvironment undergoes a range of changes, triggering the 
activation of cellular responses. The NF-κB signalling pathway is triggered to promote the 
recruitment of macrophages to the site of injury in order to minimise infection. However, 
continued chronic inflammatory state in the wounds in turn impairs wound healing, often 
resulting in delayed wound remodelling. This is a common complication in the increasing 
population of diabetic patients as well as a frequent occurrence in an aging populace. 
Additionally, following acute injury, the microenvironment of the skin wound can become 
hypoxic due to vascular disruption and high oxygen consumption by cells at the wound 
edge (Hunt, Niinikoski & Zederfeldt 1972; Niinikoski, Grislis & Hunt 1972; Varghese et 
al. 1986). The importance of HIF-1α in improving wound healing is highlighted in a study 
on aged mice where impaired wound healing was concomitant to decreased HIF-1α levels 
(Loh et al. 2009). This acute hypoxic environment has a positive role in early skin wound 
healing, triggering the expression of HIF-1α (Albina et al. 2001; Elson et al. 2001) and as 
neovascularisation occurs and the wound recovers, the wound microenvironment returns to 
normoxic levels (Tandara & Mustoe 2004). Key angiogenic mediators including VEGF, 
bFGF and MMPs have also been shown to be important in mediating the wound healing 
process (Eming, Krieg & Davidson 2007; Gurtner et al. 2008; Singer & Clark 1999). After 
wounding bFGF is released from macrophages, whilst VEGF is released from epidermal 
cells. The MMPs degrade extracellular matrix proteins allowing recruitment of activated 
monocytes to the injury site, to subsequently release pro-angiogenic factors (Singer & 
Clark 1999).  
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1.3.5. Vascular endothelial growth factor – a crucial angiogenic target 
The VEGF family of genes comprises of seven members: VEGF-A, -B, -C, -D, -E, 
-F and placental growth factor (PlGF) (Ferrara 2004; Ferrara, Gerber & LeCouter 2003). 
All VEGF family members stimulate cellular responses by binding to tyrosine kinase 
receptors (termed VEGFRs: VEGFR1, VEGFR2 and VEGFR3) on the cell surface, 
causing them to dimerise and become activated through transphosphorylation (Shibuya & 
Claesson-Welsh 2006). While the VEGF receptors are structurally highly related, each 
displays interesting differences with regard to their abilities to respond to ligand binding 
and the spectrum of transduced biological responses (Shibuya & Claesson-Welsh 2006). 
VEGFR1 and VEGFR2 are expressed on the cell surface of most blood ECs while 
VEGFR3 is restricted to lymphatic ECs. VEGFR2 is the earliest marker for endothelial cell 
development (Kabrun et al. 1997) and is considered a critical signal transducer in 
angiogenesis (Shibuya & Claesson-Welsh 2006).  
Activation of VEGFR2 stimulates vascular endothelial cell survival, growth and 
migration resulting in the augmentation of angiogenesis. VEGF-A (also known as VEGF) 
is the key growth factor involved in physiological and pathological angiogenesis and while 
it is shown to bind to both VEGFR1 and VEGFR2, its interaction with VEGFR2 has been 
reported to directly regulate tumour angiogenesis. This has therefore made VEGFR2 the 
focus of extensive research and the VEGF/VEGFR2 interaction the best characterised 
signalling pathway in angiogenesis (Ferrara, Gerber & LeCouter 2003; Shibuya 2011). In 
ischaemia-mediated angiogenesis, hypoxia is the principal regulator of VEGF expression, 
as it is a direct transcriptional target of both HIF-1α and HIF-2α (Compernolle et al. 2002; 
Forsythe et al. 1996; Liu et al. 1995). Conversely in inflammatory-driven angiogenesis, 
VEGF expression is predominantly modulated via NF-κB, and has a well-established role 
in tumour and plaque angiogenesis (Celletti et al. 2001; Ferrara 2004; Ferrara, Gerber & 
LeCouter 2003). This is possible as VEGF has both HRE and NF-B response elements in 
its promoter region as illustrated in Figure 1.4. Additionally, VEGF has 2 response 
elements of NF-B suggesting that it is more affected by inflammation than hypoxia. 
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Figure 1.4. VEGF has response elements in its promoter region for NF-B and HIF-1α 
(adapted from Ramanathan et al., 2007). 
Under inflammation, the NF-B complex (p50/p65) enters the nucleus and binds to the 
response elements in the promoter region of the VEGF. Under hypoxia, the HIF complex 
(HIF-1α./HIF-1/Cbp) enters the nucleus and binds to the HRE in the promoter region of 
VEGF. 
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1.4. Current anti-angiogenic therapies 
The development of anti-angiogenic agents are of great interest due to the high 
prevalence of diseases associated with angiogenesis. However, current anti-angiogenic 
agents target both pathological and physiological angiogenesis. This often results in several 
side effects such as vomiting, nausea, gastrointestinal perforations, and reduced wound 
healing. These side effects can be quiet severe, thus an agent able to specifically target 
inflammatory-driven angiogenesis whilst preserving hypoxia-mediated angiogenesis is 
needed. Anti-angiogenic agents such as VEGF inhibitors or VEGF receptor inhibitors are 
found to reduce plaque size and tumour growth in a variety of malignancies including 
breast, lung and prostate (Borgstrom et al. 1998; Chan 2009; Di Costanzo et al. 2008; Kerr 
2004; Moulton et al. 1999). However, the reported side effects from these agents include:  
hypertension, bleeding, severe weight loss, diarrhoea and nausea in a large proportion of 
patients (Cabebe & Wakelee 2007; Mourad et al. 2008; Satchi-Fainaro et al. 2004). 
Furthermore, the clinically available bevacizumab (an anti-vascular endothelial growth 
factor, VEGF, antibody) and multi-targeted tyrosine kinase inhibitors (TKIs, target the 
VEGF receptor), cause endothelial dysfunction and capillary rarefaction (Cabebe & 
Wakelee 2007; Mourad et al. 2008; Satchi-Fainaro et al. 2004). Both classes of drug also 
cause clinically significant elevations in blood pressure (12 – 15%), bleeding and 
haemorrhage – all of which are associated with impaired regenerative angiogenic 
responses (Cabebe & Wakelee 2007; Mourad et al. 2008; Satchi-Fainaro et al. 2004). 
These problems are due to the complete inhibition of angiogenesis in all 
pathophysiological contexts. This highlights the need for the development of novel 
therapies that have more specific targeting of pathological angiogenesis whilst preserving 
physiological angiogenesis. 
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1.5. Chemokines 
Chemokines are chemotactic cytokines that direct the migration of cells to sites of 
inflammation and injury and are secreted by a wide variety of cells. There are currently 50 
known chemokines (ligands) with 20 chemokine receptors (highlighted in Table 1.1). 
Chemokines are divided into four groups based on the placement and number of cysteine 
residue at the N-terminal (Figure 1.5). The CC-chemokine group has 2 cysteine residues 
adjacent to each other, the CXC-chemokine group has 2 cysteine residues separated by an 
amino acid. This group can be further separated based on the presence of ELR (Glu-Leu-
Arg) motif, into ELR
-
 (angiostatic) and ELR
+
 (angiogenic). The CX3C-chemokine group 
has 3 amino acids between 2 cysteine residues and the XC-chemokine group has only one 
cysteine residue at the N terminal (Chan 2009; Fernandez & Lolis 2002; Rossi & Zlotnik 
2000). Of the four chemokine groups the largest are the CC-chemokines (28 members), 
followed by the CXC-chemokines (17 members), with the CX3C- and XC-chemokines 
having 1 and 2 members respectively. Table 1 illustrates the ability of chemokines to bind 
to multiple receptors and also for receptors to bind to multiple chemokines, indicating 
some redundancy in chemokine signalling. However, chemokine/chemokine receptors 
interactions are specific within each chemokine group. The complexity and specificity of 
the chemokine network may allow for a more enhanced and specific immune response 
(Devalaraja & Richmond 1999; Mantovani 1999). 
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Table 1.1. Chemokines and chemokine receptor 
Receptor Ligands 
CCR1 CCL3, CCL5, CCL7, CCL13, CCL14, CCL15, CCL16, CCL23 
CCR2 CCL2, CCL7, CCL8, CCL13, CCL16 
CCR3 
CCL5, CCL7, CCL8, CCL11, CCL13, CCL15, CCL16, CCL24, CCL26, 
CCL28 
CCR4 CCL17, CCL22 
CCR5 
CCL3, CCL4, CCL5, CCL8, CCL11, CCL14, CCL16, CCR6, CCL20, 
CCR7, CCL19 
CCR6 CCL20 
CCR7 CCL19, CCL21 
CCR8 CCCL1 
CCR9 CCL25 
CCR10 CCL27, CCL28 
CXCR1 CXCL6, CXCL7, CXCL8 
CXCR2 CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8 
CXCR3-A CXCL9, CXCL10, CXCL11 
CXCR3-B CXCL4, CXCL9, CXCL10, CXCL11 
CXCR4 CXCL12 
CXCR5 CXCL13 
CXCR6 CXCL16 
CXCR7 CXCL12 
XCR1 XCL1, XCL2 
CX3CR1 CX3CL1 
CCXCKR CCL19, CCL21, CCL25 
D6 
CCL2, CCL3L1, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, 
CCL17, CCL22 
DARC/Duffy 
CCL2, CCL7, CCL8, CCL11, CCL13, CCL14, CCL16, CCL17, CXCL1, 
CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL11, CXCL13 
Page | 21  
 
 
Figure 1.5. Chemokine classification is based on the number and placement of cysteine 
residues at the N-terminal. CC-chemokines have 2 cysteine residues, CXC-chemokines 
have 2 cysteine residues separated by an amino acid (X), XC-chemokines have one 
cysteine residue and CX3C-chemokines have 2 cysteine residues separated by 3 amino 
acids (XXX). 
 
CC-chemokines primarily stimulate inflammatory-driven angiogenesis by first 
binding to glycosaminoglycans (GAGs) as shown in Figure 1.6. In response to an 
inflammatory stimulus, circulating CC-chemokines arrive at the site of inflammation/injury 
(Figure 1.6A) and then bind GAGs (Figure 1.6B) such as heparin and heparin sulphate, on 
the surface of endothelial cells. This is essential, as many chemokines are not activated 
unless they are bound to GAGs (Proudfoot et al. 2003b). GAGs are highly negatively 
charged and form an electrostatic interaction with the basic chemokine (Kuschert et al. 
1999), tethering the chemokines to the cell surface ready for receptor interaction. 
Chemokine retention on the cell surface configures a concentration gradient which attracts 
leukocytes and macrophages to the area of inflammation or injury. GAG binding also 
causes oligomerisation which is thought to be important in establishing chemokine activity 
but not receptor interaction (Allen, Crown & Handel 2007; Proudfoot et al. 2003a). 
Chemokines then bind to the chemokine receptors that are G Protein seven transmembrane 
Coupled Receptors (GPCR) expressed on the surface of the inflammatory cells (Figure 
1.6C). Receptor binding causes a conformational change in the chemokine leading to 
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activation of the cell and attraction of more inflammatory cells as shown in Figure 1.6D 
(Allen, Crown & Handel 2007). Alternatively CC-chemokines can bind directly to 
endothelial cells to activate angiogenesis by binding the GPCRs on the surface of 
endothelial cells as shown in Figure 1.7. This activates signalling pathways such as the 
PI3K/Akt pathway to increase NO production, and endothelial cell proliferation and 
migration leading to increased angiogenesis. 
 
 
Figure 1.6. CC-chemokine activity on endothelial cells. 
(A) CC-chemokines bind to glycosaminoglycans (GAGs) on the surface of endothelial cells 
at the injury site. (B) This produces a chemokine gradient which attracts monocytes to the 
site of inflammation or injury. (C) The monocytes bind, causing activation and 
differentiation into macrophages and migration into the injury site, (D) where 
macrophages release pro-angiogenic and pro-inflammatory cytokines and growth factors. 
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Figure 1.7. Alternate pathway of angiogenesis stimulation by CC-chemokines. 
Chemokines are recruited to the injury site, where they attach to chemokine receptors on 
the surface on endothelial cells. This activates the PI3K/Akt pathway, the release of NO, 
and stimulates endothelial cell migration and proliferation, causing the increase of 
angiogenesis. 
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1.6. Chemokines in health and disease 
The major role of chemokines is to act as a chemoattractant guide for migrating 
immune cells that are attracted to the signal of increased chemokine concentration. The 
body maintains a homeostatic environment of immune cells that are ready to respond to 
injury or inflammatory stimulation. This fine balance is regulated by chemokines. 
Chemokines are functionally divided into two groups based on the pathophysiological 
conditions: (1) homeostatic chemokines that are constitutively expressed and are involved 
in physiological basal leukocyte migration; and (2) inflammatory chemokines that are 
stimulated under pathological conditions and actively recruit immune cells to the site of 
inflammation/injury. The CXC-chemokine ligands (CXCL) and receptors (CXCR) are the 
main group of chemokines involved in physiological homeostasis, while the CC-
chemokine ligands (CCL) and receptors (CCR) regulate the migration of cells under 
inflammatory pathological conditions. 
 
1.6.1. Homeostatic immune cell trafficking under physiological conditions 
The control of chemokine immune cell trafficking begins in the bone marrow. In 
the bone marrow, haematopoietic stem cells (HSC) are in close proximity to CXCL12 
abundant reticular (CAR) cells. The homeostatic regulation of immune cells such as 
neutrophils, B-cells, and monocytes under physiological conditions is dependent on 
CXCR4/CXCL12 chemokine interaction. Although not activated, immune cells are needed 
to patrol the peripheral blood and tissue until they are needed. As neutrophils mature, the 
expression of CXCR4 is reduced to allow for the release of neutrophils into the 
bloodstream. However neutrophils are unable to survive for more than a few hours in 
circulation, undergoing senescence and increasing the expression of CXCR4 to facilitate 
their return to the bone marrow for apoptosis (Martin et al. 2003). Circulating neutrophils 
do not enter the peripheral tissue site unless stimulated in an inflammatory response. 
Eosinophils and basophils, stimulated under allergic reactions are predominantly found in 
the gastrointestinal tract during physiological conditions. Their migration into peripheral 
tissue is dependent on the interaction between CCR3 and CCL11 (Mishra et al. 1999). 
CCL11 also promotes the release of mature eosinophils and basophils from the bone 
marrow. Mature monocytes released from the bone marrow is dependent on CCR2 
interaction and reduced CXCR4 interaction. Under homeostasis, monocytes can 
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differentiate into either pro-inflammatory (CCR2
high
) or anti-inflammatory (CX3CR1
high
) 
states. The majority of monocytes in physiological conditions are CX3CR1
high
 and are 
found throughout peripheral blood and tissue (Foussat et al. 2000; Geissmann, Jung & 
Littman 2003). They function to monitor the bloodstream for infection and promote tissue 
homeostasis. The CCR2
high
 monocytes are only found in the bloodstream and have 
minimal expression under physiological conditions (Geissmann, Jung & Littman 2003). 
 
1.6.2. Inflammatory immune cell trafficking under pathological conditions 
Under inflammatory conditions there is a reduction of systemic granulocyte-colony 
stimulating factor (G-CSF) levels which leads to the decrease of CXCL12 production in 
the bone marrow (Kawakami et al. 1990). This causes the release of various immune cells 
including neutrophils and monocytes.  For neutrophils, the reduction of CXCL12 coincides 
with the increase of CXCL2 on the endothelium. This combination of events causes the 
release of neutrophils into the bloodstream under inflammation (Kawakami et al. 1990; 
Kim et al. 2006; Semerad et al. 2002). Once in the bloodstream, neutrophils are attracted to 
chemokine gradients of CCL3, CCL5, CXCL1, and CXCL2 through the CCR1 and 
CXCR2 receptors, to promote the migration of neutrophils to the inflammatory site of the 
tissue (Chou et al. 2010). Neutrophils can release various chemokines including CCL3, 
CCL4, CCL5, CCL20 CXCL1, CXCL8, CXCL9 and CXCL10 to further promote the 
inflammatory response and recruit more immune cells (Bennouna et al. 2003). Monocytes 
released from the bone marrow are promoted upon reduction of CXCL12, and is stimulated 
by CCL2 through the CCR2 receptor. Detection of CCL2 in the serum during infection and 
inflammation indicates the release of monocytes from the bone marrow to the bloodstream 
(Shi & Pamer 2011). In the bloodstream, monocytes primarily interact with CCL2, but also 
have receptors to allow for interaction with CCL3, CCL4, CCL5, and CCL7, highlighting 
the importance of the CC-chemokine class in inflammation. CCL2 attaches to tissue by 
GAG binding, creating a chemokine gradient to attract CCR2
high 
monocytes to the inflamed 
tissue site, and differentiation to macrophages (Kuziel et al. 1997). Monocytes also express 
CXCR2, a receptor for CXCL8 and macrophage migration inhibitory factor (MIF). These 
chemokines have been found to promote adhesion and migration across the endothelium, 
but are not responsible for migration to the inflammatory site (Bernhagen et al. 2007; 
Gerszten et al. 1999). In vitro studies have also found that CCR1 and CCR5 are essential 
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for monocyte migration across the endothelium (Weber et al. 2001). Other than neutrophils 
and monocytes, eosinophils migrate from the bone marrow, through CCR3 signalling with 
CCL11. Eosinophils also express CCR1 receptors to respond to CCL24 and CCL26 
stimulation. CCL11, CCL24 and CCL26 promote the accumulation and migration of 
eosinophils in the tissue. 
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1.7. Chemokines in angiogenesis associated diseases 
In addition to their role in maintaining immune cell homeostasis, some chemokines 
have also been shown to have roles in the development of and, in particular, the promotion 
of angiogenesis. Each chemokine class has been shown to elicit angiogenic activity by 
distinct but overlapping mechanisms. The CC-chemokine class is primarily involved in 
stimulating pathological inflammatory-driven angiogenesis, while a number of the CXC-
chemokine family members direct physiological ischaemia-mediated angiogenesis. 
 
1.7.1. Chemokines in pathological inflammatory-driven angiogenesis 
CC-chemokines are increasingly implicated in disease pathologies in which 
inflammatory-driven angiogenesis plays a key role. They are largely known to promote 
angiogenesis indirectly by recruiting macrophages to the site of inflammation or injury 
where they release pro-inflammatory cytokines and growth factors that are required for 
neovessel formation. For example in liver fibrosis, angiogenesis is due to macrophage 
recruitment stimulated by CCL2 (Ehling et al. 2014). Under inflammation, chemokines are 
secreted by a wide variety of cells including endothelial cells, smooth muscle cells and 
inflammatory cells. Chemokines are located away from the luminal surface of the 
endothelium. It is believed that chemokines bind to the outer surface of the endothelium 
and are then internalised into caveolae to be transported to the luminal surface as observed 
with CCL5 (Ebnet et al. 1996; Middleton et al. 1997). However, transportation of CCL19 
is thought to occur via high endothelial venules rather than through caveolae (Baekkevold 
et al. 2001). Once at the luminal surface, chemokines attach to GAGs on the endothelium 
causing a chemokine gradient (Middleton et al. 2002). Chemokines are displayed to the 
inflammatory cells, such as monocytes, which attracts them to the site of inflammation or 
injury (Hub & Rot 1998). CC-chemokines bind to and activate monocytes through binding 
of the chemokine receptor GPCRs presented on the surface of the cell. Attachment through 
the N-terminal of the CC-chemokine is the most important as it causes a conformational 
change to activate the monocyte (Fernandez & Lolis 2002). Activation of the monocyte 
causes migration into the tissue and differentiation into macrophages. It is well-established 
that this process is facilitated by CC-chemokines (Yamamoto, Nagata & Sakamoto 2005) 
and the interaction of vascular cell adhesion molecule-1 (VCAM-1).  
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Recent evidence demonstrates that CC-chemokines can also directly regulate 
inflammatory-driven angiogenesis. For example, CC-chemokines have been shown to 
promote signalling pathways which induce inflammatory-driven angiogenesis including 
the signalling proteins phosphatidylinositol 3-kinase (PI3K), Akt and mitogen-activated 
protein kinase (MAPK) and ERK1/2 (Galvez et al. 2005; Stamatovic et al. 2006). 
Stimulation of these pathways subsequently increases the production of VEGF to further 
augment angiogenesis (Hong, Ryu & Han 2004). Additionally, CCL2 is associated with 
the increase of MMP14, essential for endothelial cell migration and neovessel formation 
(Galvez et al. 2005). CCL2 has also been shown to accelerate endothelialisation through 
the recruitment of EPCs (Fujiyama et al. 2003). Endothelial tubule formation in vitro was 
seen following incubation with CCL1, CCL2, CCL11, CCL15 and CCL16 (Bernardini et 
al. 2000; Hwang et al. 2004; Salcedo et al. 2001; Stamatovic et al. 2006; Strasly et al. 
2004). Furthermore, all CC-chemokines contain NF-B binding motifs and their 
expression is dramatically increased under inflammatory conditions (Charo & Ransohoff 
2006; Werts et al. 2007; Weyrich et al. 1995). A summary of the direct and in-direct 
effects of chemokines on pathological inflammatory-driven angiogenesis is depicted in 
Figure 1.8. 
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Figure 1.8. The direct and in-direct effects of chemokines on pathological inflammatory-
driven angiogenesis. 
 
Taken together, CC-chemokines play a critical role in the development of 
inflammatory-driven diseases reliant on macrophage infiltration, such as in atherosclerosis. 
In support of this a number of CC-chemokines have been identified in human 
atherosclerotic plaques, including: CCL2, CCL3, CCL5, CCL11, CCL13, CCL18, CCL19 
(Berkhout et al. 1997; Bursill et al. 2003; Reape et al. 1999; Weber, Schober & Zernecke 
2004). Furthermore the double knockout CCR2
-/-
/ApoE
-/-
 mice exhibit diminished lesion 
development and in targeted CC-chemokine receptor or CC-chemokine deletion studies 
ApoE
-/-
 mice have less plaque development (Boring et al. 1998; Gosling et al. 1999; Gu et 
al. 1998). Met-RANTES (an antagonist to CCL5) also reduced the size of atherosclerotic 
lesions in hypercholesterolaemic LDLR
-/-
 mice (Veillard et al. 2004).  
Studies have shown that in rheumatoid arthritis (RA), another inflammatory-driven 
pathology, new blood vessels are abundant in the synovial tissue. Neovessels promote the 
infiltration of leukocytes that increase the progression of RA (Szekanecz et al. 2009). 
Previous studies have found that production of CCL2, CCL3, CCL5, and CCL20 are 
associated with increased leukocyte infiltration and angiogenesis in models of RA 
(Schutyser, Struyf & Van Damme 2003; Szekanecz & Koch 2001; Szekanecz et al. 2009). 
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While CC-chemokines have been shown to be the primary family involved in 
inflammatory-driven pathologies, studies have shown that members from other chemokine 
classes also play a role. For example, it has been previously reported that a member of the 
CXC-chemokine family, CXCL8 (IL-8) is important in the development of atherosclerosis, 
particularly in monocyte adhesion on endothelial monolayers expressing E-selectin under 
flow conditions (Kraaijeveld et al. 2007). Additionally, the expression of CX3CL1 
(fractalkine) and its receptor CX3CR1 is upregulated in early and late atherosclerotic 
plaques (Stolla et al. 2012). The CX3CR1 receptor is also found on endothelial cell and 
smooth muscles in the plaque (Lucas et al. 2003; Yang et al. 2007) 
 
1.7.2. Chemokines in physiological ischaemia-mediated angiogenesis 
In contrast to their critical role in inflammatory-driven angiogenesis, the CC-
chemokines have little involvement in ischaemia-mediated angiogenesis. It is the CXC-
chemokines that are involved in important developmental processes including 
haematopoiesis, organogenesis and tissue repair. Extensive studies have shown that the 
critical hypoxia transcription factor HIF-1α augments the increased expression of the 
CXC-chemokine CXCL12 (also known as stromal-cell derived factor-1α, SDF-1α). 
CXCL12 is the single natural ligand for the chemokine receptor CXCR4 (Liekens, Schols 
& Hatse 2010) and the CXCL12/CXCR4 axis is important in the mobilisation, migration 
and recruitment of progenitor stem cells to sites of ischaemia (Dar, Kollet & Lapidot 2006; 
van Weel et al. 2007) with CXCL12 expression in ischaemic sites directly correlating with 
the degree of hypoxia (Ceradini et al. 2004). Furthermore, increased CXCL12 levels have 
been reported in infarcted myocardium in both human and rodent studies (Askari et al. 
2003; Ma et al. 2005; Pillarisetti & Gupta 2001; Wang et al. 2006), with increased 
CXCL12 levels detected as early as 1 hour following ischaemic induction in the 
myocardium or in hindlimbs, indicative of a role in the initiation of tissue repair and 
revascularisation (De Falco et al. 2004; Lee et al. 2006; Yang et al. 2004). The importance 
of CXCL12 is highlighted in CXCL12 knockout mice that are not viable due to the 
absence of vessel development (Schober et al. 2006).  
In parallel with CXCL12, HIF-1α also increases the production of VEGF. VEGF 
stimulates the production of endothelial nitric oxide synthase (eNOS) to stimulate nitric 
oxide production, which is essential for endothelial cell migration. Simultaneously, 
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CXCL12 mobilises bone marrow-derived EPCs, critical in the regenerative response to 
ischaemia and injury, through PI3K/Akt/eNOS activation (Zheng et al. 2007). The 
upregulation of eNOS mobilises EPCs and further increases the production of VEGF 
(Aicher et al. 2003). A summary of the role of chemokines in physiological ischaemia-
mediated angiogenesis is depicted in Figure 1.9. 
 
 
Figure 1.9. The role of chemokines in physiological ischaemia-mediated angiogenesis. 
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1.7.3. Chemokines in tumour neovascularisation 
CC-chemokines have been associated with a number of malignancies. Studies 
reveal that CCL2 and CCL5 expression is elevated in breast and prostate cancer (Soria & 
Ben-Baruch 2008; Zhang, Lu & Pienta 2010b), CCL1 and CCL3 are shown to promote 
development of leukaemia and CCL19 and CCL21 direct tumour metastasis (Tanaka et al. 
2005). Murine cancer models have shown that CC-chemokines are important in tumour 
development in vivo. Inhibition of CCL2 reduced haemangioma size in nude mice 
inoculated with cancer cells, while infusion of Met-RANTES inhibited tumour 
development in murine models of breast cancer (Robinson et al. 2003). The CXC-
chemokine class has also been shown to play a role in tumour neovascularisation, with IL-
8 (CXCL8) shown to play an important role in tumour growth, angiogenesis and metastasis 
(Li et al. 2003). Furthermore, CXCL12 has been implicated in the promotion of tumour 
growth in mouse prostate tumours following overexpression of its receptor CXCR4 
(Darash-Yahana et al. 2004). Consistent with this, CXCL12 production in tumour cells is 
triggered under hypoxic environments (Kryczek et al. 2005). 
 
1.7.4. Chemokines in wound healing 
CC-chemokines have been shown to regulate inflammation and angiogenesis, two 
key processes of wound healing. In the wound healing process, macrophage infiltration is 
highly regulated by CC-chemokine gradients released by hyper-proliferating keratinocytes, 
fibroblasts and other macrophages (Eming, Krieg & Davidson 2007; Gillitzer & Goebeler 
2001). In human wounds, a host of CC-chemokines including CCL1, CCL2, CCL3, CCL4, 
CCL5 and CCL7 are expressed in the wound during the first week after injury and high 
levels of CCL2 have been found in human burns (Engelhardt et al. 1998; Gibran et al. 
1997). Additionally studies in excisional wounds showed localised expression of CCL2 
and CCL3 in the epidermis, while CCL3 was also expressed in follicular epithelium, and 
sebaceous glands (Jackman et al. 2000). CC-chemokines have also been shown to regulate 
key processes involved in wound angiogenesis (Folkman & Shing 1992), such as the 
recruitment of inflammatory cells to the wound to provide support for proliferating and 
migrating cells, and the formation of granulation tissue (Gillitzer & Goebeler 2001). 
Furthermore, CC-chemokines were found to have direct effects on wound angiogenesis, 
for example stimulating tubulogenesis and endothelial cell migration through stimulation 
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of Ets-1 by CCL2 (Stamatovic et al. 2006), and through interactions with CCL16 (Strasly 
et al. 2004), and the CCL11/CCR3 complex (Salcedo et al. 2001). Additionally, CCL2 is 
involved in the regulation of MMP1 to breakdown the extracellular matrix for cell 
migration (Galvez et al. 2005), and CCL5/CCR5 interaction is critical for recruitment of 
endothelial progenitor cells to the wound site (Ishida et al. 2012).  
In summary, the CC-chemokine class plays an important role in the regulation of 
inflammatory-driven pathological angiogenesis, with little to no role in ischaemia-
mediated physiological angiogenesis. This difference in angiogenic regulation raises the 
possibility that specifically inhibiting the CC-chemokine class will inhibit pathological 
inflammatory-driven angiogenesis, while preserving physiological ischaemia-mediated 
angiogenesis. Furthermore, there is redundancy in CC-chemokine class signalling, where 
chemokines in one class can bind to several receptors from the same class. Conversely, 
receptors can have multiple ligands within a chemokine class. Therefore, due to this 
redundancy, targeting just a single chemokine may not be completely effective (Devalaraja 
& Richmond 1999; Mantovani 1999). A broad-spectrum CC-chemokine blockade 
approach may therefore be a more successful therapeutic approach. Chemokine inhibitors 
of this nature have already evolved from viruses allowing the virus to bypass the 
inflammatory pathway preventing detection. They are expressed following host invasion to 
propagate their own infection. The clear utility of these „chemokine-binding proteins‟ is a 
growing area of medical research. 
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1.8. Viral mimicry 
Viruses have evolved mechanisms to evade detection and destruction of host 
immune systems. One such mechanism used by large DNA viruses, such as Poxviruses and 
Herpes viruses, is to target the chemokine network by encoding homologues of 
chemokines and chemokine receptors to block chemokine activity. Viruses have 3 
mechanisms to interfere with the chemokine network. Viruses may produce viral 
chemokines (vCKs) which assist in viral spreading and growth, viral chemokine receptors 
(vCKRs) which influence the endothelial cells ability to respond to chemotactic signals, or 
they produce viral chemokine binding proteins (vCKBPs) which disrupt chemokine-GAG 
binding, chemokine-GPCR interaction or both (Alcami 2003).  
There are 3 types of vCKBPs produced by large viruses, firstly those that block 
GAG binding such as M-T7, which is expressed from the myxoma virus. M-T7 interferes 
with the IFN-γ receptor binding to CC-, CXC- and XC-chemokines (Lalani et al. 1997; 
Mossman et al. 1996). Secondly, there are vCKBPs that bind to chemokines with high 
affinity and therefore compete for binding to GPCRs, such as 35K from the Vaccinia virus 
(Alcami et al. 1998; Beck et al. 2001; Graham et al. 1997; Smith et al. 1997; Zhang et al. 
2006). Thirdly, viruses produce vCKBPs that bind both GAGs and GPCRs, such as M3. 
M3 is expressed from the mouse herpes virus and uniquely binds to a number of key 
inflammatory chemokines from all 4 chemokine classes (Alexander-Brett & Fremont 2007; 
Parry et al. 2000; Webb, Smith & Alcami 2004). This thesis is focused on the vCKBP 
„35K‟ that binds with high affinity to nearly all of the CC-chemokine class. 
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1.9. 35K – broad-spectrum CC-chemokine inhibitor 
35K is a soluble 35 kDa protein (previously known as vCCI, vCKBP2, VV-35kDa) 
from the Vaccinia virus (Figure 1.10). It is a globular protein, composed primarily of two 
parallel β-sheets, two short α-helices and large loops connecting the secondary structure 
elements (Carfí et al. 1999). This β-sandwich topology is unique and does not resemble 
any other chemokine receptor. It is mainly composed of non-polar residues and is highly 
acidic. 35K has been shown to have high affinity binding to a broad range of CC-
chemokines but has low or no affinity for chemokines belonging to other chemokine 
classes (Zhang et al. 2006). This is due to the fast association and slow dissociation rate 
with CC-chemokines, where in some cases 35K has 10 times greater affinity to the CC-
chemokine than its cognate receptor (Seet et al. 2001; Smith et al. 1997).  Despite this high 
binding affinity to CC-chemokines, 35K has no sequence homology to host CC-chemokine 
receptors, instead it is thought to recognise common structural features shared by most CC-
chemokines (Carfí et al. 1999). 
 
 
 
Figure 1.10. Structure of 35K. A and B are related by 90° rotation. Green arrows 
represent β-strands, blue ribbons, α-helices (Carfí et al. 1999). 
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35K has no resemblance to any known chemokine receptor, however it is able to 
bind to all CC-chemokines with high affinity. It has been identified that 35K binds to 
residues conserved throughout all CC-chemokines. In doing this, 35K binds over the 
receptor sites inevitably blocking chemokine receptor interaction. Previous binding studies 
with 35K show that point mutations on CCL2 at residues Tyr13, Arg18 and Arg24 greatly 
affected the binding affinity of 35K (Beck et al. 2001; Lau et al. 2004). These residues are 
highly conserved within the entire CC-chemokine class and were found to be critical for 
binding with 35K (Beck et al. 2001; Seet et al. 2001). Additionally, Arg18 is critical for 
binding to 35K, as CCL1 which contains glutamine at position 18 has low binding affinity 
with 35K (Seet et al. 2001). Furthermore, replacing Arg18 with alanine drastically reduced 
CC-chemokine binding affinities with 35K (Seet et al. 2001). 
Binding tests on the most widely characterised CC-chemokine, CCL2 revealed that 
35K has no sequence homology to CCL2 or CCR2, however it recognises similar residues 
that are important for CCR2 receptor binding as illustrated in Figure 1.11 (Seet et al. 
2001). Most importantly these residues span the area in which CCR2 binds, suggesting that 
residues bound to 35K overlap with the binding site of CC-chemokine receptors thereby 
causing direct inhibition of CCR2 binding to CCL2 indicative of competitive binding 
between 35K and CC-chemokine receptors (Bahar et al. 2008).  
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Figure 1.11. Binding sites on CCL2 for 35K and CCR2 (adapted from Beck et al, 2001). 
CCR2 and 35K high affinity (red) binding sites overlap at Arg-24 and Tyr-13 (yellow 
circles).  
 
More recent binding studies looking at the interaction between 35K and CCL11 
(eotaxin-1) show that the basic residues (Arg16, Arg22 and Lys44) are important in 35K-
CCL11 binding. These positions are equivalent to the residues found in CCL2 (Kuo et al. 
2014). When bound to 35K, these residues bind to highly acidic negatively charged 
residues within 35K‟s -sheet. Sequence alignment analysis also revealed that CC-
chemokines with high affinity binding to 35K all have basic positively charged residues at 
this equivalent position. The equivalent residue to Arg16, in CCL4 (Arg18), is found 
within the GAG binding region suggesting that 35K may affect the production of a 
concentration gradient in relation to some CC-chemokines (McCornack, Cassidy & 
LiWang 2003; Zhang et al. 2006). Given that GAG binding is important to chemokine 
function, studies also looked at whether this impacts on 35K binding. This was done by 
either overexpressing or inhibiting GAGs. Studies overexpressing heparin and heparin 
sulphate (the main GAG group) in pre-incubation studies with CCL3 did not affect binding 
of 35K to CCL3 (Alcami et al. 1998). Similarly, 35K binding is unaffected when GAG 
binding to CCL2 was lost through substitution of Lys58 and His66 by alanine (Beck et al. 
2001). These findings suggest that whilst a chemokine gradient is still achieved through 
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GAG binding, 35K prevents the activation of receptors on the inflammatory cells, 
suggesting that 35K can bind both free and unbound CC-chemokines.  
When 35K binds, the release of intracellular calcium which normally occurs with 
CC-chemokine and CC-chemokine receptor binding is suppressed, causing a reduction in 
CC-chemokine activity (Lalani et al. 1998). Despite this, 35K does not prevent receptor 
activation. This is because CC-chemokine receptor and ligand activation is facilitated 
through N-terminal binding (Carfí et al. 1999; Salanga & Handel 2011) and 35K does not 
bind over the N-terminal or bind to residues within this site. Instead, activity is suppressed 
when 35K binds due to the loss of the essential connection of the CC-chemokine and CC-
chemokine receptor thereby preventing activation through the N-terminal. To further 
confirm the specificity of 35K binding to only the CC-chemokine class, it was found that 
incubation of 35K with CXCL8 did not affect the release of calcium (Alcami et al. 1998; 
Lalani et al. 1998; Smith et al. 1997). 
 
1.9.1. 35K in inflammatory disease 
The effect of broad-spectrum CC-chemokine inhibition by 35K has been 
investigated in a number of inflammatory-driven diseases. In the atherosclerosis-prone 
ApoE knockout mouse model, systemic delivery of an adenovirus to overexpress 35K 
protein (Ad35K) inhibited CC-chemokine activity in the plasma and aortas (Ali et al. 2005; 
Bursill et al. 2009). Ad35K infused mice also had reduced plaque macrophage recruitment 
and atherosclerotic plaque size in both short and long term 35K treatment studies as shown 
in Figure 1.12 (Bursill et al. 2004; Bursill et al. 2009). In short term studies, ApoE
-/-
 mice 
fed on a western diet for 6 weeks developed large atherosclerotic lesions in the aortic root 
(Figure 1.12A). However, intervention with adenovirus overexpressing 35K (Ad35K), 2 
weeks prior to sacrifice decreased atherosclerotic lesions by more than 50% compared to 
PBS and adenoviral controls (AdGFP). Additionally, macrophage infiltration was 
significantly reduced in the Ad35K treated mice compared to PBS and AdGFP. Similar 
results were seen, in a long term (12 week) study, in which ApoE
-/-
 mice fed a regular diet, 
were injected with a lentivirus to overexpress 35K (Lenti35K) (Figure 1.12B). Mice were 
found to have significantly reduced atherosclerotic plaques and macrophages in the aortic 
sinus of the mice injected with Lenti35K compared to PBS or LentiGFP. The beneficial 
effects of 35K have also been reported in other inflammatory-driven diseases, such as 
Page | 39  
 
acute peritonitis, where mice injected with an adenovirus overexpressing membrane-bound 
35K had less inflammatory cells in peritoneal exudates (Bursill et al. 2006). Studies in 
mouse livers that received Ad35K infusions exhibited reduced hepatitis and liver fibrosis 
in mice (Bursill et al. 2006; Seki et al. 2009). Additionally, 35K attached to a Fc fusion 
protein (35K-Fc) improved pulmonary function and reduced inflammation in the lung 
(Dabbagh et al. 2000) 
In summary, broad-spectrum CC-chemokine inhibition by 35K has potent anti-
inflammatory effects in disease pathologies associated with inflammation. However, its 
effects have not as yet been investigated or compared in pathological and physiological 
angiogenesis. 
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Figure 1.12. Short and long term expression studies with 35K in ApoE
-/-
 mice. (Bursill et 
al. 2004; Bursill et al. 2009). 
(A) Short term expression with adenovirus overexpressing 35K, and (B) long term 
expression with lentivirus overexpressing 35K, reduced lesion size detected by determining 
area of the lesion, and macrophage infiltration detected by staining for Mac-3, in ApoE
-/-
 
mice compared to PBS and GFP controls.  
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1.10. Hypothesis and aims 
Angiogenesis associated diseases are widespread globally, with the World Health 
Organisation reporting that cardiovascular disease (CVD) and cancer are the leading 
causes of mortality worldwide (WHO 2013). Current anti-angiogenic agents cause severe 
side effects due to the inhibition of angiogenesis in both pathological and physiological 
conditions. Thus, there is a need to find an alternate therapeutic approach to overcome the 
shortcomings of current treatments. 
Angiogenesis is regulated via different, yet partially overlapping, pathways in 
inflammation and hypoxia. There is increasing evidence that chemokines regulate 
angiogenesis, with the CC-chemokine class playing an important role in pathological 
inflammatory-driven neovascularisation, while having little to no effect on physiological 
ischaemia-mediated angiogenesis. With this in mind, broad-spectrum inhibition of the CC-
chemokine class may be an alternate approach to overcome the often severe side effects 
caused by the global inhibition of angiogenesis by current anti-angiogenic therapies. This 
strategy will also have advantages over single CC-chemokine inhibition due to 
redundancies in chemokine signalling and the multifaceted role of CC-chemokines in 
inflammatory diseases. The broad-spectrum CC-chemokine inhibitor 35K has been shown 
to have positive outcomes in pre-clinical models of inflammatory-driven diseases including 
atherosclerosis, liver fibrosis and acute peritonitis. However, its role in the regulation of 
angiogenesis, and a comparison between inflammatory and hypoxic conditions remains to 
be explored. 
Given the above rationale, the central hypothesis of this thesis is that broad-
spectrum inhibition of the CC-chemokine class may suppress unwanted pathological 
inflammatory-driven angiogenesis whilst preserving physiological ischaemia-mediated 
angiogenesis. Broad-spectrum inhibition of the CC-chemokine class by 35K may be an 
alternate therapeutic strategy to reduce neovascularisation in pathological angiogenesis-
associated diseases such as atherosclerosis and cancer, without the severe side effects of 
current non-selective angiogenic inhibitors that block angiogenesis in all 
pathophysiological contexts. 
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The main aims of this work are to determine the importance of chemokines, 
specifically the CC-chemokine class, in the regulation of angiogenesis in both pathological 
and physiological contexts. Specifically, using the broad-spectrum CC-chemokine inhibitor 
35K, we seek to: 
1. Elucidate the role of broad-spectrum CC-chemokine inhibition on functional 
angiogenic assays and key angiogenic mediators in vitro in inflammatory and 
hypoxic conditions. 
2. Investigate the effect of broad-spectrum CC-chemokine inhibition in two 
animal models that represent pathological and physiological angiogenesis: (a) 
the peri-arterial femoral cuff model and (b) the hindlimb ischaemia model. 
3. Explore the effect of broad-spectrum CC-chemokine inhibition in a tumour 
neovascularisation model that is driven by both inflammation and ischaemia.  
4. Determine the effect of broad-spectrum CC-chemokine inhibition in a mouse 
model of wound healing, where angiogenesis is critical in the early-mid phases 
of healing. 
 
To achieve these aims we tested purified 35K protein in in vitro angiogenesis 
studies outlined in Chapters 3 and 4. We next investigated in Chapter 5 the effect of 35K in 
in vivo angiogenesis models using an adenoviral gene transfer approach in which mice 
were injected with an adenovirus overexpressing 35K (Ad35K) protein systemically. 
Chapter 5 compares and contrasts the effects of 35K on two murine surgical models of 
angiogenesis, namely the peri-arterial cuff model (inflammatory-driven) and the hindlimb 
ischaemia model (ischaemia-mediated). Chapter 6 explores the effect of 35K on a Lewis 
Lung cancer model and Chapter 7 describes the effect of CC-chemokine inhibition in a 
murine model of wound healing with topical application of purified 35K protein. 
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CHAPTER 2.       
GENERAL METHODS 
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This Chapter will outline the general materials and methods used throughout the thesis. 
2.1. Solutions 
Reagents Manufacture 
1-Bromo-3-Chloropropane  Sigma-Aldrich, Missouri, USA 
3,3′-Diaminobenzidine Substrate Dako, Glostrup, Denmark 
Acetic Acid Sigma-Aldrich, Missouri, USA 
Acetone Sigma-Aldrich, Missouri, USA 
Acid Fuchsin Sigma-Aldrich, Missouri, USA  
Alexa Fluor® 350 Goat Anti-Rat IgG 
(H+L) 
Invitrogen, California, USA 
Antibody Diluent With Background 
Reducing Compound 
Dako, Glostrup, Denmark 
Anti-CD31 Antibody Abcam, Cambridge, UK 
Anti-CD31 Antibody [390] 
(Phycoerythrin) 
Abcam, Cambridge, UK 
Anti-CD68 Antibody [ED1] Abcam, Cambridge, UK 
Anti-HA Tagged Bead Conjugate Sigma-Aldrich, Missouri, USA  
Anti-Laminin Antibody [AL-4] Abcam, Cambridge, UK 
Anti-TATA Binding Protein TBP 
Antibody [1TBP18] - Nuclear Loading 
Control And Chip Grade 
Abcam, Cambridge, UK 
Anti-VEGF Antibody Abcam, Cambridge, UK 
BCA Reagent A 
Thermo Fisher Scientific, Massachusetts, 
USA 
BCA Reagent B (Copper Sulphate) 
Thermo Fisher Scientific, Massachusetts, 
USA 
Bolt® MES SDS Running Buffer  Life Technologies, California, USA 
Bovine Serum Albumin Sigma-Aldrich, Missouri, USA 
Caesium Chloride Sigma-Aldrich, Missouri, USA 
Calcein AM Invitrogen, California, USA 
Cholesterol E Kit  Wako Diagnostics, Virginia, USA  
Clarity Western ECL Subs Biorad, California, USA 
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Click-iT® EdU Alexa Fluor 488 Cell 
Proliferation Kit 50 Assays 
Life Technologies, California, USA 
DMEM 293 Cell Culture Media Sigma-Aldrich, Missouri, USA  
DPX mountant for histology Sigma-Aldrich, Missouri, USA  
EBM-2 Lonza, Basel, Switzerland 
Envision™ FLEX Wash Buffer Dako, Glostrup, Denmark 
Ethanol Sigma-Aldrich, Missouri, USA 
Fluorescent Mounting Media Dako, Glostrup, Denmark 
Foetal Bovine Serum Bovogen Biologicals, Victoria, Australia 
Formaldehyde 16% Solution (From 
Paraformaldehyde) 
Sigma-Aldrich, Missouri, USA  
Glycerol Sigma-Aldrich, Missouri, USA  
Goat Anti-Mouse Secondary Antibody 
Conjugated With HRP 
Santa Cruz Biotechnologies, Texas, USA 
Goat Anti-Rabbit Secondary Antibody 
Conjugated With Horse-Radish Peroxidase 
(HRP) 
Santa Cruz Biotechnologies, Texas, USA 
Growth Factor Reduced Matrigel BD Bioscience, Massachusetts, USA 
HBSS Sigma-Aldrich, Missouri, USA  
HEPES Sigma-Aldrich, Missouri, USA  
HIF-1 Alpha Antibody Novus Biological, Colorado, USA 
Hydrochloric Acid Sigma-Aldrich, Missouri, USA  
Hydrogen Peroxide 
Thermo Fisher Scientific, Massachusetts, 
USA 
iBlot® Transfer Stack, Mini 
(Nitrocellulose) 
Life Technologies, California, USA 
Interferon Gamma Human Sigma-Aldrich, Missouri, USA  
IQ SYBR Green Supermix Biorad, California, USA 
iScript cDNA Synthesis Kit  Biorad, California, USA 
Isopropanol Sigma-Aldrich, Missouri, USA  
L-Glutamine Lonza, Basel, Switzerland 
Magnesium Chloride Sigma-Aldrich, Missouri, USA  
MesoEndo Endothelial Cell Media Cell Applications Inc., California, USA 
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Methanol Sigma-Aldrich, Missouri, USA  
Methoxyflurane Lyppard Australia, NSW, Australia 
Monoclonal Anti-Actin, -Smooth Muscle 
- Alkaline Phosphatase Antibody Produced 
In Mouse 
Sigma-Aldrich, Missouri, USA  
Monoclonal Anti-Actin, -Smooth Muscle 
- FITC Antibody Produced In Mouse 
Sigma-Aldrich, Missouri, USA  
Monoclonal Anti-HA−Agarose Antibody 
Produced In Mouse 
Sigma-Aldrich, Missouri, USA  
Mouse CCL2/MCP-1 Quantikine ELISA 
Kit 
R&D Scientific, Minnesota, USA 
Mouse VEGF Quantikine ELISA Kit, 2 
Plate 
R&D Scientific, Minnesota, USA 
Mouse/Rat CCL5/RANTES Quantikine 
ELISA Kit, 2 Plate (1 KT) 
R&D Scientific, Minnesota, USA 
NE-PER Nuclear And Cytoplasmic 
Extraction Kit 
Thermo Fisher Scientific, Massachusetts, 
USA 
Normal Goat Serum Abcam, Cambridge, UK 
Novex® LDS Sample Buffer  Life Technologies, California, USA 
Novex® Reducing Agent   Life Technologies, California, USA 
Nuclease Free Water Promega, Wisconsin, USA 
PBS Sigma-Aldrich, Missouri, USA  
Phosphomolybdic Acid Sigma-Aldrich, Missouri, USA  
Polyethylene Glycol Sigma-Aldrich, Missouri, USA  
Potassium Chloride Sigma-Aldrich, Missouri, USA  
Potassium Dichromate Sigma-Aldrich, Missouri, USA  
Pre-Diluted HRP Secondary Antibody -
Rabbit 
Dako, Glostrup, Denmark 
Rabbit Anti-NF-B p65 Abcam, Cambridge, UK 
Rabbit Anti-VEGF  Abcam, Cambridge, UK 
Rat Tail Collagen Coating Solution (20 
mL) 
Cell Applications Inc., California, USA 
RPMI 1640 Sigma-Aldrich, Missouri, USA  
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Seeblue® Plus2 Pre-Stained Protein 
Standard  
Life Technologies, California, USA 
Sepharose® CL-4B Sigma-Aldrich, Missouri, USA  
Smooth Muscle -Actin FITC Sigma-Aldrich, Missouri, USA  
Sodium Chloride Sigma-Aldrich, Missouri, USA  
Sodium Citrate Dihydrate Sigma-Aldrich, Missouri, USA 
Sodium Fluoride Sigma-Aldrich, Missouri, USA 
Sodium Orthovanadate Sigma-Aldrich, Missouri, USA  
Sodium Pyrophosphate Tetrabasic Sigma-Aldrich, Missouri, USA 
Sodium Thiocyanate Sigma-Aldrich, Missouri, USA 
Tissue-Tek® O.C.T. COMPOUND  Proscitech, Queensland, Australia 
TRI Reagent Sigma-Aldrich, Missouri, USA 
Triglyceride E Kit  Wako Diagnostics, Virginia, USA  
Tris-HCl Sigma-Aldrich, Missouri, USA  
Triton X-100 Sigma-Aldrich, Missouri, USA  
Tween-20 Sigma-Aldrich, Missouri, USA  
VECTOR Red Alkaline Phosphatase 
Substrate Kit 
Vector Laboratories, California, USA 
Xylene Fronine, NSW, Australia 
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2.2. In vitro methodology 
2.2.1. Cell Culture 
Cell culture experiments were conducted under 3 different conditions: 1) 
unstimulated controls, 2) inflammation or 3) hypoxia. To mimic the inflammatory 
environment, human coronary artery endothelial cells (HCAECs) were incubated with 
macrophage-conditioned media (MCM), while the hypoxic environment was achieved by 
incubation in a hypoxic incubator with conditions of 1% O2/5% CO2. 
 
2.2.1.1 Human monocyte derived macrophages (HMDM) 
Human monocyte derived macrophages (HMDMs) were used to produce 
macrophage-conditioned media (MCM). MCM was used instead of TNF-α or IFN-γ as the 
release of pro-inflammatory cytokines and growth factors, such as VEGF, bFGF, PDGF, 
TNF-α, and IFN-γ, from stimulated HMDMs, is more physiologically relevant to the 
endothelial cells. Human monocytes were isolated by elutriation and seeded at 1x106 
cells/well in 6 well plates, and grown for 12 days in RPMI 1640 supplemented with 10% 
(v/v) FBS. To stimulate the release of pro-inflammatory cytokines and growth factors into 
the media, HMDMs were stimulated with 10 ng/mL of interferon-γ at day 10 for 48 hours. 
After stimulation, the media was collected and centrifuged at 2,500 rpm for 5 minutes to 
remove cellular debris, and the supernatant was stored in 1 mL aliquots at -80oC until 
further use.  
 
2.2.1.2 Human coronary artery endothelial cells (HCAEC) 
Human coronary artery endothelial cells (sourced from ATCC) were used from 
passage 3 up to passage 6 and maintained in MesoEndo endothelial media. 
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2.2.1.3 AD293 cells 
Frozen AD293 cells were re-suspended in DMEM 293 media containing 10% (v/v) 
FBS. For viral amplification, cells were grown to 70 – 80% confluency in 20 T175 cm2 
flasks. 
 
2.2.2. Generation of Adenovirus expressing 35K 
A recombinant adenovirus expressing 35K (Ad35K) was generated by cloning the 
35K open reading frame which also contains a HA epitope tag upstream from its promoter 
region (Figure 2.1) into a pShuttle-CMV (ps) plasmid (Figure 2.2), creating the ps35K 
plasmid. The ps35K plasmid was then transfected into AD293 cells to create recombinant 
Ad35K virus. Adenovirus overexpressing GFP (AdGFP) was generated in the same way to 
use as an adenoviral control.  
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Figure 2.1. Ad35K construct (Bursill et al. 2003) 
 
 
Figure 2.2.Cloning map of pShuttle-CMV (He et al. 1998) 
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2.2.3. Large scale Adenovirus production 
To generate large quantities of Ad35K and AdGFP, 5 – 6 x 1011 virus particles (vp) 
of the recombinant Ad35K or AdGFP virus were added to 400 mL DMEM 293 cell culture 
media (D5546, Sigma-Aldrich, Missouri, USA) supplemented with 10% (v/v) foetal 
bovine serum (SFBS, Bovogen Biologicals, Victoria, Australia) and L-Glutamine (17-
605C, Lonza, Basel, Switzerland). This media containing the virus was divided equally 
over 20 T175cm
2
 flasks (20 mL/flask) of AD293 cells at 70 – 80 % confluency in the 
incubator at 37
o
C. After 24 – 48 hours cells were then microscopically examined for 
evidence of complete cytopathic effect (CPE). This is indicated by the cells in the 
monolayer starting to round up and they then start to detach from the flask. A change in 
media colour was also observed from pink to orange. Flasks were forcefully tapped to 
detach remaining cells. Pooled media and cells were centrifuged at 4,500 rpm for 30 
minutes. The media, known to contain high amounts of secreted 35K protein following 
Ad35K infection, was removed from the cell pellet that contains the viral particles, 
collected in 50 mL Falcon tubes and stored at -20
o
C to be used for in vitro studies. The cell 
pellet was resuspended in 10 mL hypotonic VSB (26 mM Tris-HCl, 5 mM KCl, 2 mM 
MgCl2, pH 7.4) and stored at -80
o
C overnight. The following day the cell suspension was 
freeze thawed twice, before centrifuging at 2,200 rpm for 10 minutes. The supernatant was 
removed and kept on ice, while the pellet was resuspended in a further 10 mL of hypotonic 
VSB and re-spun at 2,200 rpm for 10 minutes. The supernatant was pooled and density 
adjusted to 1.1 – 1.2 g/mL by adding caesium chloride (CsCl) before filtering with 0.22 
m filter. 
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2.2.4. Purification of Adenovirus 
To purify adenovirus from the pooled supernatant, 2.5 mL hypertonic VSB (26 mM 
Tris-HCl, 5 mM KCl, 2 mM MgCl2, 139 mM NaCl, pH 7.4) solution with a density of 1.4 
g/mL was carefully underlayed under 2.5 mL hypertonic VSB solution with a density of 
1.3 g/mL in a 12 mL polyallomer centrifuge tube (331372, Beckman Coulter, California, 
USA). The viral supernatant was overlayed above this solution to fill the remainder of the 
tube (approximately 7 mL) leaving 5 mm without solution. Tubes were transferred to 
centrifuge holders from the SW 41 Ti rotor (Beckman Coulter). Three tubes were made per 
viral construct. Tubes were centrifuged at 30,000 rpm at 4
o
C for 2 hours in the 
ultracentrifuge. After 2 hours the resolving virus band was collected by piercing the tube 
approximately 1 cm below the white virus band (Figure 2.3) with an 18 gauge needle 
(SG2-1838, Terumo Medical Corporation, New Jersey, USA) and drawn out with a 1 mL 
syringe (SS+01T, Terumo [Philippines] Corporation, Laguna, Philippines), extra care was 
taken to avoid collection of any cellular debris present above the virus band. The virus was 
further purified in a caesium chloride density gradient via a second ultracentrifugation at 
30,000 rpm at 4
o
C for 15 hours. After 15 hours the virus was collected and desalted by 
centrifuge filtration in columns of 50% (v/v) CL-4B sepharose (CL4B200, Sigma-Aldrich) 
at 1,000 rpm for 3 minutes. The sepharose column was initially washed twice with 
hypotonic VSB and the virus was run over two separate columns as part of the de-salting 
process. 
Total virus particles of the purified Ad35K or AdGFP were measured using a 
spectrophotometer (SmartSpec Plus, BioRad, California, USA) by measuring the 
absorbance at 260 nm (1 A260 = 1x10
12
 vp). Purified virus was diluted 1:1 in a mix of 80% 
foetal bovine serum (FBS) and 20% glycerol, and aliquots of 1x10
11
 vp were frozen at -
80
o
C.  
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Figure 2.3. Virus band seen following 2 hour CsCl gradient ultracentrifugation with 
cellular debris above 
 
2.2.5. Protein 35K isolation 
Column purification was used to isolate HA-tagged 35K protein from the viral 
media. Anti-HA tagged bead conjugate (A2095, Sigma-Aldrich) was added to an empty 
chromatography column and allowed to settle by gravity flow, the beads were packed into 
the column with 3 washes of PBS. The column was further washed with 15 mL 3 M 
sodium thiocyanate, to lower the pH, and then washed once more with 15 mL PBS. To 
bind HA-tagged 35K protein to the anti-HA beads, 40 mL of the 35K adenoviral media, 
collected during virus production, was passed through the column by gravity flow. The 
35K protein was eluted from the beads in 1 mL aliquots of 3 M sodium thiocyanate and 
collected in Eppendorf tubes containing 50 L 1 M Tris-HCl (pH 8) to neutralise the 
solution. A total of 10 fractions were collected and tested via Western blot to confirm the 
presence of 35K. 
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2.2.6. Western blot to determine 35K in fraction 
To confirm the presence of 35K isolated protein, eluted column fractions were run 
on a Western blot. From each fraction 10 L was taken and combined with 5 L Novex® 
LDS sample buffer (B0007, Life Technologies, California, USA) and 1 L Novex® 
reducing agent (NP0009, Life Technologies) and heated at 95
o
C for 5 minutes, before 
placing the tubes on ice for 2 minutes. Reduced samples and SeeBlue
®
 Plus2 Pre-stained 
Protein Standard (LC5925, Life Technologies) were loaded onto wells of a 12-well Bolt
®
 
4% Bis-tris plus gel (NW04122BOX, Life Technologies) and ran at 100 V for 90 minutes 
in 1X Bolt
®
 MES SDS Running Buffer (B0002, Life Technologies). Proteins from the gel 
were then transferred onto nitrocellulose membranes using the iBlot
®
 Transfer Stack 
(IB3010-31, Life Technologies) and iBlot Gel Transfer system (IB21001, Life 
Technologies). Membranes were blocked in 10% (w/v) skim milk in TBST (20 mM Tris, 
136 mM NaCl, and 0.1% [w/v] Tween 20, pH 7.4) for 1 hour at room temperature on a 
rocking platform. Following this, membranes were washed 3 times in TBST for 5 minutes 
at room temperature before incubating with rabbit anti-35K primary antibody (1:1000, 
Peter Turner, University of Florida, Gainesville, FL, USA) overnight at 4
o
C. The 
membranes were washed before incubating with goat anti-rabbit secondary antibody 
conjugated with horse-radish peroxidase (HRP) (sc-2030, Santa Cruz Biotechnologies, 
Texas, USA) (1:1000) in 2% (w/v) skim milk in TBST for 2 hours at room temperature. 
Membranes were developed by chemiluminescence on the Chemidoc MP Imaging 
System (170-8280, BioRad with ECL reagents in a 1:1 ratio of Clarity Western Peroxide 
Reagent and Clarity Western Luminol/Enhancer Reagent (170-5061, Biorad). Images were 
recorded every 1 second using Image Lab Software (v.5.0, 170-9692, BioRad) with a total 
exposure time of 10 seconds.  
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Figure 2.4. Western blot of eluted column fractions showed that isolated 35K protein is 
detected predominantly in the second fraction. 
 
2.2.7. Functional studies 
Three functional angiogenic assays were used to assess the effect of 35K on the 
functional angiogenic properties of HCAECs. All experiments were performed in triplicate 
and repeated at least 3 times under inflammatory conditions stimulated by MCM or 
hypoxic conditions stimulated by 1% O2/5% CO2 and N2 balance in a hypoxic incubator. 
 
2.2.7.1 Proliferation assay 
Human coronary artery endothelial cells (HCAECs) were plated on 6-well plates at 
3.8 x 10
4
 cells/well in EBM-2 (Lonza) supplemented with 5% (v/v) FBS to serum starve 
cells overnight. 
Cells were then incubated for 4 hours with 50% (v/v) PBS (control) in EBM-2 with 
FBS or 50% (v/v) MCM in EBM-2 with FBS and 35K (0 – 400 nM) or subjected to 
hypoxia (1% O2/ 5% CO2) in EBM-2 with FBS. After incubation, 0.1% (v/v) EdU in 
MesoEndo media or RPMI media was added overnight. Proliferation was determined the 
following day using the Click-IT
®
 EdU assay (C10425, Life Technologies) and 
proliferating cells were detected by flow cytometry (FC-500, Beckman and Coulter, CA, 
USA). Briefly, cells were harvested in PBS with 10% (v/v) FBS and centrifuged at 3.4 rcf 
for 4 minutes. The pellet was resuspended in 50 L PBS with 10% (v/v) FBS. Cells were 
fixed in 50 L Click-iT fixative D (4% paraformaldehyde) and incubated for 15 minutes 
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protected from light at room temperature before washing in PBS with 10% FBS and 
centrifuged for 4 minutes at 3.4 rcf. Samples were vortexed with 50 L 1X saponin 
permeabilisation buffer (E) and 50 L Click-iT reaction mix (285 L Click-iT reaction 
buffer [G], 6.5 L CuSO4 [H], 1.6 L fluorescent dye azide – Alex Fluor 488 [B] and 32.5 
L 1xClick-iT-EdU buffer [I]). Samples were incubated for 30 minutes at room 
temperature protected from light. Following incubation cells were washed in 1 mL 1X 
buffer E and centrifuged at 3.4 rcf for 4 minutes. Supernatant was discarded and cells 
resuspended in 500 L buffer E. Cells were transferred to FACs tubes and measured by 
flow cytometry. 
 
2.2.7.2 Migration assay 
Lab-Tek chamber slides (177437, Thermo Fisher Scientific, Massachusetts, USA) 
were coated in 670 L/well rat tail collagen coating solution (122-20, Cell Applications 
Inc.) and incubated at 37
o
C for 1 hour. During this time 5 mL of HCAECs at a cell density 
of 8x10
4
 cells/mL were prepared by resuspending in EBM-2 media with 5% FBS. 
Following the 1 hour incubation, the remaining collagen was removed and each well 
washed with HT-PBS at least 3 times. Finally, wells were rinsed with EBM-2, 5% FBS and 
L-glutamate before 1 mL/well of cell suspension at a density of 8 x 10
4
 cells/mL was 
added. Cells were allowed to adhere for 6 hours before proceeding with scratch assay.  
A P200 pipette tip was used to scratch a basic grid pattern through the cell layer. 
The media was removed and replaced with treatments in MesoEndo media. Cells were then 
incubated in PBS (control) or MCM and 35K (0 – 50 nM) and monitored over at least 10 
hours by live cell imaging (Zeiss Axiovert 200M, Germany) at 37
o
C/ 5% CO2. Images 
were measured from three sites along the scratch per well. For hypoxic conditions, cells 
were plated out and allowed to adhere overnight. Media was changed in the morning to 
MesoEndo media and cells were subjected to hypoxia (1% O2/ 5% CO2) or normoxia for 6 
hours. A grid pattern scratch was then made through the cell layer and cells were incubated 
in PBS and 35K (0 – 50 nM) then subjected to live cell imaging as described above. The 
average distance between cell fronts of the scratch was measured at 2 hour intervals for up 
to 10 hours; this was used to determine the speed of migration. 
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2.2.7.3 Tubulogenesis assay 
Thawed growth factor reduced matrigel (356231, BD Bioscience, Massachusetts, 
USA) were carefully plated at 40 L/well into a 96 well plate, ensuring no bubbles were 
present, and left to polymerise at 37
o
C for 30 minutes. HCAECs were plated at 9x10
4
 
cells/mL in 100 L MesoEndo Endothelial Cell Media (212-500, Cell Applications Inc., 
California, USA) and 35K (0 – 50 nM) under inflammation, stimulated with 50% MCM 
(v/v), or hypoxic (1% O2/ 5% CO2) conditions at 37
o
C for 4 – 6 hours. HCAEC tubule 
formation was imaged at 10X magnification and counted in a minimum of 3 fields of view 
per well using Image J (National Institutes of Health, Maryland, USA).  
 
2.2.8. Mechanistic studies 
2.2.8.1 Protein extraction 
To elucidate the mechanisms of 35K action, key angiogenic markers were detected 
by Western blot. To measure protein expression, HCAECs were plated in 6 well plates at a 
cell density of 1.5x10
5
 cells/mL for inflammation and 8x10
4
 cells/mL for hypoxia. 
For the experiments with an inflammatory stimulus, cells were incubated for 4 
hours in either control conditions of MesoEndo endothelial media only or the inflammatory 
stimulus comprised of 50% (v/v) MCM + 50% (v/v) MesoEndo endothelial media and 35K 
(0 – 200 nM). Likewise in hypoxia, cells were incubated for 4 hours in MesoEndo 
endothelial media with or without 35K (50 – 200 nM) in hypoxia (1% O2/5% CO2) or 
normoxia. 
To collect treated cells, media was removed and cells washed once in cold PBS. 
Cells were scraped in 100 L radioimmunoprecipitation assay (RIPA) lysis buffer (20 mM 
Tris-HCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl 
fluoride, 1.5 μg/mL aprotinin, 1 μg/mL leupeptin, 1 μg/mL pepstatin, 1 mM sodium 
orthovanadate, and 0.2% Triton X-100; pH 7.4), protease inhibitor cocktail (1:100, P8340, 
Sigma-Aldrich), and phenylmethanesulfonyl fluoride solution (93482, Sigma-Aldrich), and 
transferred to Eppendorf tubes. Each sample was sonicated for 2 seconds to further lyse the 
sample. Samples were centrifuged for 10 minutes at 14,000 rpm at 4
o
C and stored at -80
o
C. 
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2.2.8.2 Nuclear extraction 
To extract the nuclear fraction of incubated cells the NE-PER Nuclear and 
Cytoplasmic Extraction kit (PIE78833, Thermo Fisher Scientific) was used. In 6 well 
plates, cells were washed in cold PBS prior to adding 100 L ice cold CER I reagent to 
each well. Cells from each well were scraped on ice and transferred to Eppendorf tubes 
kept on ice. Tubes were vortexed for 15 seconds before incubation on ice for 10 minutes. 
Following this, 5 L CER II reagent was added, tubes were vortexed for 5 seconds and 
allowed to incubate on ice for 1 minute. Tubes were vortexed once more prior to 
centrifugation at 16,000 g for 5 minutes at 4
o
C. The supernatant containing the cytoplasmic 
fraction was transferred to a new tube and stored at -80
o
C. The pellet containing the 
nuclear fraction was resuspended in 50 L ice cold NER reagent by vortexing for 15 
seconds at 10 minute intervals for a total of 40 minutes. Samples were kept on ice between 
vortexing. Finally samples were centrifuged at 16,000 g for 10 minutes and the supernatant 
containing the nuclear fraction was transferred to new Eppendorf tubes and stored at -80
o
C.  
 
2.2.8.3 Protein estimation 
The protein concentration for each sample was determined using the Bicinchoninic 
(BCA) Protein Assay (Thermo Fisher Scientific). A standard curve using bovine serum 
albumin (BSA, A7906-100G, Sigma-Aldrich ) concentrations of 0, 0.25, 0.5, 0.75, 1.0, 
1.25, 1.5, 2.0 mg/mL was constructed from 2 mg/mL BSA stock as prepared in Table 2.1. 
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Table 2.1. Standard protein concentrations 
BSA (mg/mL) BSA stock (L) MilliQ water (L) 
0.0 0 600 
0.25 75 525 
0.5 150 450 
0.75 225 375 
1.0 300 300 
1.25 375 225 
1.5 450 150 
2.0 600 0 
  
The assay was conducted in a 96 well plate. Each well contained 10 μL of standard  
or sample in duplicate, and 190 μL of reagent mix consisting of 50 parts reagent A (23223, 
Thermo Fisher Scientific) and 1 part reagent B (copper (II) sulphate) (23224, Thermo 
Fisher Scientific). The assay was incubated at 37
o
C for 30 minutes and absorbance of each 
well measured at 595 nm using microplate reader (Flex Station 3, Molecular Devices, 
California, USA) using the SoftMax Pro program (v5.3, Molecular Devices, California, 
USA) for microplate data acquisition and analysis. The protein concentration of unknown 
samples were interpolated from the standard curve. 
 
2.2.8.4 Western blot 
Extracted whole cell protein lysate was used to determine changes in VEGF, HIF-
1α, PHD1-3. The nuclear fraction was used to detect protein levels of the active subunit of 
NF-κB (p65). 
Equal protein (20 g for VEGF, HIF-1α, PHD1, PHD2, PHD, 3 g for p65) was 
loaded on each gel. To prepare samples, protein was added to 5 L Novex® LDS sample 
buffer (Life Technologies) with 1 L Novex® reducing agent (Life Technologies) and 
made up to 40 L with distilled H2O. Samples were denatured by heating at 95
o
C for 5 
minutes before placing on ice for 2 minutes. Samples and SeeBlue
®
 Plus2 Pre-stained 
Protein Standard (Life Technologies) were loaded into 12 well Bolt
®
 4% Bis-tris plus gel 
(Life Technologies) and run at 100 V for 90 minutes in Bolt
®
 MES SDS Running Buffer 
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(Life Technologies) diluted in distilled H2O. Proteins from the gel were then transferred 
onto nitrocellulose membranes (Life Technologies) using the iBlot Gel Transfer system 
(Life Technologies) run at 20 V for 7 minutes. Membranes were blocked in 10% (w/v) 
skim milk in TBST (20 mM Tris, 136 mM NaCl, and 0.1% [w/v] tween 20, pH 7.4) for 1 
hour at room temperature on a rocking platform. Following this, membranes were washed 
3 times in TBST for 5 minutes at room temperature before probing with primary antibodies 
for either rabbit anti-VEGF (1:1000, Ab46154, Abcam, Cambridge, UK), mouse anti- HIF-
1α (1:1000, NB100-105, Novus Biologicals, Colorado, USA), mouse anti-PHD1 (NB100-
310, Novus Biological), mouse anti-PHD2 (NB100-2219, Novus Biological), mouse anti-
PHD3 3 (NB100-303, Novus Biological), or rabbit anti-NF-B p65 (1:1000, Ab32536, 
Abcam) in 2% (w/v) skim milk overnight at 4
o
C. The membranes were washed before 
incubating with goat anti-rabbit secondary antibody conjugated with horse-radish 
peroxidase (HRP) (1:1000, sc-2030, Santa Cruz Biotechnologies) or goat anti-mouse 
secondary antibody conjugated with HRP (1:1000, sc-2005, Santa Cruz Biotechnologies) 
in 2% (w/v) skim milk in TBST for 2 hours at room temperature. To account for protein 
loading, membranes were probed for either anti--tubulin (AB40742, Abcam) in the whole 
cell lysate samples or anti-TATA-binding protein TBP (AB818, Abcam) for the nuclear 
fractions. 
Membranes were developed by chemiluminescence on the Chemidoc MP Imaging 
System (170-8280, BioRad) with ECL reagents in a 1:1 ratio of Clarity Western Peroxide 
Reagent and Clarity Western Luminol/Enhancer Reagent (170-5061, Biorad). Images were 
recorded using Image Lab Software (v.5.0, 170-9692, BioRad). 
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2.3. In vivo methodology 
2.3.1. Animal studies 
All experimental procedures and protocols were conducted with approval from the 
Central Sydney Area Health Service Animal Welfare Committee (#2013/027A), and 
conformed to the Guide for the Care and Use of Laboratory Animals (USA National 
Institute of Health). For all animal studies male C57BL/6J mice were used at 6 – 8 weeks 
old. Mice were housed for up to one week in quarantine prior to experimentation. Four in 
vivo studies were completed; these included the peri-arterial cuff model, the hindlimb 
ischaemia model, the tumour neovascularisation model, and the wound healing model.  
The peri-arterial cuff model, is a model of inflammatory-driven angiogenesis. A 
non-occlusive polyethylene cuff is placed around the femoral artery. This induces 
inflammation, which triggers macrophage recruitment. The macrophages secrete growth 
factors to the site of injury. The opposite leg is sham operated. The hindlimb ischaemia 
model is a model of hypoxia/ischaemia-mediated angiogenesis. The femoral artery and 
vein is removed from the hindlimb to induce ischaemia. The opposite leg is sham operated. 
The tumour neovascularisation model, involves injecting Lewis Lung Carcinoma (LLC) 
cells into the right flank of the treatment mice. The tumour grows over a time period of 12 
days and angiogenesis in this model is driven by both hypoxia and inflammation. For the 
wound healing model, where angiogenesis is critical in the early phases of the process, 
subcutaneous wounds are created on the back of the mice and silicone splints were secured 
to mimic the human process of wound healing. Expanded details of these animal models 
will be discussed in the relevant chapters. 
For the peri-arterial cuff, hindlimb ischaemia, and tumour neovascularisation model 
mice were injected intravenously with adenovirus overexpressing either 35K (Ad35K) or 
GFP (AdGFP) or PBS three days prior to surgery. While for the wound healing model, 
topical delivery of treatments (purified 35K protein or PBS vehicle control) were used.  
 
2.3.2. Tail-vein injection 
For systemic delivery of adenovirus, intravenous injections were performed via the 
tail vein using 27 gauge x ½” Terumo insulin needle (SS10M2713, Terumo Medical 
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Corporation, New Jersey, USA). The mouse was warmed prior to injection and the animal 
was restrained during the procedure. Frozen virus was diluted in HT-PBS to a final 
injection volume of 200 L. 
 
2.3.3. Sacrifice  
Sacrifice was performed by an overdose of methoxyflurane anaesthetic followed by 
right ventricular puncture. For peri-arterial cuff model this was followed by circulatory 
perfusion with 10 mL of saline via the left ventricle.  
Mice were dissected and tissue, liver and blood samples were collected for 
histology, lipid profile, mRNA expression, and protein expression analyses. 
 
2.3.4. Blood collection 
At sacrifice, blood was collected by right ventricular puncture with a heparinised 1 
cc/mL syringe. Blood was kept on ice until centrifugation at 5,000 rpm for 5 minutes. 
Plasma was stored in 50 µL aliquots at -80°C. 
 
2.3.5. Laser Doppler 
The Laser Doppler imaging system (moorLDI2-IR, Moor instruments, Devon, UK) 
was used to determine blood flow perfusion to the site of injury. This was measured in the 
hindlimb ischaemia and wound healing models. Mice were anaesthetised by inhalation of 
methoxyflurane. After imaging mice were allowed to recover before returning to housing. 
For the hindlimb ischaemia study, mice were placed in the dorsal recumbent 
position to image the left and right hindlimbs. Images were taken pre- and post-surgery and 
at 2, 4, 7, 10, 12 and 14 days post-surgery, with three scans taken per mouse at each time 
point. 
For the wound healing study, mice were placed flat in the prone position to image 
the dorsum. Images were taken at either 1, 2, 3, and 4 days post-surgery for the early stage 
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cohort or at 2, 4, 7, 10 days post-surgery for the late stage cohort, with three scans taken 
per mouse at each time point. 
 
2.3.6. Histology 
2.3.6.1 Sample preparation 
Samples from the peri-arterial cuff and wound healing models, harvested for 
paraffin processing were placed in 4% (v/v) paraformaldehyde in PBS solution for 2 hours 
at room temperature before storing in 70% ethanol for processing. Samples were infused 
with paraffin using automated overnight processing with graded ethanol concentrations and 
then paraffin in a 7-hour run, before being embedded in blocks and stored at room 
temperature. 
Samples taken from the hindlimb ischaemia and tumour neovascularisation models, 
for fresh frozen processing were immediately placed in OCT, snap frozen in liquid 
nitrogen and stored at -80
o
C. 
 
2.3.6.2 Immunofluorescence 
Samples from the hindlimb ischaemia and tumour neovascularisation models, were 
sectioned on the CryoStar™ NX70 Cryostat (Thermo Fisher Scientific) at 7 m using the 
MX35 Premier Disposable Low-Profile Microtome Blades (3052835, Thermo Fisher 
Scientific) and mounted on to StarFrost
®
 advanced adhesive slides (G313, Proscitech) 
before drying at room temperature for at least 15 minutes. To stain, slides were fixed in 
cold acetone for 10 minutes and washed in PBS before staining in the DAKO Autostainer 
Plus (Dako, Glostrup, Denmark). The Autostainer Plus was programmed to rinse slides in 
1X Envision™ FLEX wash buffer (K8007, Dako), before proceeding with a 1 hour 
incubation in primary antibody solution comprised of antibodies for CD31 (1:500, 
AB25644, Abcam) to assess neovessels, smooth muscle -actin (1:1000, F3777, Sigma-
Aldrich) to assess arterioles, and laminin (1:300, AB79057, Abcam) to assess myocytes, in 
antibody diluent with background reducing agent (S080983-2, Dako). Following 
incubation with primary antibody, the autostainer was programmed to rinse slides in wash 
Page | 64  
 
buffer two times before a 1 hour incubation with Alexa Fluor 350 secondary antibody 
(1:500, A21093, Invitrogen, California, USA) in antibody diluent. Coverslips were 
mounted onto stained slides in fluorescent mounting media. Slides were allowed to dry for 
24 hours and kept in the dark before imaging. Samples were imaged at 10X magnification 
with 3 fields of view per section. 
 
2.3.6.3 Immunohistochemistry 
Paraffin samples were sectioned at 5 m using the microtome (Microm HM 200 
Ergostar, Walidorf, Germany) with  MX35 Premier Disposable Low-Profile Microtome 
blades and mounted to StarFrost
®
 advanced adhesive slides, drying overnight at 42
o
C 
before staining in Milligan‟s Trichrome or staining to detect CD31, smooth muscle -
actin, or CD68. To stain, slides were deparaffinised in 2 x 10 minute incubations of xylene 
and rehydrated in decreasing ethanol concentrations comprised of 2 x 2 minute washes in 
absolute ethanol, 90% ethanol and 70% ethanol to water.  
 
2.3.6.3.1 Milligan‟s Trichrome 
Milligan‟s Trichrome stain was used to visualise: muscle (pink), collagen (green), 
red blood cells (orange/red) and nuclei (purple) as seen in Figure 2.5. This stain was 
performed only in samples from the peri-arterial cuff and wound healing study. For the 
trichrome stain, slides were fixed in Bouin‟s solution (25088A, Polyscience Inc., 
Pennsylvania, USA) for 1 hour at 60
o
C before thoroughly rinsing in running water for 5 
minutes. Slides were incubated in solution A (2.25% [w/v] potassium dichromate, 2.25 mL 
HCl, 25% absolute ethanol [v/v] in distilled H2O) for 5 minutes. The potassium dichromate 
acts as a secondary fixative to preserve fine cell structures. Following a quick rinse by 
immersion in water, slides were stained for muscle by incubating in solution B (0.1% [w/v] 
acid fuchsin in distilled H2O) for 5 minutes. This produces a dark pink stain. After rinsing 
in water a differentiation step to differentiate between muscle and collagen occurs, where 
slides were incubated in solution C (1% [w/v] phosphomolybdic acid in distilled H2O) for 
5 minutes and rinsed in water. Red blood cells were stained by incubating slides in solution 
D (2% orange G [w/v], 1% [w/w] phosphomolybdic acid in distilled H2O) for 10 minutes 
and rinsed in water. Finally to stain collagen, slides were incubated in solution E (1% [v/v] 
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acetic acid in distilled H2O) for 2 minutes, before a 10 minute incubation in solution F 
(0.1% [w/v] Fast green FCF, 0,2% [v/v] acetic acid in distilled H2O) and an additional 3 
minute incubation in solution E. Acetic acid was used to further differentiate collagen from 
muscle and to maximise the intensity of the dye. Slides were dehydrated in increasing 
gradients of ethanol and cleared in xylene before mounting in dibutyl-pthalate in xylene 
(DPX). 
 
 
Figure 2.5. A Milligan’s trichrome stained femoral artery subjected to peri-arterial 
cuffing. 
 
2.3.6.3.2 CD31 staining to detect presence of capillaries 
To determine capillaries, CD31 immunohistochemical staining was performed on 
paraffin embedded tissue sections from the peri-arterial cuff and wound healing models. 
Antigen retrieval was performed by microwaving sections on a high power setting for 10 
minutes in citrate buffer. Slides were cooled in ice water before rinsing in PBST (PBS with 
0.1% [v/v] Tween-20) for 5 minutes. Endogenous peroxidase was blocked by incubation in 
hydrogen peroxide solution (3% H2O2 in methanol) for 30 minutes at room temperature 
followed by a 5 minute wash in PBST. Non-specific binding was prevented by blocking in 
goat serum (10% [v/v] normal goat serum [Ab156046, Abcam]  in PBS) for 4 hours at 
room temperature, which was followed by an overnight incubation of primary antibody 
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CD31 (1:100, Ab28364, Abcam) in antibody diluent at 4
o
C. Excess primary antibody was 
removed with two 5 minute washes in PBST, before a 30 minute incubation of pre-diluted 
HRP secondary antibody α-rabbit (K4011, Dako) for 30 minutes at room temperature. 
Excess secondary antibody was removed by two 5 minutes washes in PBST, prior to 
detection of horse radish peroxidase (HRP) enzyme by incubation in 3,3′-
Diaminobenzidine (DAB) substrate (K4007, Dako) as per the manufacturer‟s instructions. 
Slides were counterstained with haematoxylin, dehydrated in increasing gradients of 
ethanol and cleared in xylene before mounting in DPX. 
 
2.3.6.3.3 Smooth muscle α-actin staining to detect presence of arterioles 
To determine arterioles, smooth muscle α-actin staining was performed on sample 
sections. Antigen retrieval was performed by microwaving on high for 10 minutes in 
citrate buffer (10 mM sodium citrate tribasic dehydrate in 0.05% [w/v] Tween-20 at pH 
6.0). Slides were cooled in ice water before rinsing in PBST for 5 minutes. Endogenous 
peroxidase was blocked by incubation in hydrogen peroxide solution (3% H2O2 in 
methanol) for 30 minutes at room temperature followed by a 5 minute wash in PBST. Non-
specific binding was prevented by blocking in goat serum (10% [v/v] normal goat serum in 
PBS) for 2 hours at room temperature (ab156046, Abcam). This was followed by overnight 
incubation with a mouse α-smooth muscle cell-actin primary antibody conjugated to 
alkaline phosphatase (AP) at 1:100 (A5691, mouse monoclonal, Sigma-Aldrich) at 4
o
C. 
Excess primary antibody was removed by two 5 minute washes in PBST, followed by a 5 
minute incubation with 200 mM Tris-HCl. Vector Red alkaline phosphatase substrate (SK-
5100, Vector Laboratories, California, USA) was then incubated with the sections for 10 
minutes and colour change was halted in H2O. Slides were counterstained in haematoxylin, 
dehydrated in increasing gradients of ethanol and cleared in xylene before mounting in 
DPX. 
 
2.3.6.3.4 CD68 staining to detect presence of macrophages 
To determine macrophage infiltration, CD68 immunohistochemical staining was 
performed on paraffin embedded tissue sections. Antigen retrieval was performed by 
microwaving on high for 10 minutes in citrate buffer. Slides were cooled in ice water 
before rinsing in PBST for 5 minutes. Endogenous peroxidase was blocked by incubation 
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in hydrogen peroxide solution (3% H2O2 in methanol) for 30 minutes at room temperature 
followed by 5 minute wash in PBST. Non-specific binding was prevented by blocking in 
goat serum (10% [v/v] normal goat serum in PBS) for 4 hours at room temperature, which 
was followed by an overnight incubation of primary antibody CD68 (1:100, Ab31630, 
Abcam) in antibody diluent at 4
o
C. Excess primary antibody was removed with two 5 
minute washes in PBST, before 30 minute incubation of pre-diluted HRP secondary 
antibody α-rabbit (Dako) for 30 minutes at room temperature. Excess secondary antibody 
was removed by two 5 minutes washes in PBST, prior to detection of horse radish 
peroxidase (HRP) enzyme by incubation with DAB substrate as per the manufacturer‟s 
instructions. Slides were counterstained in haematoxylin, dehydrated in increasing 
gradients of ethanol and cleared in xylene before mounting in DPX. 
 
2.3.6.4 Image capture and processing 
Histology samples were photographed using a Zeiss microscope, attached to a 
digital camera (Axio Imager.Z2, Carl Zeiss Microscopy GmbH, Göttingen, Germany). 
Images were recorded digitally using a computer-assisted video-imaging system (v1.1.2.0, 
ZEN 2012, Carl Zeiss Microscopy, Göttingen, Germany). On the first image the megapixel 
count, aperture, shutter speed, white balance and ISO were set and used for all subsequent 
images. 
Images of arteries from the peri-arterial cuff model were taken at 20X 
magnification in one field of view. Images of skin samples from the wound healing model 
were taken at 10X using the tile function to image the whole sample by stitching multiple 
fields of view. Gastrocnemius muscle was imaged under fluorescent channels for FITC, 
alexa fluor 350 and phycoerythrin (R-PE) at 10X magnification in 3 fields of view per 
section. Similarly, tumour tissue was imaged under fluorescent channels for FITC and 
alexa fluor 350 at 10X magnification in 3 fields of view. 
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2.3.6.5 Image quantification 
All images were analysed digitally while being blinded to the treatment allocation. 
Image-Pro Premier software (v9.0.4, Media Cybernetics, Maryland, USA) was used for all 
analyses. 
For images taken under bright field (artery, from peri-arterial cuff model and 
wounds, from wound healing model), neovessels, arterioles, macrophages and collagen 
were quantified by setting the colour threshold of CD31, α-actin, CD68 and collagen 
(green) staining and optimised visually on the first image respectively, and the same 
parameters were used for all subsequent images. 
For images taken under fluorescence (muscle, from hindlimb ischaemia model and 
tumour, from tumour neovascularisation model), neovessels, arterioles and myocytes were 
quantified by setting the light threshold for CD31 and -actin, and the dark threshold for 
laminin, and optimised visually on the first image respectively with the same parameters 
then used for all subsequent images.  
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2.3.7. Real-time Polymerase Chain Reaction (RT-PCR) 
Real time PCR was used to detect changes in mRNA expression from samples 
obtained from femoral arteries, gastrocnemius muscle, tumours and wounds. 
 
2.3.7.1 RNA extraction 
Total RNA was isolated from femoral arteries following peri-arterial cuff surgery, 
gastrocnemius muscle following hindlimb surgery, tumours following the Lewis Lung 
carcinoma studies and healed wounds following wound healing studies. 
To homogenise artery samples from the peri-arterial cuff model, samples were 
sonicated in frozen 100 L TRI reagent (Sigma-Aldrich) for 10 seconds at 30% amplitude. 
To ensure complete homogenisation, samples were sonicated 3 times allowing TRI reagent 
to harden on dry ice after each sonication. 
For hindlimb muscle and wound samples, tissues were homogenised with 1.4 mm 
zirconium oxide beads (03961-1-103, Bertin Technologies) in 500 L TRI reagent, using 
the Precellys 24 homogeniser (Bertin Technologies) at 6,000 rpm for 30 seconds, 4 times. 
Between homogenisation, samples were centrifuged at 14,000 rpm for 1 minute at 4
o
C and 
allowed to rest on ice. Homogenised lysates were transferred to clean Eppendorf tubes. 
Following homogenisation of samples, 1/10 volume 1-Bromo-3-chloropropane 
(BCP) was added to the lysates. Volume was adjusted based on initial TRI reagent volume 
i.e. 10 L BCP to artery samples and 50 L BCP to muscle and skin samples. Samples 
were vortexed for 15 seconds, ensuring both phases were completely mixed, before 
centrifugation at 14,000 rpm for 15 minutes at 4
o
C. The aqueous (top) layer was 
transferred to a new Eppendorf tube containing 50 L (for artery) or 250 L (for muscle 
and skin) isopropanol and kept at -20
o
C overnight. 
The following day, samples were centrifuged at 14,000 rpm for 15 minutes at 4
o
C. 
Supernatant was removed, leaving a small RNA pellet at the bottom of the tube. The pellet 
was washed by adding 250 L of ice cold 75% (v/v) ethanol, vortexed and centrifuged 
again at 14,000 rpm for 10 minutes at 4
o
C. Ethanol was removed and the sample was air-
dried for 10 minutes in the hood. 20 L pre-warmed nuclease free water was added to the 
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RNA pellet and resuspended by pipetting. To aid in complete dissolution, samples were 
agitated in an Eppendorf thermomixer at 300 rpm for 5 minute intervals at 60
o
C for up to 
15 minutes.  
For the tumour samples the RNeasy fibrous tissue mini kit (74701, QIAGEN, 
Hilden, Germany) was used. Tissues were homogenised with 1.4 mm zirconium oxide 
beads (Bertin Technologies) in 300 L buffer RTL, using the Precellys 24 homogeniser 
(Bertin Technologies) spun at 6,000 rpm for 30 seconds, 2 times. Between 
homogenisation, samples were centrifuged at 14,000 rpm for 1 minute at 4
o
C and allowed 
to rest on ice. Homogenised lysates were transferred to clean Eppendorf tubes and 590 L 
RNase-free water and 10 L warmed (to 55oC on heating block) proteinase K was added. 
Eppendorf tubes were incubated at 55
o
C for 10 minutes before centrifuging for 3 minutes 
at 10,000 x g at room temperature. The supernatant was then transferred to a new 
eppendorf tube, being careful not to remove pellet. To the supernatant, 450 L ethanol is 
added and mixed thoroughly. 700 L of mixture was transferred to an RNeasy Mini spin 
column and place in a 2 ml collection tube. The column and tube was spun at 10,000 rpm 
for 15 seconds. After centrifuge, the flow through was discarded and the remainder of the 
sample mixture was centrifuged and flow through discarded. To the spin column, 350 L 
buffer RW1 was added, column was centrifuged for 15 seconds at 10,000 rpm. DNase 1 
mix (10 L DNase1 and 70 L buffer RDD) was added to the spin column and allowed to 
incubate for 15 minutes at room temperature. After incubation, 350 L RW1 was added to 
the spin column and centrifuged at 10,000 rpm for 15 seconds. Flow through was discarded 
before adding 500 L buffer RPE and centrifuged at 10,000 rpm for 15 seconds. Flow 
through was discarded before centrifuging again in 500 L RPE at 10,000 rpm for 2 
minutes. Finally a new collection tube is used to elute RNA by centrifuging with 50 L 
RNase-free water at 10,000 rpm for 1 minute. 
The amount of RNA was quantitated using a spectrophotometer (Nanodrop 
2000/2000c, Thermo Scientific, Massachusetts, USA). Absorbance was measured at 260 
and 280 nm, and the relative purity of the isolated RNA was calculated from the 
absorbance ratio (A260/A280). The RNA concentration was calculated from the 
absorbance reading at 260 nm, corrected for the conversion factor as follows, [RNA]=A260 
x 40. For all samples, the ratio was within the range of 1.7 – 2.0. RNA samples were 
normalised to 100±3 ng/mL and stored at -80
o
C until further use. 
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2.3.7.2 Complementary DNA synthesis – reverse transcriptase PCR 
To synthesise complementary DNA (cDNA), 300 ng RNA was reverse transcribed 
using the iScript cDNA synthesis kit (170-8890, Bio-Rad), performed in triplicate.  
The PCR cycle was run on the T100 Thermal Cycler (BioRad) using the pre-set 
protocol for first-strand cDNA synthesis: annealing 25°C for 5 minutes, extension 42°C for 
30 minutes, inactivation 95°C for 5 minutes. Triplicate samples were pooled, diluted 1:5 in 
water and stored at -20°C until ready to use for real-time PCR. 
 
Table 2.2.  Reverse transcription reaction mix  
Components Volume (µL) 
iScript Reverse Transcriptase 0.5 
5X iScript Reaction Buffer 2.0 
Nuclease-free water 4.5 
RNA sample 3 
Total 10 
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2.3.7.3 Quantitative real-time PCR 
The mRNA expression of our genes of interest, including CC-chemokines; CCL2, 
CCL5, inflammatory markers; CD68, p65, hypoxic markers; Siah1/2, PHD1-3, angiogenic 
markers; VEGF, MIF, HIF-1α CXCL12, tumour markers; p53, BCL-2, caspase 3, caspase 
8, caspase 9, Ki67, c-Jun, MMP2, MMP9, were measured quantitatively by real-time PCR. 
Primers for our genes of interest were designed in house using the Primer-BLAST 
program (National Centre for Biotechnology Information, NCBI). Primer sets used were 
manufactured by Geneworks, Australia and sequences shown in Table 2.3 -   
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Table 2.8. Primers were optimised by generating standard curves using tissue from 
the tumour neovascularisation or hindlimb ischaemia model as seen in Figure 2.6. Mouse 
36B4 was used as housekeeping gene to correct for variations between samples in RT-PCR 
efficiency and to control for small differences in sample quantification. Relative changes in 
mRNA levels of the genes of interest were normalised using the 
ΔΔ
Ct method to 36B4. 
 
 
Figure 2.6. Example of standard curve generated using tissue from hindlimb ischaemia 
model for mouse MIF primers.  
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Table 2.3. Primer sequences for housekeeping gene 36B4 and CC-chemokine 
Primer Sequence 
mouse 36B4 F' 5‟-CAACGGCAGCATTTATAACCC-3‟ 
mouse 36B4 R' 5'-CCCATTGATGATGGAGTGTGG-3‟ 
mouse CCL2 F' 5‟-GCTGGAGCATCCACGTGTT-3‟ 
mouse CCL2 R' 5'-ATCTTGCTGGTGAATGAGTAGCA-3‟ 
mouse CCL5 F' 5'-GCAAGTGCTCCAATCTTGCA-3' 
mouse CCL5 R' 5'-CTTCTCTGGGTTGGCACACA-3' 
 
Table 2.4. Primer sequences for markers of inflammation 
Primer Sequence 
mouse p65 F' 5‟-AGTATCCATAGCTTCCAGAACC-3‟ 
mouse p65 R' 5‟-ACTGCATTCAAGTCATAGTCC-3‟ 
mouse CD68 F' 5‟-GGGGCTCTTGGGAACTACAC-3‟ 
mouse CD68 R' 5‟-GTACCGTCACAACCTCCCTG-3‟ 
 
Table 2.5. Primer sequences for markers of hypoxia 
Primer Sequence 
mouse HIF-1α F' 5‟-TCCCTTGCTCTTTGTGGTTGGGT-3‟ 
mouse HIF-1α R' 5‟-AACGTAAGCGCTGACCCAGG-3‟ 
mouse Siah1 F' 5‟-GACTGCTACAGCATTACCCACT-3‟ 
mouse Siah1 R' 5‟-GTTGGATGCAGTTGTGCCG-3‟ 
mouse Siah2 F' 5‟-CTAACGCCCAGCATCAGGAA-3‟ 
mouse Siah2 R' 5‟-GAACAGCCCGTGGTAGCATA-3‟ 
mouse PHD1 F' 5'-TAAGGTGCATGGCGGCCTGC-3' 
mouse PHD1 R' 5'-TGGCTGCTGCCCGTTCCTTG-3' 
mouse PHD2 F' 5'-ATCACCTGGATCGAGGGCAA-3' 
mouse PHD2 R' 5'-CGTTCGGCCGTTTATCCTGT-3' 
mouse PHD3 F' 5'-GAGCCGGCTGGGCAAATACT-3' 
mouse PHD3 R' 5'-GGGGTTGTCCACATGGCGAA-3' 
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Table 2.6. Primer sequences for markers of angiogenesis 
Primer Sequence 
mouse HIF-1α F' 5‟-TCCCTTGCTCTTTGTGGTTGGGT-3‟ 
mouse HIF-1α R' 5‟-AACGTAAGCGCTGACCCAGG-3‟ 
mouse VEGF F' 5‟-GGCTGCTGTAACGATGAAG-3‟ 
mouse VEGF R' 5‟-CTCTCTATGTGCTGGCTTTG-3‟ 
mouse MIF F' 5‟-AGAACAGCGGTGCAGGTAAG-3‟ 
Mouse MIF R' 5‟ATTACGACATGAACGCTGCC-3‟ 
mouse CXCL12 F' 5‟-CACCTCGGTGTCCTCTTG-3‟ 
mouse CXCL12 R' 5‟-GGTCAATGCACACTTGTCTG-3' 
 
Table 2.7. Primer sequences for markers of proliferation and metastasis 
Primer Sequence 
mouse Ki67 F' 5'-GAACAGACTTGCTCTGGCCT-3' 
mouse Ki67 R' 5'-GCTGTGAGTGCCAAGAGACT-3' 
mouse c-Jun F' 5'-TGGGCACATCACCACTACAC-3' 
mouse c-Jun R' 5'-TCTGGCTATGCAGTTCAGCC-3' 
mouse MMP2 F' 5'-CCCCATGTGTCTTCCCCTTC-3' 
mouse MMP2 R' 5'-GTGTAGATCGGGGCCATCAG-3' 
mouse MMP9 F' 5'-GTCCAGACCAAGGGTACAGC-3' 
mouse MMP9 R' 5'-ATACAGCGGGTACATGAGCG-3' 
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Table 2.8. Primer sequences for markers of apoptosis 
Primer Sequence 
mouse p53 F' 5'-GGCAACTATGGCTTCCACCT-3' 
mouse p53 R' 5'-CTCCGTCATGTGCTGTGACT-3' 
mouse BCL-2 F' 5'-TACGAGTGGGATGCTGGAGA-3' 
mouse BCL-2 R' 5'-CGGTAGCGACGAGAGAAGTC-3' 
mouse Caspase-3 F' 5'-GGGAGCAAGTCAGTGGACTC-3' 
mouse Caspase-3 R' 5'-CCGTACCAGAGCGAGATGAC-3' 
mouse Caspase-8 F' 5'-CAGGAGACCATCGAGGATGC-3' 
mouse Caspase-8 R' 5'-CCCACCGACTGATGTGGAAA-3' 
mouse Caspase-9 F' 5'-AGAACGACCTGACTGCCAAG-3' 
mouse Caspsae-9 R' 5'-TGCCTTGAGAGGAAGTGCAG-3' 
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Table 2.9. Real-time PCR reaction mix  
Components Volume (µL) 
iQ SYBR Green Supermix 7.5 
Primer F‟ 0.6 
Primer R‟ 0.6 
Nuclease-free water 1.3 
cDNA sample 5.0 
Total 15 
 
PCR reactions were performed in triplicate. Primers were used at 20 pM using the 
iQ SYBR green Supermix (Bio-Rad) in a Bio-Rad Cfx96 thermocycler with the pre-set 
protocol for real-time PCR. This includes: initial denaturation and enzyme activation 95°C 
for 3 minutes; 40 cycles of denaturation 95°C for 30 seconds, annealing 60°C for 30 
seconds, followed by extension 72°C for 30 seconds. A non-template control (NTC) was 
included to monitor contamination and primer-dimer formation that could produce false 
positive results. 
 
2.3.8. Protein analysis 
2.3.8.1 Tissue homogenisation 
Protein expression was also measured in the samples from the hindlimb ischaemia 
and wound healing studies. Tissue lysates for ELISA or Western blot were obtained by 
homogenising gastrocnemius muscles from the hindlimb ischaemia model and the wounds 
from the wound healing model. Homogenisation was done by lysing in 750 L cell lysis 
buffer (0.1 M Tris HCl, 0.1 M NaCl, 0.05 M NaF,0.005 M Na4P2O7, 1 mL Triton-X 100, 
pH 7.4), protease inhibitor cocktail (Sigma-Aldrich), and phenylmethanesulfonyl fluoride 
solution (Sigma-Aldrich) for up to 5 times with a quick spin in between homogenisations. 
Tubes were kept on ice at all times. After tissue homogenisation, cell debris was pelleted 
by centrifugation at 1,000 rpm for 1 minute, before cell lysate was collected into a new 
Eppendorf tube.  
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2.3.8.2 ELISA 
ELISA kits were used to determine the concentration of VEGF (MMV00, R&D 
Scientific, Minnesota, USA), CCL2 (MJE00, R&D Scientific), CCL5 (MMR00, R&D 
Scientific) and MIF (SEA698Mu, Cloud-Clone Corp, Texas, USA) protein. For circulating 
protein levels, blood from mice injected with AdGFP or Ad35K was spun at 2,500 rpm for 
5 minutes to collect mouse plasma. For detection of CCL2 and CCL5, 75 L of plasma 
was used while 100 L of plasma was used to measure VEGF levels. For tissue protein 
levels, from the hindlimb ischaemia model, 200 g of tissue lysate was used to measure 
VEGF and MIF, 500 g of tissue lysate was used to measure CCL5 and 1000 g of tissue 
lysate was required for the detection of CCL2 expression. For tissue from the wound 
healing model, 100 g of tissue lysate was used to measure VEGF, CCL2, and CCL5. 
 
2.3.8.3 Western blot 
Western blot was performed to determine protein levels of PHD1, PHD2, PHD3 as 
in Section 2.2.8.4 with 50 g of hindlimb tissue lysate, with even protein loading measured 
by probing for -tubulin. Following transfer, membranes were blocked in 3% (w/v) BSA 
and then probed with antibody diluted in 3% (w/v) BSA. 
 
2.3.9. Boyden chamber assay 
The Boyden Chamber assay was used to determine chemokine activity in mouse 
plasma. Cells were placed in an insert and a solution containing a chemoattractant placed 
in the bottom chamber to encourage cell migration across the membrane. Human monocyte 
derived macrophages (HMDMs) in RPMI media were incubated with 5 M Calcein AM 
(C34852, Invitrogen) at 37
o
C for 30 minutes. Cells were spun at 2,500 rpm for 5 minutes 
and 5x10
5
 cells/mL was resuspended in filtered chemotaxis media (25 mM HEPES, 0.1% 
[w/v] BSA in RPMI media). In a 24 well, 6.5 mm transwells with 3.0 m pore 
polycarbonate membrane insert (CLS3415-48EA, Sigma-Aldrich), 2 L of mouse plasma 
in 600 L chemotaxis media was aliquoted into the bottom chamber. HMDMs, as a 100 
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L cell suspension, were distributed into each insert. The inserts were then placed inside 
each well containing the mouse plasma solution.  
The plate was incubated for 1 hour at 37
o
C. For analysis of cell migration on the 
underside of the membrane, wells and inserts were emptied and washed with PBS. A 
cotton tip was used to scrape excess cells from the inside of the insert, ensuring that the 
outer bottom of the insert was not touched. To remove the membrane, a scalpel blade was 
carefully inserted into the side wall of the membrane and the membrane carved out. The 
membrane was mounted to slides cell side up with fluorescent mounting media. Five 
images per membrane were taken at 10X magnification. Images were analysed using 
Image Pro software. 
 
2.3.10. Total cholesterol 
Total cholesterol concentration was determined using the Cholesterol E kit (439-
17501, Wako Diagnostics, Virginia, USA). The kit is an enzymatic colorimetric method 
for the quantitative determination of total cholesterol in serum. Standards were provided in 
the kit. To a 96 well plate, 10 L of mouse plasma or standard was added to 190 L colour 
reagent and incubated at 37
o
C for 5 minutes. Plates were read at an absorbance of 505 nm 
on a microplate reader (Flex Station 3, Molecular Devices, California, USA) using the 
SoftMax Pro program (v5.3, Molecular Devices, California, USA) for microplate data 
acquisition and analysis. Total cholesterol for unknown samples were interpolated from the 
standard curve. 
 
2.3.10.1 HDL and LDL Cholesterol 
Plasma (30 L) was mixed 1:1 with 20% (w/v) polyethylene glycol (PEG) (81260, 
Sigma-Aldrich) in H2O and incubated at room temperature for 5 minutes. Subsequently, 
samples were centrifuged at 13,000 rpm for 5 minutes to pellet the non-HDL precipitate. 
Total cholesterol was then determined using 10 µL of the HDL-containing supernatant, as 
per the same protocol as described in 2.3.10. LDL levels were determined by subtracting 
total HDL from total cholesterol. 
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2.3.11. Triglycerides 
Triglyceride levels were determined using the Triglyceride E kit (432-40201, Wako 
Diagnostics). Standards were provided in the kit. To a 96-well plate, 10 L mouse plasma 
or standard was added to 190 L colour reagent and incubated at 37oC for 5 minutes. 
Plates were read at an absorbance of 600 nm on a microplate reader (Flex Station 3, 
Molecular Devices, California, USA) using the SoftMax Pro program (v5.3, Molecular 
Devices, California, USA) for microplate data acquisition and analysis. Total triglycerides 
for unknown samples were interpolated from the standard curve. 
 
2.3.12. Statistics 
Data was analysed on GraphPad Prism software (v6.0, Software MacKiev, 
California, USA). All results are expressed as mean±SEM. All data were compared using 
either an unpaired t-test or a One-way ANOVA, followed by post hoc comparison using 
Tukey‟s multiple comparison tests, with p<0.05 considered statistically significant. 
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CHAPTER 3.  
CONDITIONAL 
REGULATION OF          
ANGIOGENESIS BY 35K 
IN KEY FUNCTIONAL 
ASSAYS IN VITRO  
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3.1. Introduction 
Angiogenesis, the formation of new blood vessels from pre-existing blood vessels, 
is induced by both hypoxia and inflammation. Hypoxia-mediated angiogenesis is essential 
during embryo development, but more importantly plays a critical role in postnatal 
physiological processes such as wound healing and tissue regeneration in response to tissue 
ischaemia. Uncontrolled inflammatory-driven angiogenesis occurs in diseases such as 
cancer and atherosclerosis and causes the exacerbation of the disease. Upon activation of 
angiogenesis, endothelial cells proliferate and migrate towards the site of angiogenic 
stimulation where they then assemble into tubular structures to form the basis of new blood 
vessels (Carmeliet 2000). Current anti-angiogenic therapies inhibit angiogenesis in all 
pathophysiological contexts, resulting in severe side effects. This highlights the need for 
alternate therapeutic strategies that can specifically target inflammatory-driven 
angiogenesis whilst having minimal or no effects in hypoxia-mediated angiogenesis.  
CC-chemokines have been show to play a dominant role in diseases associated with 
inflammation, but their effects in angiogenesis across all pathophysiological contexts are 
not well established. Previous in vitro studies have found that a host of CC-chemokines 
including CCL1 (Bernardini et al. 2000), CCL2 (Stamatovic et al. 2006), CCL5 (Liu et al. 
2014), CCL11 (Salcedo et al. 2001), CCL15 (Hwang et al. 2004), and CCL16 (Strasly et 
al. 2004) augment endothelial cell migration and tubule formation, highlighting the critical 
role of the CC-chemokine family in two key cellular angiogenic processes. Interestingly, 
CC-chemokines were unable to directly promote endothelial cell proliferation (Bernardini 
et al. 2000; Hwang et al. 2004; Salcedo et al. 2001; Strasly et al. 2004). Instead it has been 
shown that CC-chemokines facilitate endothelial cell proliferation by promoting the 
production of the key pro-angiogenic mediator VEGF through the PI3K/Akt signalling 
pathway (Liu et al. 2014; Strasly et al. 2004). Taken together, these studies suggest that 
CC-chemokines are critical to angiogenesis, however whether they are involved in both 
inflammatory-driven and hypoxia-mediated angiogenesis has not been fully elucidated in 
vitro. 
The current study aims to elucidate the importance of CC-chemokines in 
angiogenesis upon either inflammatory or hypoxic stimulation using in vitro functional 
assays representing the 3 key cellular angiogenic processes. These assays were conducted 
in human coronary artery endothelial cells (HCAEC) to measure: (1) proliferation assessed 
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by incorporation of 5-ethynyl-2´-deoxyuridine (EdU), (2) migration assessed by scratch 
assay and (3) tubulogenesis assessed by matrigel assay. For these studies, HCAECs were 
incubated with purified 35K protein, in inflammatory (stimulated with 50% [v/v] 
macrophage conditioned media, MCM) or hypoxic conditions (1% O2). The use of MCM 
from IFN- stimulated human monocyte derive macrophages was chosen due to its 
physiological relevance in inflammation-stimulated angiogenesis (Prosser et al. 2014). 
Stimulated macrophages secrete every pro-inflammatory cytokine and growth factor 
required to stimulate angiogenesis. 
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3.2. Methods 
3.2.1. Endothelial cell proliferation under inflammation and hypoxia 
In this study, the Click-iT
®
 EdU Alexa Fluor 488 assay was used, where EdU is 
taken up by newly proliferating cells during DNA synthesis and the percentage of cells in 
S-phase was detected by fluorescence using flow cytometry. Cells were serum starved 
before stimulation to make sure cells were in an unstimulated state and all in a similar cell 
cycle phase before treatments. Proliferation was tested in both inflammation and hypoxia 
with 35K treatment at concentrations between 50 nM – 400 nM, to observe any differential 
effects of 35K.  
 
3.2.2. Endothelial cell migration under inflammation and hypoxia 
A scratch assay on collagen coated chamber slides were used to assess HCAEC 
migration speed in response to 50 nM 35K under inflammatory or hypoxic conditions. This 
was monitored by live cell imaging over 10 hours. 
 
3.2.3. Endothelial cell tubulogenesis under inflammation and hypoxia 
In vitro tubule formation was assessed using growth factor reduced matrigel as the 
matrix to allow for HCAEC attachment and tubule formation in vitro. Cells were plated on 
to the growth factor reduced matrigel and stimulated with 30 nM – 50 nM 35K under both 
inflammation and hypoxia. 
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3.3. Results 
3.3.1. The effect of broad-spectrum CC-chemokine inhibitor 35K on endothelial cell 
proliferation 
As CC-chemokines promote inflammatory-driven angiogenic processes, it was 
therefore anticipated that broad-spectrum inhibition of CC-chemokines would suppress cell 
proliferation in response to the inflammatory stimulus of macrophage conditioned media 
(MCM) but have no effects in response to hypoxia. When cells were incubated with the 
broad-spectrum CC-chemokine inhibitor 35K, there was a concentration dependant 
reduction of endothelial cell proliferation in both the unstimulated and inflammatory-
stimulated (MCM) conditions (Figure 3.1). Comparative analysis of the effects of 35K in 
both the unstimulated and inflammatory-stimulated conditions showed that the ability of 
35K to suppress proliferation was more pronounced in the inflammatory-stimulated cells, 
where at the lowest concentration of 50 nM, the ability of 35K to suppress proliferation 
was only seen in the inflammatory-stimulated cells, with a 23.7% (p<0.05) reduction. As 
the concentration of 35K increases, the effects of 35K were more prominent in the MCM-
stimulated cells; although 35K was also able to significantly suppress proliferation in the 
unstimulated cells. When unstimulated cells were exposed to 100 nM of 35K, there was a 
48.5% (p<0.001) decrease in proliferation. However, at the same concentration, 35K 
suppressed inflammatory-stimulated proliferation by 60.8% (p<0.001). At the higher 
concentration range of 200 – 400 nM, the effect of broad-spectrum CC-chemokine 
inhibition was more striking in the inflammatory-stimulated cells. In the unstimulated 
control cells, 35K inhibited cell proliferation at the three highest concentrations with a 
69.0%, 72.8% and 80.7% decrease seen at 200 nM, 300 nM and 400 nM respectively 
(p<0.001 for all). 35K also retained its inhibitory effects in cells stimulated by MCM, 
where a 59.7% decrease was seen at 200 nM of 35K (p<0.001). Finally, at the highest 
concentrations of 300 nM and 400 nM, 35K attenuated inflammatory-induced proliferation 
by 85.4% and 88.3% respectively (p<0.001 for all). 
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Figure 3.1. 35K inhibits endothelial cell proliferation in unstimulated and inflammatory-
stimulated endothelial cells. 
HCAECs were incubated with PBS or 35K (0 – 400 nM) in the presence of unstimulated 
control media or macrophage conditioned media (MCM) to stimulate inflammation. Cell 
proliferation was assessed by the Click-iT EdU assay. Data is expressed as meanSEM. 
Statistical analysis was performed using a One-way ANOVA with Tukey’s post hoc 
analysis. ***p<0.001 compared to unstimulated control. ^p<0.05, ^^^p<0.001 compared 
to inflammatory MCM-stimulated control.  
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Compared to the striking inhibitory effect of 35K in inflammation, broad-spectrum 
CC-chemokine inhibition by 35K showed more modest inhibitory effects on hypoxia-
stimulated proliferation concentration (Figure 3.2). While the inhibitory effects of 35K on 
proliferation were retained at both the higher concentrations of 300 nM and 400 nM in 
unstimulated normoxic conditions (25.7%, p<0.05 and 50.0%, p<0.01 decrease 
respectively), only the highest concentration of 400 nM was effective in inhibiting 
hypoxia-mediated proliferation compared to its hypoxia-stimulated control (43.9% 
decrease, p<0.001). These effects were significantly more modest compared to 
inflammatory-driven proliferation, particularly at the highest concentration of 400 nM, 
where a near complete inhibition (88.3%) was seen.  
 
 
Figure 3.2. High concentrations of 35K inhibits endothelial cell proliferation in 
unstimulated and hypoxia-stimulated endothelial cells. 
HCAECs were incubated with PBS or 35K (0 – 400 nM) in unstimulated normoxic or 
hypoxia-stimulated (1% O2/5% CO2) conditions. Cell proliferation was assessed by the 
Click-iT EdU assay. Data is expressed as meanSEM. Statistical analysis was performed 
using a One-way ANOVA with Tukey’s post hoc analysis. *p<0.05, **p<0.01 compared to 
unstimulated normoxic control. ^^^p<0.001 compared to hypoxia-stimulated control.  
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3.3.2. The effect of broad-spectrum CC-chemokine inhibitor 35K on endothelial cell 
migration 
A single concentration of 50 nM was chosen to elucidate the effects of broad-
spectrum CC-chemokine inhibition in inflammation- and hypoxia-induced cell migration. 
This medium-level concentration was chosen rather than a higher concentration of 35K as 
they were strongly inhibitory and may not allow for the detection of conditional regulation 
by 35K. Only a single concentration of 35K could be assessed in the chamber slide set up 
of the live cell imager that only allowed for the assessment of four treatments/experiment, 
including the controls. 
In the presence of 50 nM of 35K, migration speed significantly decreased by 22.3% 
(p<0.05) compared to the inflammatory-stimulated control (Figure 3.3). The ability of 35K 
to hamper cell migration was not seen in the unstimulated cells.  
Similar to the observations seen with the proliferation assay broad-spectrum CC-
chemokine inhibition by 35K at a 50 nM concentration did not affect migration speed in 
hypoxia-stimulated cells (Figure 3.4). 
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Figure 3.3. 35K reduces endothelial cell migration speed in inflammatory conditions. 
HCAECs were incubated with PBS or 35K (50 nM) in the presence of unstimulated control 
media or macrophage conditioned media (MCM) to stimulate inflammation. Endothelial 
cell migration was assessed by live cell imaging. Representative images in the upper panel 
indicate distance between cell fronts 10 hours after the initial scratch. Data is expressed as 
meanSEM. Statistical analysis was performed using a One-way ANOVA with Tukey’s 
post hoc analysis. ^p<0.05 compared to inflammatory MCM-stimulated control. 
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Figure 3.4. 35K does not effect hypoxia-stimulated endothelial cell migration speed. 
HCAECs were incubated with PBS or 35K (50 nM) in unstimulated normoxic or hypoxia-
stimulated (1% O2/5% CO2) conditions. Endothelial cell migration was assessed by live 
cell imaging. Representative images in the upper panel indicate distance between cell 
fronts 10 hours after the initial scratch. Data is expressed as meanSEM.   
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3.3.3. The effect of broad-spectrum CC-chemokine inhibitor 35K on endothelial cell 
tubulogenesis 
The final in vitro assay used to elucidate the effects of 35K on angiogenic processes 
is the matrigel assay that allows cells to attach and form tubules within a cellular matrix, 
thereby resembling in vivo tubule formation. Three concentrations of 35K within the lower 
range (30 – 50 nM) were used for this study. Firstly, the inflammatory stimulus (50% [v/v] 
MCM) significantly increased (55.0% p<0.01) endothelial cell tubule formation compared 
to unstimulated cells (Figure 3.5). Similar to our observations in the proliferation and 
migration assays, we found that 35K was able to significantly inhibit inflammatory-driven 
tubule formation, even at the lower concentration range of 30 – 50 nM, with 58.1% 
(p<0.01), 43.9% (p < 0.05) and a near complete 95.8% (p<0.001) inhibition seen at 30, 40 
and 50 nM respectively. Furthermore, the ability of 35K to inhibit tubule formation was 
also observed in the unstimulated cells, with 41.2% (p<0.05) and 100% (p<0.001) 
reductions seen at 30 nM and 50 nM respectively. 
As was seen in the earlier angiogenic assays, the inhibitory effects of 35K were 
substantially more modest under hypoxic stimulation compared to inflammation. When 
compared to the hypoxia-stimulated control, 35K attenuated tubule formation in a 
concentration dependent manner with decreases of 25.4%, 30.9% and 45.3% seen at 30, 40 
and 50 nM of 35K respectively (all p<0.01, Figure 3.6). 35K was more potent in 
suppressing tubule formation in the unstimulated control cells with decreases of 40.4% 
(p<0.05), 72.6% (p<0.001), and 72.0% (p<0.001) at 30, 40 and 50 nM respectively.  
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Figure 3.5. 35K inhibits endothelial cell tubule formation in unstimulated and 
inflammatory-stimulated cells. 
HCAECs were incubated with PBS or 35K (0 – 50 nM) in the presence of unstimulated 
control media or macrophage conditioned media (MCM) to stimulate inflammation. 
Endothelial cell tube formation was assessed by matrigel assay. Representative images in 
the upper panel indicate tubule formation. Scale bars represent 100 m. Data is expressed 
as meanSEM. Statistical analysis was performed using a One-way ANOVA with Tukey’s 
post hoc analysis. *p<0.05, **p<0.01, ***p<0.001 compared to unstimulated control. 
^p<0.05, ^^p<0.01, ^^^p<0.001 compared to inflammatory MCM-stimulated control.  
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Figure 3.6. 35K inhibits endothelial cell tubule formation in unstimulated and hypoxia-
stimulated cells. 
HCAECs were incubated with PBS or 35K (0 – 400 nM) under unstimulated normoxic or 
hypoxia-stimulated (1% O2/5% CO2) conditions. Endothelial cell tube formation was 
assessed by matrigel assay. Representative images in the upper panel indicate tubule 
formation. Scale bars represent 100 m. Data is expressed as meanSEM. Statistical 
analysis was performed using a One-way ANOVA with Tukey’s post hoc analysis. 
*p<0.05, **p<0.01, ***p<0.001 compared to unstimulated normoxic control. ^^p<0.01 
compared to hypoxia-stimulated control.   
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3.4. Discussion 
In vitro functional angiogenic assays are an important tool to determine the key 
steps modulated in the process of angiogenesis by a treatment. To elucidate the effects of 
broad-spectrum CC-chemokine inhibition, three key functional assays that reflected the 
key cellular processes involved in angiogenesis, namely endothelial cell proliferation, 
migration and tubule formation, were used. We have shown for the first time that broad-
spectrum CC-chemokine inhibition by 35K conditionally regulates functional angiogenic 
assays in vitro. In this study we found that 35K significantly reduced inflammatory-driven 
angiogenesis across all three key functional assays in a concentration dependant manner. 
However, the effects of 35K on these assays in response to hypoxia were more modest by 
comparison. 
The first assay, proliferation, assessed the ability of endothelial cells to divide from 
a quiescent state when treated with broad-spectrum CC-chemokine inhibitor, 35K, under 
inflammation or hypoxia. We found that 35K significantly attenuated inflammatory-driven 
proliferation at higher concentrations (200 – 400 nM), whilst at these same concentrations, 
these effects were more modest in response to hypoxic stimulation. The requirement for 
high concentrations of 35K suggests a less significant role for CC-chemokines in the 
stimulation of proliferation. This aligns with previous studies in which increased CC-
chemokine levels had no effect on proliferation compared to bFGF or VEGF stimulation 
(Hwang et al. 2004; Strasly et al. 2004), although we were able to induce inhibition at the 
higher concentrations. Previous studies have shown that CCL2 is highly expressed during 
proliferation of smooth muscle cells (Salcedo et al. 2000). However it appears that CCL2 
has different effects depending on the cell type as it was shown to have no effect on 
proliferation in endothelial cells (Weber et al. 1999). Our broad-spectrum CC-chemokine 
inhibition findings suggest that other members of the CC-chemokine family may play a 
more important role in endothelial proliferation than CCL2, and therefore our broad-
spectrum approach is more effective. Furthermore, given that the effects of 35K protein 
were only seen at the higher concentrations, this suggests that the CC-chemokines involved 
in endothelial cell proliferation may not be highly expressed in endothelial cells. 
The second functional assay performed was the migration assay to replicate 
endothelial cell migration in vitro. The assay was performed in 4 well chamber slides, 
limiting the number of concentrations tested to one per experiment. The 50 nM 
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concentration was chosen as higher concentrations showed complete inhibition of 
migration (data not shown). This study found that broad-spectrum CC-chemokine 
inhibition, even at a small concentration of 35K, reduced the speed of migration in 
inflammation but had no effect in hypoxia. This verifies the important role of CC-
chemokines in endothelial cell migration as a medium-level concentration caused 
significant inhibition of migration. This suggests that several CC-chemokines may be 
involved in the migration of endothelial cells. Alternatively, there may be a high 
abundance of a few specific CC-chemokines that play an important role in stimulating the 
migration of endothelial cells. Previous studies show that the CC-chemokine CCL2 
directly phosphorylates cytoskeletal proteins essential for endothelial cell migration 
(Galvez et al. 2005). Additionally, CCL1 was shown to stimulate chemotaxis and invasion 
of endothelial cells in vitro (Bernardini et al. 2000).  
The final assay to assess angiogenesis in vitro was the matrigel tubulogenesis 
assay. Tubule formation was assessed using growth factor reduced matrigel where 
endothelial cells, plated on matrigel, form a network of tube-like structures over 4 – 6 
hours. Inhibition of the CC-chemokine class caused near-complete attenuation of 
endothelial cell tubule formation in inflammatory conditions, particularly at the 50 nM 
concentration. Interestingly, the effects of 35K on hypoxia-stimulated tubule formation 
were far more modest at these same concentrations. In previous studies, tubulogenesis was 
induced with the incubation of CC-chemokines CCL2, CCL11, and CCL16 in vitro 
(Salcedo et al. 2001; Stamatovic et al. 2006; Strasly et al. 2004). Endothelial neovessel 
formation was also directly stimulated by CCL2 (Galvez et al. 2005). Our findings suggest 
that CC-chemokines might be more important in mediating inflammatory-driven tubule 
formation, whilst exerting only minimal regulatory effects on hypoxia-mediated 
tubulogenesis.  
Overall, our observations from this study found that the effects of broad-spectrum 
CC-chemokine inhibition by 35K were more modest in the three in vitro functional 
angiogenic assays in hypoxia, suggesting that broad-spectrum CC-chemokines may play a 
minimal role in promoting physiological hypoxia-driven angiogenesis. Previous studies 
have shown that the expression of CCR5 and the production of CCL2 are inhibited 
following hypoxic stimulation, resulting in an inhibition of macrophage recruitment to 
hypoxic sites (Bosco, Puppo, et al. 2004; Bosco, Reffo, et al. 2004; Turner et al. 1999). 
Furthermore in hypoxic conditions, the CXC chemokines such as CXCL1, CXCL2, 
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CXCL5 CXCL8, CXCL9, CXCL10, CXCL11, and CXCL12 are the dominant chemokines 
and are expressed to regulate vascular repair (Frangogiannis 2007; Schober 2008). CXC-
chemokines with the ELR (Glu-Leu-Arg) motive such as CXCL1, CXCL2, CXCL5 and 
CXCL8 are also involved in the recruitment of neutrophils to the ischaemic site (Bizzarri et 
al. 2006; Clark-Lewis et al. 1995; Clark-Lewis et al. 1991).  
In conclusion, we have shown that broad-spectrum CC-chemokine inhibition by 
35K conditionally regulated angiogenesis-related in vitro processes. 35K has striking 
inhibitory effects in inflammation and more modest or no effects in hypoxia. Our findings 
show that concentrations of 35K as low as 50 nM were sufficient to see significant 
reductions in both inflammatory-driven endothelial cell migration and tubule formation, 
whilst upon hypoxic stimulation, this concentration had no effect. Similarly endothelial 
cell proliferation was significantly reduced with 35K in inflammation but these effects 
were again more modest in response to hypoxia at the same concentration. Furthermore, 
35K required higher concentrations of up to 400 nM to exhibit its inhibitory effects in 
endothelial cell proliferation. These findings correlate with previous studies in which CC-
chemokines are reported to be highly involved in migration and tubulogenesis of 
endothelial cells but appear to play a lesser role in proliferation. The mechanism by which 
35K exerts the conditional regulation of angiogenesis remains to be explored. Accordingly, 
the aim of our next chapter was to examine the cellular mechanisms by which 35K 
conditionally regulates angiogenesis. 
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CHAPTER 4.  
ELUCIDATING THE 
MECHANISMS OF         
CC-CHEMOKINE 
INHIBITION BY 35K        
IN VITRO 
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4.1. Introduction 
Our functional in vitro angiogenic assay studies in Chapter 3 showed that broad-
spectrum CC-chemokine inhibition with 35K conditionally regulates angiogenesis, 
suppressing inflammatory-driven angiogenesis with more modest or minimal effects on 
hypoxia-mediated angiogenesis. This suggests that the CC-chemokine class play a more 
important role in inflammatory-driven angiogenesis and little to no role in hypoxia-
mediated angiogenesis. However, the mechanism by which 35K exerts these differential 
effects remains to be elucidated. The studies outlined in this chapter sought to elucidate the 
role of 35K on two critical signalling pathways involved in angiogenesis.  
Angiogenesis is driven by two distinct yet overlapping pathways, depending on the 
angiogenic stimulation. Inflammatory-driven angiogenesis is driven by the key 
inflammatory transcription factor nuclear factor-κB (NF-κB). A subunit of NF-B, p65 
also known as RelA, is critical in activating the canonical pathway of NF-B for innate 
immunity and cell survival (Beg & Baltimore 1996). Conversely, hypoxia-inducible factor-
1α (HIF-1α) is the main transcription factor for hypoxia-mediated angiogenesis. HIF-1α 
can also be post-translationally modulated by prolyl hydroxylases (PHD 1-3). Under 
normoxic conditions the PHDs hydroxylate HIF-1α allowing von Hippel-Lindau proteins 
(pVHL) to bind, targeting it for proteasomal degradation (Berra, Ginouvès & Pouysségur 
2006). However under hypoxic conditions, the action of PHDs are inhibited by the 
activation of the E3 ubiquitin ligases Siah1 and Siah2 (Nakayama et al. 2004). Both NF-κB 
and HIF-1α augment the expression of the key pro-angiogenic mediator VEGF. In 
angiogenesis VEGF promotes growth of endothelial cells derived from arteries, veins and 
lymphatics (Ferrara & Davis-Smyth 1997). Additionally, VEGF promotes 
monocyte/macrophage migration from the bone marrow (Clauss et al. 1990; Shibuya 
2011). In inflammatory-driven angiogenesis, the expression of VEGF expression is 
modulated by NF-κB, as seen in tumour and plaque angiogenesis studies (Celletti et al. 
2001; Ferrara 2004; Ferrara, Gerber & LeCouter 2003). Conversely in hypoxia-mediated 
angiogenesis, VEGF is regulated by HIF-1α (Forsythe et al. 1996; Liu et al. 1995). This 
multi-conditional regulation of VEGF is possible, as VEGF has response elements for both 
NF-B and HIF-1α in its promoter region that allows for activation of both signalling 
pathways (Ramanathan et al. 2007).  
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Previous studies show that CC-chemokine expression can be triggered by both the 
NF-κB and HIF-1α signalling pathways. NF-B binding motifs have been found on CC-
chemokines including CCL2 and CCL5 (Nelson et al. 1993; Ueda et al. 1994) possibly 
complementing their role in inflammatory-driven angiogenesis. Furthermore, CC-
chemokines have indirect effects in inflammatory-driven angiogenesis, whereby CC-
chemokines recruit monocytes/macrophages to the inflammatory site that secrete pro-
angiogenic growth factors and cytokines. Interestingly, despite having no reported role in 
hypoxia-mediated angiogenesis, CCL2, CCL5, and CCL12 were found to contain hypoxic 
response elements in its promoter region (Mojsilovic-Petrovic et al. 2007; Yeligar et al. 
2009). These were studied in pathologies where ischaemia is critical, such as in allergic 
airway inflammation or ischaemic brain damage (Baay-Guzman et al. 2012; Mojsilovic-
Petrovic et al. 2007). Additionally, HIF-1α was induced by CCL5 in the liver under 
chronic alcohol consumption (Yeligar et al. 2009).  
Based on our findings in Chapter 3, we hypothesise that 35K through its inhibition 
of CC-chemokines reduces inflammation and subsequently prevents further activation of 
NF-B. This, in turn, prevents the activation of endothelial cell migration, proliferation and 
tubule formation. However under hypoxia we propose that 35K will have no effect on HIF-
1α, thereby allowing for the preservation of hypoxia-mediated angiogenesis. 
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4.2. Methods 
4.2.1. Cell culture treatments 
To determine the mechanism of action of 35K, HCAECs were treated with 35K (0 
– 200 nM) and subjected to either inflammatory or hypoxic stimulation as detailed in 
Chapter 2 (2.2.7). Protein was isolated from whole cell lysates or nuclear fraction from 
treated cells (Section 2.2.8) and run on a Western blot to determine the expression of the 
key angiogenic markers including p65 (active subunit of NF-κB), HIF-1α, VEGF, and 
PHD1-3. Even protein loading was confirmed by probing for either α-tubulin for whole 
cell lysates or TATA-binding protein (TBP) for nuclear fractions. 
 
  
Page | 101  
 
4.3. Results  
4.3.1. The effect of broad-spectrum CC-chemokine inhibitor 35K on p65 in 
inflammation 
Western blot analysis revealed a non-significant 107.7% (~2 fold) increase in 
nuclear p65 protein levels in response to the inflammatory stimulus (MCM) compared to 
unstimulated control (Figure 4.1). However, despite no significant changes, 35K appeared 
to suppress this increase, although these effects were not significant. The addition of 50 
nM of 35K reduced p65 nuclear levels by 35.9% and 200 nM of 35K resulted in a 37.3% 
reduction when compared to inflammatory MCM-stimulated controls. Unexpectedly, in the 
unstimulated cells, non-significant increases of p65 levels were detected in the cells treated 
with 35K when compared to the unstimulated control, where incubation with 35K 
increased p65 protein levels by 256.6% at the lower 50 nM dose, but only a 91.1% increase 
was seen at the higher dose of 200 nM. 
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Figure 4.1. 35K did not affect p65 protein levels in inflammatory-stimulated endothelial 
cells. 
HCAECs were incubated with PBS or 35K (0 – 200 nM) in the presence of unstimulated 
control media or macrophage conditioned media (MCM) to stimulate inflammation. 
Nuclear p65 protein levels were assessed by Western blot analysis. Even protein loading 
was confirmed by TATA-binding protein (TBP). Data is expressed as meanSEM. 
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4.3.2. The effect of broad-spectrum CC-chemokine inhibitor 35K on HIF-1α in 
inflammation and hypoxia. 
HIF-1α has an NF-κB response element upstream of its promoter region. As CC-
chemokines mediate inflammatory cellular responses, the effects of 35K on HIF-1α protein 
levels were measured in both inflammation and hypoxia. Upon inflammatory stimulation 
with MCM, HIF-1α protein levels increased by 45.7% (p<0.05), compared to the 
unstimulated control (Figure 4.2). More importantly, HIF-1α protein levels were 
significantly decreased in cells treated with 35K at both the 50 nM (68.8%, p<0.01) and 
200 nM (73.5%, p<0.001) concentrations. However, the inhibition of HIF-1α protein by 
35K was more modest in the unstimulated cells with non-significant decreases seen at both 
50 nM (26.5%) and 200 nM (58.8%) doses.  
In contrast to the inflammatory environment, there was only a non-significant 
23.1% increase in HIF-1α protein levels in response to hypoxia compared to the 
unstimulated controls (Figure 4.3). Compared to the hypoxia-stimulated control, 35K was 
only able to significantly suppress HIF-1α protein levels at the highest concentration of 
200 nM (68.8% decrease, p<0.001), with a non-significant 26.3% decrease seen at the 
lower concentration of 50 nM. These effects were also observed in the normoxic 
unstimulated cells, with 35K significantly inhibiting HIF-1α protein levels at the 200 nM 
concentration (54.9% decrease, p<0.05).  
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Figure 4.2. 35K reduced HIF-1α protein levels in inflammatory-stimulated endothelial 
cells. 
HCAECs were incubated with PBS or 35K (0 – 200 nM) in the presence of unstimulated 
control media or macrophage conditioned media (MCM) to stimulate inflammation. HIF-
1α protein levels were assessed by Western blot analysis. Even protein loading was 
confirmed by -tubulin. Data is expressed as meanSEM. Statistical analysis was 
performed using a One-way ANOVA with Tukey’s post hoc analysis. *p<0.05 compared to 
unstimulated control. ^^p<0.01, ^^^p<0.001 compared to inflammatory MCM-stimulated 
control. 
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Figure 4.3. 35K reduced HIF-1α protein levels in hypoxia-stimulated endothelial cells. 
HCAECs were incubated with PBS or 35K (0 – 200 nM) in unstimulated normoxic or 
hypoxia-stimulated (1% O2/5% CO2) conditions. HIF-1α protein levels were assessed by 
Western blot analysis. Even protein loading was confirmed by -tubulin. Data is expressed 
as meanSEM. Statistical analysis was performed using a One-way ANOVA with Tukey’s 
post hoc analysis. *p<0.05 compared to unstimulated normoxic control. ^^^p<0.001 
compared to hypoxia-stimulated control. 
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4.3.3. The effect of broad-spectrum CC-chemokine inhibitor 35K on VEGF in 
inflammation and hypoxia. 
The effects of broad-spectrum CC-chemokine inhibition on the critical pro-
angiogenic mediator VEGF was measured next. Upon inflammatory MCM-mediated 
stimulation, there was a slight, non-significant 23.1% increase in VEGF protein levels 
compared to the unstimulated controls (Figure 4.4). In inflammation, 35K suppressed 
VEGF protein levels in a dose dependent fashion, with a non-significant 24.9% decrease 
seen at the lower concentration of 50 nM, while at the highest concentration of 200 nM, 
VEGF levels were significantly inhibited by 42.2% (p<0.05). In contrast to the effects seen 
in inflammation, 35K had no effect on VEGF protein levels in hypoxic conditions (Figure 
4.5).  
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Figure 4.4. 35K reduced VEGF protein levels in inflammatory-stimulated endothelial cells. 
HCAECs were incubated with PBS or 35K (0 – 200 nM) in the presence of unstimulated 
control media or macrophage conditioned media (MCM) to stimulate inflammation. VEGF 
protein levels were assessed by Western blot analysis. Even protein loading was confirmed 
by -tubulin. Data is expressed as meanSEM. Statistical analysis was performed using a 
One-way ANOVA with Tukey’s post hoc analysis. ^p<0.05 compared to inflammatory 
MCM-stimulated control. 
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Figure 4.5. 35K did not affect VEGF protein levels in hypoxia-stimulated endothelial cells. 
HCAECs were incubated with PBS or 35K (0 – 200 nM) in unstimulated normoxic or 
hypoxia-stimulated (1% O2/5% CO2) conditions. VEGF protein levels were assessed by 
Western blot analysis. Even protein loading was confirmed by -tubulin. Data is expressed 
as meanSEM.  
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4.3.4. The effect of broad-spectrum CC-chemokine inhibitor 35K on post-translational 
HIF-1α modulators, the prolyl hydroxylases (PHDs) in hypoxia. 
It is well established that HIF-1α can be post-translationally modulated by the 
prolyl hydroxylase family, of which there are three members (PHD1-3). 35K suppressed 
HIF-1α protein levels in hypoxia (although not as strikingly as in inflammation) but had no 
effect on VEGF expression. We therefore sought to determine the effect of 35K on prolyl 
hydroxylase expression. Following hypoxic stimulation, endothelial cell PHD1 protein 
levels decreased by 20.6% compared to normoxic controls, although these changes were 
not significant (Figure 4.6). Overall, 35K had no effects on PHD1 expression, whether in 
normoxic or hypoxic conditions. A similar pattern was also observed when measuring 
PHD2 protein levels. Again, there was a non-significant 30.4% decrease in response to 
hypoxic stimulation compared to unstimulated normoxic controls (Figure 4.7), but no 
significant effects with 35K where found. These observations were also seen in PHD3 
protein levels, where a non-significant 16.2% reduction in PHD3 protein levels was 
detected in response to hypoxic stimulation (Figure 4.8). However, 35K treatment had no 
effect on PHD3 expression levels in either normoxic or hypoxic conditions. 
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Figure 4.6. 35K did not affect PHD1 protein levels in hypoxia-stimulated endothelial cells. 
HCAECs were incubated with PBS or 35K (0 – 200 nM) in unstimulated normoxic or 
hypoxia-stimulated (1% O2/5% CO2) conditions. PHD1 protein levels were assessed by 
Western blot analysis. Even protein loading was confirmed by -tubulin. Data is expressed 
as meanSEM.  
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Figure 4.7. 35K did not affect PHD2 protein levels in hypoxia-stimulated endothelial cells. 
HCAECs were incubated with PBS or 35K (0 – 200 nM) in unstimulated normoxic or 
hypoxia-stimulated (1% O2/5% CO2) conditions. PHD2 protein levels were assessed by 
Western blot analysis. Even protein loading was confirmed by -tubulin. Data is expressed 
as meanSEM.  
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Figure 4.8. 35K did not affect PHD3 protein levels in hypoxia-stimulated endothelial cells. 
HCAECs were incubated with PBS or 35K (0 – 200 nM) in unstimulated normoxic or 
hypoxia-stimulated (1% O2/5% CO2) conditions. PHD3 protein levels were assessed by 
Western blot analysis. Even protein loading was confirmed by -tubulin. Data is expressed 
as meanSEM.  
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4.4. Discussion 
To elucidate the mechanism for the conditional regulation of in vitro angiogenesis 
by broad-spectrum CC-chemokine inhibition, the effect of 35K on two key signalling 
pathways that mediate angiogenesis were assessed in this chapter. We found that 35K 
conditionally regulated VEGF protein levels, such that VEGF was inhibited by 35K in 
inflammation but had no effect on VEGF in hypoxia. Interestingly, we found that 35K 
significantly inhibited HIF-1α levels under both stimulated conditions, although these 
inhibitions were more striking in inflammation and the effects were more modest in 
hypoxia. This could not be explained by changes in the post-translational regulation of 
HIF-1α, as 35K had no effect on the expression of the prolyl hydroxylase family (PHD1-
3).  Finally, 35K had no effect on NF-κB in inflammation. 
The current study found that, despite a 37.3% reduction in the protein expression of 
the active subunit of NF-κB (p65) in inflammation, broad-spectrum inhibition of the CC-
chemokine class had no significant effect on p65. Previous studies have demonstrated that 
specific inhibition of NF-B in lung epithelial cells reduces inflammation by suppressing 
CC-chemokine expression of CCL2, CCL5, CCL11, CCL20 (Poynter et al. 2004). The 
current data showing a lack of change in NF-B by 35K indicate that the anti-
inflammatory/angiogenic effects of 35K are influenced by alternate inflammatory 
mediators in the promoter region of chemokines such as the TPA response element (TRE) 
which target AP-1, also known to modulate inflammation (Schonthaler, Guinea-Viniegra 
& Wagner 2011; Ueda et al. 1994). Interestingly, in unstimulated conditions, 35K 
increased p65 levels. This was not significant however, it raises the possibility that in these 
conditions, the inhibition of CC-chemokines causes NF-B to exhibit cell survival mode 
characteristics, whereby NF-B prevents TNF-induced apoptosis in macrophages, T-cells, 
hepatocytes, and the inhibition of NF-B increases cell susceptibility to apoptosis (Cardoso 
& Oliveira 2003; Shih et al. 2011). 
While HIF-1α is the primary transcription factor involved in hypoxia-mediated 
angiogenesis, it can also be driven by the NF-B signalling pathway as HIF-1α has 
response elements for both HIF and NF-B in its promoter region. In hypoxic conditions, 
HIF-1α is the critical mediator of the cellular angiogenic response. The current study found 
that HIF-1α was inhibited by 35K in both inflammation and hypoxia, although these 
effects were more modest in hypoxia. The ability of 35K to suppress HIF-1α significantly 
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in hypoxia was surprising but these observations could explain why 35K had mild 
inhibitory effects in the functional angiogenic assays in response to hypoxia. HIF-1α is 
known to be post-translationally modulated by prolyl hydroxylases (PHDs 1-3), which 
trigger HIF-1α degradation (Berra, Ginouvès & Pouysségur 2006). Here we find that 35K 
did not affect PHDs 1-3 under hypoxic conditions. This suggests that 35K may be affecting 
HIF-1α through a pathway separate to the post translational modification of HIF-1α. In 
hypoxia, the normal inhibition of PHDs increases NF-B activation through 
phosphorylation of its upstream enzyme IKK (Cummins et al. 2006), however when 
IKK is inhibited it impairs HIF-1α in hypoxia (Rius et al. 2008), suggesting that NF-B 
plays a role in the regulation of HIF-1α in hypoxia. Thus, HIF-1α regulation may be 
indirectly linked to the regulation of inflammatory-driven angiogenesis by CC-
chemokines. 
Our studies show that broad-spectrum CC-chemokine inhibition by 35K had 
differential effects on VEGF expression in response to inflammation and hypoxia, where 
35K was able to strikingly suppress inflammatory-driven VEGF expression while having 
no effect on hypoxia-mediated VEGF augmentation. Conditional regulation of VEGF by 
35K is possible as VEGF has response elements for both NF-B and HIF-1α in its 
promoter region (Ema et al. 1997; Forsythe et al. 1996; Levy et al. 1995; Shi et al. 2001). It 
was interesting to note that in hypoxia, VEGF levels in 35K-treated cells were maintained 
in spite of a decrease in HIF-1α expression. Previous studies have shown that while HIF-
1α is the main transcription factor driving VEGF expression in hypoxia-mediated 
angiogenesis, the NF-B signalling pathway may also be activated in response to hypoxia. 
Given that NF-B can be triggered in response to hypoxia, activation of NF-B may help 
to maintain VEGF levels in spite of the suppression of HIF-1α by CC-chemokine 
inhibition. Furthermore, studies show that CCL2 induces VEGF production through p42/44 
MAPK (Hong, Ryu & Han 2004), which has also been shown to induce expression of HIF-
1α through non-hypoxic signalling and in turn increased VEGF expression (Bardos & 
Ashcroft 2004).  
In conclusion, the studies of this chapter have found that the conditional regulation 
of angiogenesis by 35K is mediated via the critical pro-angiogenic mediator VEGF. 
Moreover, 35K has no effect on post-translational HIF-1α modulation. Overall, the in vitro 
findings from Chapter 3 and the present chapter have demonstrated that broad-spectrum 
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CC-chemokine inhibition by 35K suppresses inflammatory-driven angiogenesis whilst 
having minimal to no effects on hypoxia-mediated angiogenesis in vitro. Whether these 
differential angiogenic effects of 35K can be translated in vivo was investigated in the next 
chapter using two murine surgical models of angiogenesis. 
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CHAPTER 5.                   
THE EFFECT OF   
BROAD-SPECTRUM                     
CC-CHEMOKINE 
INHIBITION IN MODELS 
OF ANGIOGENESIS  
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5.1. Introduction 
The studies in Chapters 3 and 4 found that broad-spectrum CC-chemokine 
inhibition using 35K strikingly suppressed inflammatory-driven functional angiogenesis in 
vitro (Chapter 3) and inhibited key mediators of the inflammatory angiogenic pathway 
specifically HIF-1α and VEGF (Chapter 4). Conversely, in the context of hypoxia, broad-
spectrum CC-chemokine inhibition had minimal to no effects in vitro, where 35K had no 
effect on proliferation, migration, and VEGF expression. The aim of this study was to 
determine if the observed in vitro effects of 35K could be translated in vivo in murine 
models of angiogenesis. To compare inflammatory-driven and hypoxia-mediated models 
of angiogenesis in vivo, the peri-arterial femoral cuff model and hindlimb ischaemia model 
were utilised. 
Inflammatory-driven angiogenesis is regulated primarily by the NF-κB signalling 
pathway which creates an inflammatory response that then promotes the recruitment of 
monocytes/macrophages to the inflamed sites. Recruited macrophages, in turn, secrete pro-
angiogenic proteins such as VEGF, bFGF, TNF-α, and IFN- (Mantovani et al. 2008; 
Sunderkotter et al. 1994) that promote neovascularisation. In hypoxia, HIF-1α is the key 
transcription factor that drives the angiogenic response. HIF-1α promotes the recruitment 
of endothelial progenitor cells (EPC) to the ischaemic site, by upregulation of CXCL12. 
The pro-angiogenic mediator VEGF is a critical stimulator of angiogenesis in both 
inflammation and hypoxia. In inflammation, VEGF expression is released by macrophages 
at the injury site. Macrophages are recruited by CC-chemokines, however MIF 
(macrophage migration inhibitory factor) also plays a role in the recruitment of 
macrophages particularly in inflammation.  
Previous in vivo studies with 35K found that CC-chemokine activity was inhibited 
in plasma and aortas (Ali et al. 2005; Bursill et al. 2009). Additionally, in ApoE
-/-
 mice, 
atherosclerotic plaque size and macrophage infiltration was reduced in mice treated with 
35K (Ali et al. 2005; Bursill et al. 2004). Furthermore, 35K has been shown to inhibit a 
host of inflammatory-driven diseases including acute peritonitis, in which mice injected 
with adenovirus overexpressing 35K (Ad35K) had reduced inflammatory cells in 
peritoneal exudates (Bursill et al. 2006). Additionally, mice treated with Ad35K had 
reduced liver fibrosis and reduced hepatitis compared to the adenoviral controls (Bursill et 
al. 2006; Seki et al. 2009). Currently, 35K has only been investigated in in vivo models 
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associated with inflammatory pathologies, but its effects in pathological and physiological 
angiogenic in vivo models have not yet been investigated.  
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5.2. Method 
5.2.1. Peri-arterial cuff surgery 
Three days prior to surgery mice were injected with either 200 L PBS, 1x1011 vp 
AdGFP in PBS (total volume 200 L), or 1x1011 vp Ad35K (total volume 200 L) (n = 12 
per treatment group). To induce inflammatory-driven neovascularisation, the peri-arterical 
cuff model was used as described previously (Moroi et al. 1998; Prosser et al. 2014). Prior 
to surgery, mice were anaesthetised by inhalation of methoxyflurane. A 1 cm incision was 
made along the length of the femoral artery, above the knee towards the medial thigh. The 
femoral artery was isolated from the neuromuscular bundle by carefully placing fine tip 
forceps between the vessels and under the artery. Once the artery was isolated, a 2 mm 
non-constricting polyethylene cuff made of PE50 tubing (427410 BD Bioscience), with 
inner diameter 0.56 mm and outer diameter 0.965 mm, was placed around the artery 
(Figure 5.1). To do this, the cuff was slit along the length of one side, opened with forceps 
and closed around the artery before tying with 6-0 PERMA HAND silk suture (639G, 
ETHICON LLC, San Lorenzo, Puerto Rico). The surgical site was sutured closed with 6-0 
PROLENE™ polypropylene suture (8805H, ETHICON LLC). A sham procedure was 
performed on the opposite hindlimb. After surgery mice were injected subcutaneously with 
carprofen to prevent pain during recovery. For this study two cohorts were completed, one 
for histology and another for RNA processing of the cuffed femoral artery.  
 
 
Figure 5.1. Polyethylene cuff placed around the mouse femoral artery 
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5.2.2. Hindlimb ischaemia surgery 
As with the peri-arterial cuff model, the mice were injected with PBS, AdGFP or 
Ad35K three days prior to surgery (n =12 per treatment group). To induce hypoxia-
mediated angiogenesis, the hindlimb ischaemia model was used as described previously 
(Niiyama et al. 2009), where the femoral artery and vein was removed from the left 
hindlimb. This procedure involved the separation of the vessels from the nerve in the 
neuromuscular bundle. Once separated, the femoral artery and vein was ligated above the 
epigastrica and profunda femoris, using 6-0 PROLENE™ polypropylene suture (8805H, 
ETHICON LLC) (Figure 5.2). The vessels were severed distal to the ligation and excised 
as distal to the popliteal from the hindlimb of the mice. A sham procedure was performed 
on the opposite hindlimb. After surgery mice were injected subcutaneously with carprofen 
to prevent pain during recovery. Laser Doppler images (moorLDI2-IR, Moor instruments, 
Devon, UK) were taken pre- and immediately post-surgery and then at days 2, 4, 7, 10, 12 
and 14 post-surgery (Figure 5.3).  
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Figure 5.2. Ligation of the mouse femoral artery for the hindlimb ischaemia model 
(Niiyama et al. 2009). 
 
 
Figure 5.3. Representative Laser Doppler images taken pre- and post- surgery and at the 
Day 14 end point  
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5.2.3. Processing of animal tissues 
For the peri-arterial cuff model, 21 days after surgery mice were euthanised by 
overdose of anaesthesia with methoxyflurane followed by right ventricular puncture. 
Circulatory perfusion flushing with 10 mL of saline was then performed through the left 
ventricle. Whole blood was collected during the ventricular puncture for plasma analysis 
and the femoral artery from each hindlimb was dissected out (cuff and non-cuff). The 
femoral artery was dissected 1 – 2 mm from each end of the cuff. To remove the cuff, the 
suture was cut and surrounding connective tissue was removed before sliding the cuff off. 
For histological analysis, the sample was sandwiched between 2 pieces of biopsy foam in 
an embedding cassette and placed in 4% (v/v) paraformaldehyde in PBS solution for 2 
hours at room temperature, then stored in 70% ethanol at 4
o
C prior to processing in graded 
ethanol concentrations before paraffin embedding. For RNA analysis, tissues were snap 
frozen in Eppendorf tubes and stored at -80
o
C. 
For the hindlimb ischaemia model, 14 days after surgery mice were euthanised by 
overdose of anaesthesia with methoxyflurane followed by right ventricular puncture. 
Whole blood was collected during the ventricular puncture for plasma analysis. The 
gastrocnemius muscle was dissected from the hindlimb, half the muscle was snap frozen at 
-80
o
C in Eppendorf tubes for RNA/protein analysis. The other half was placed in a tube 
containing Tissue Tek
®
 OCT™ compound (IA018, ProSciTec, QLD, Australia). The 
muscle was snap frozen in liquid nitrogen and stored at -80
o
C until ready to be processed 
for histology. 
 
5.2.4. Plasma isolation from whole blood 
Whole blood collected by right ventricular puncture was kept on ice until 
centrifugation at 5000 rpm for 5 minutes. The plasma layer was collected in three 50 L 
aliquots with a fourth aliquot of remaining plasma, and stored at -80
o
C. Plasma was used to 
determine CC-chemokine concentration by ELISA, CC-chemokine activity by chemotaxis 
assay and lipid profile (Chapter 2, Section 2.3.8 – 2.3.11). 
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5.2.5. Tissue processing 
After collection of femoral artery or hindlimb muscle tissue, samples were prepared 
for immunohistochemical or immunofluorescence histological staining as stated in Chapter 
2 Section 2.3.6. Histological staining was used to detect CD31, smooth muscle -actin, 
CD68, or collagen. A portion of this tissue was set aside for gene analysis by RT-PCR 
(Chapter 2, Section 2.3.7) to detect CCL2, CCL5, markers of inflammation, hypoxia, and 
angiogenesis. For analyses in the hindlimb model, a portion of hindlimb tissue was used to 
detect protein levels of CC-chemokines, MIF, and VEGF, by ELISA (Chapter 2, Section 
2.3.8.2) and PHDs and HIF-1α by Western blot (Chapter 2, Section 2.3.8.3).  
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5.3. Results 
5.4. Plasma lipids 
Assessment of total cholesterol, HDL, LDL and total triglycerides showed no 
significant differences between treatment groups for both the peri-arterial cuff (Table 5.1) 
and hindlimb ischaemia (Table 5.2) models.  
 
Table 5.1. Plasma lipids in the peri-arterial cuff model. 
PERI-ARTERIAL CUFF PBS AdGFP Ad35K 
Total Cholesterol (mg/mL) 1.53  0.02 1.81  0.03 1.61  0.02 
HDL (mg/mL) 1.21  0.31 1.18  0.93 1.06  0.55 
LDL (mg/mL) 0.31  0.75 0.62  0.89 0.55  0.79 
Triglycerides (mg/mL) 0.74  0.01 0.59  0.01 0.73  0.02 
Data is expressed as meanSEM.  
 
Table 5.2. Plasma lipids in the hindlimb ischaemia model. 
HINDLIMB ISCHAEMIA PBS AdGFP Ad35K 
Total Cholesterol (mg/mL) 1.82  0.02 1.46  0.01 1.84  0.01 
HDL (mg/mL) 1.58  0.23 1.09  0.38 1.42  0.42 
LDL (mg/mL) 0.23  0.90 0.38  0.73 0.42  0.91 
Triglycerides (mg/mL) 0.45  0.02 0.76  0.06 0.47  0.01 
Data is expressed as meanSEM.  
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5.5. Confirmation of adenoviral gene transfer of Ad35K and AdGFP 
To confirm the successful gene transfer of Ad35K by systemic delivery, plasma 
from mice of each group were run on a Western blot following immunoprecipitation of 
35K with Anti-HA agarose (Chapter 2, Section 2.2.5). Figure 5.4A shows that 35K protein 
was only detected in the plasma of mice injected with Ad35K, whilst the plasma from mice 
injected with PBS and AdGFP produced no band. Additionally in Figure 5.4B, gene 
transfer was confirmed for AdGFP, a cytosolic protein, represented by green fluorescence 
detected in the livers of the AdGFP mice only. Levels of both circulating 35K protein and 
green liver fluorescence were higher in the mice from the hindlimb ischaemia study 
(euthanised 14 days post-surgery) compared to the peri-arterial cuff model (euthanised 21 
days post-surgery).  
 
 
  
Page | 126  
 
 
Figure 5.4. Confirmation of adenoviral gene transfer. 
(A) Western immunoblotting was used to detect the presence of circulating 35K protein in 
plasma samples from mice injected with PBS, AdGFP or Ad35K for the peri-arterial cuff 
and hindlimb ischaemia model. (B) Livers of mice injected with PBS, AdGFP, or Ad35K 
from both the peri-arterial cuff and hindlimb ischaemia model were sectioned (5 m) and 
viewed for green fluorescence using fluorescence microscopy. Scale bars represent 100 
m. 
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5.6. Histological analysis of in vivo angiogenesis models 
5.6.1. The effect of broad-spectrum CC-chemokine inhibition by Ad35K on 
neovascularisation in the in vivo model of inflammatory-driven angiogenesis 
Neovessels and arterioles were determined by histological staining for CD31 
(endothelial cells in neovessels) and smooth muscle -actin (smooth muscle in arterioles) 
as seen in Error! Reference source not found.A. Neovessels indicate vessels in the early 
stage of development whilst arterioles represent the more advanced vessels that contain a 
smooth muscle cell outerlayer. In the peri-arterial cuff model, the Ad35K injected mice 
displayed a non-significant 30.9% reduction in the number of neovessels compared to PBS 
injected mice (Figure 5.5B), while the AdGFP injected mice displayed a non-significant 
28.4% increase of neovessels compared to PBS injected mice. Comparison of adenoviral 
cohorts showed that Ad35K injected mice also had reduced neovessels (49.2%, ns) 
compared to the AdGFP viral mice. Upon analysis of the number of arterioles in the cuffed 
artery (Figure 5.5C), arterioles in the AdGFP injected mice increased substantially 
(223.3%, p<0.01) compared to the PBS injected mice. However, there were significantly 
less arterioles in Ad35K infused mice when compared to AdGFP infused mice (85.7%, 
p<0.001 vs. AdGFP). Furthermore, there were fewer arterioles (52.7%, ns) formed in the 
Ad35K cohort compared to the PBS control.  
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Figure 5.5. Ad35K inhibits neovascularisation and arteriole formation in the peri-arterial 
cuff model. 
(A) Representative images of neovessels as detected by CD31 staining (brown) and 
arterioles identified by -actin staining (pink) in the femoral artery adventitia of PBS, 
AdGFP and Ad35K injected mice following peri-arterial cuffing. (B) Number of neovessels 
was determined as CD31
+
 cells in the adventitia. (C) Number of arterioles was determined 
as α-actin+ staining in the adventitia. Scale bars represent 50 m. Data is expressed as 
meanSEM. Statistical analysis was performed using a One-way ANOVA with Tukey’s 
post hoc analysis **p<0.01 compared to PBS. ^^^p<0.001 compared to AdGFP. 
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5.6.2. The effect of broad-spectrum CC-chemokine inhibition by Ad35K on 
macrophage infiltration in the in vivo model of inflammatory-driven angiogenesis  
Macrophage infiltration was assessed in the peri-arterial cuff model as a marker of 
inflammation (Figure 5.6). In the Ad35K injected mice there was a significant decrease in 
CD68
+
 staining compared to the PBS group (69.5%, p<0.05) while no significant 
differences were seen between AdGFP and Ad35K.  
 
 
Figure 5.6. Macrophage infiltration is reduced with Ad35K in the peri-arterial cuff model. 
Representative images of macrophage infiltration as detected by staining for CD68 
(brown) staining in the femoral artery adventitia of PBS, AdGFP and Ad35K injected mice 
following peri-arterial cuffing. Scale bars represent 50 m. Data is expressed as 
meanSEM. Statistical analysis was performed using a One-way ANOVA with Tukey’s 
post hoc analysis. *p<0.05 compared to PBS. 
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5.6.3. The effect of broad-spectrum CC-chemokine inhibition by Ad35K on the 
intima:media ratio in the in vivo model of inflammatory-driven angiogenesis 
For the peri-arterial cuff model, the intima:media ratio was assessed by first 
staining sections of the artery with Milligan‟s trichrome to differentiate between the 
intima, media and adventitia of the vessel (Figure 5.7). When assessing the intima:media 
ratio we found no differences in the intima:media ratio across all three treatment groups.  
 
 
Figure 5.7. Intima:media ratio is unchanged with Ad35K treatment in the peri-arterial cuff 
model. 
Sections of cuffed femoral arteries were stained with Milligan’s trichrome stain in mice 
receiving PBS, AdGFP or Ad35K. Solid red line indicates the media, dotted red line 
indicates the intima. Scale bars represent 50m. Data is expressed as meanSEM. 
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5.6.4. The effect of broad-spectrum CC-chemokine inhibition by Ad35K on blood flow 
recovery in the in vivo model of ischaemia-mediated angiogenesis 
In the hindlimb ischaemia model, laser Doppler imaging (LDI) was used to assess 
blood perfusion as a marker of angiogenesis (Figure 5.8). The LDI perfusion ratio was 
determined as the ratio of the ischaemic leg compared to the non-ischaemic, sham leg, for 
each mouse. Blood flow was equally reduced in hindlimbs of all treatment groups 
following unilateral femoral artery ligation. Comparison of LDI perfusion ratios confirmed 
that sufficient blood flow returned to all treatment groups by day 14. No differences in 
blood flow perfusion were seen between the Ad35K cohort compared to both AdGFP and 
PBS controls. 
 
 
Figure 5.8. Blood flow recovery was not inhibited in the Ad35K mice of the hindlimb 
ischaemia model.  
Representative Laser Doppler imaging (LDI) images of ischaemic (Isc) and non-ischaemic 
(Non) hindlimbs from mice injected with PBS, AdGFP, or Ad35K at day 14 end point (left 
panel). Cool colours represent low blood flow, whilst warm colours represent high blood 
flow. In these mice, LDI perfusion ratio was calculated as a ratio of ischaemic:non-
ischaemic hindlimb (right panel). Data is expressed as meanSEM.  
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5.6.5. The effect of broad-spectrum CC-chemokine inhibition by Ad35K on 
neovascularisation in the in vivo model of ischaemia-mediated angiogenesis 
In contrast to the strong inhibitory effects of 35K in the peri-arterial cuff model, 
broad-spectrum CC-chemokine inhibition in the Ad35K mice had no effect on the 
neovasculature compared to the AdGFP and PBS controls in the hypoxia-mediated 
angiogenesis model of hindlimb ischaemia (Figure 5.9). The capillary density, as indicated 
by the amount of red CD31
+
 staining relative to blue laminin (myocytes) staining (Figure 
5.9A), was not affected by the injection of Ad35K compared to injections with AdGFP or 
PBS (Figure 5.9B). In contrast to the suppression in arterioles seen in the peri-arterial cuff 
model, a significant increase in arterioles was seen in the Ad35K injected mice (191.8%, 
p<0.05, Figure 5.9C). 
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Figure 5.9. Ad35K increases arterioles in the hindlimb ischaemia model. 
(A) Representative images of neovessels detected by CD31 (red), arterioles identified by -
actin (green), and myocytes detected by laminin (blue) in the ischaemic hindlimb tissue of 
the PBS, AdGFP, or Ad35K injected mice. Arrows indicate presence of neovessels in the 
tissue. (B) Capillary density was determined as CD31
+
 cells/myocyte. (C) Arteriole density 
was determined as α-actin+ cells/myocyte. Scale bars represent 100 m. Data is expressed 
as meanSEM. Statistical analysis was performed using a One-way ANOVA with Tukey’s 
post hoc analysis. *p<0.05 compared to PBS.  ^p<0.05 compared to AdGFP.  
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5.7. CC-chemokine analysis 
5.7.1. Circulating CC-chemokines 
In this study, we found that circulating levels of CC-chemokines CCL2 and CCL5 
drastically increased in the plasma of Ad35K injected mice in both the peri-arterial cuff 
and hindlimb ischaemia models compared to both the non-viral (PBS) and adenoviral 
(AdGFP) controls (Figure 5.10). In the peri-arterial cuff model, injection of Ad35K 
increased circulating CCL2 when compared to both the non-viral PBS and adenoviral 
AdGFP control groups (834.1% and 368.5% respectively, p<0.001, Figure 5.10A). 
Furthermore, Ad35K also increased circulating CCL5 levels above the non-viral PBS 
(142.1%, p<0.001) control group (Figure 5.10B). Similarly, in the hindlimb ischaemia 
study, Ad35K increased circulating CCL2 levels by 1324.5% (p<0.001) compared to PBS, 
whilst a 238.5% increase (p<0.001) was seen when compared to AdGFP control (Figure 
5.10C). Ad35K also increased circulating CCL5 levels above both the PBS and AdGFP 
groups (410.1% and 152.4% respectively, p<0.001, Figure 5.10D). 
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Figure 5.10. Circulating CC-chemokines are increased in Ad35K mice. 
Circulating (A) CCL2 and (B) CCL5 levels was assessed by ELISA in mouse plasma from 
peri-arterial cuff model. Circulating (C) CCL2 and (D) CCL5 levels were also measured in 
the hindlimb ischaemia model. Data is expressed as meanSEM. Statistical analysis was 
performed using a One-way ANOVA with Tukey’s post hoc analysis. *p<0.05, ***p<0.001 
compared to PBS. ^^^p<0.001 compared to AdGFP. 
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5.7.2. CC-chemokine activity 
To determine the activity of the circulating CC-chemokines, the chemotaxis assay 
was used. For this assay, fluorescently-labelled monocytes are allowed to migrate across a 
porous membrane towards a stimulus (i.e. CC-chemokines in plasma). 
There was no difference in the number of monocytes migrating towards the plasma 
samples of Ad35K mice compared to the PBS cohort, however a 27.1% decrease (p<0.05) 
was seen when compared to the adenoviral AdGFP controls from the peri-arterial cuff 
model (Figure 5.11A). Similarly when comparing the samples from the hindlimb 
ischaemia model, the number of monocytes migrating towards the Ad35K plasma stimulus 
decreased by 21.2% (p<0.05) compared to PBS plasma (Figure 5.11). These results 
demonstrate that 35K suppresses CC-chemokine acitivity in the plasma of Ad35K injected 
mice in both models. 
 
 
Figure 5.11. Reduction of CC-chemokine activity in Ad35K plasma. 
Chemokine activity was determined using the Boyden chamber assay to assess monocyte 
migration towards plasma samples from PBS, AdGFP or Ad35K injected groups from both 
the (A) peri-arterial cuff model and (B) hindlimb ischaemia model. Data is expressed as 
meanSEM. Statistical analysis was performed using a One-way ANOVA with Tukey’s 
post hoc analysis. *p<0.05 compared to PBS. ^ p<0.05 compared to AdGFP. 
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5.7.3. CC-chemokine tissue expression 
The expression of CC-chemokines in tissue was determined by measuring mRNA 
and protein levels in homogenised tissue. 
In the peri-arterial cuff model 35K significantly reduced CCL2 mRNA levels by 
76.6% (p<0.05) compared to PBS, whilst a non-significant 45.6% decrease was observed 
when compared to AdGFP (Figure 5.12). Overall, CCL5 mRNA levels were unchanged 
across all three groups (Figure 5.12B). 
Conversely in the hindlimb ischaemia model, Ad35K injected mice had reduced 
CCL2 mRNA levels compared to the adenoviral AdGFP control group (31.4% decrease, 
p=0.051, Figure 5.13A). This trend in reduction of CCL2 in the Ad35K injected mice 
appeared to be consistent with the protein expression, with a non-significant 26.8% 
decrease seen when compared to AdGFP (Figure 5.13C). Interestingly, CCL5 mRNA 
(Figure 5.13) and protein (Figure 5.13) levels were significantly higher in the AdGFP 
group compared to the PBS controls (675.2% and 332.4% respectively, p<0.05). More 
importantly, 35K was able to suppress this increase, with decreases seen at both the mRNA 
(66.0%) and protein (70.5%) levels (p<0.001).  
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Figure 5.12. CCL2 and CCL5 expression in peri-arterial cuff model. 
RT-PCR was used to detect mRNA levels of (A) CCL2 and (B) CCL5 in peri-arterial cuff 
tissue of PBS, AdGFP, or Ad35K injected mice. Data is expressed as meanSEM. 
Statistical analysis was performed using a One-way ANOVA with Tukey’s post hoc 
analysis. *p<0.05 compared to PBS. 
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Figure 5.13. CCL2 and CCL5 expression in hindlimb ischaemia model. 
RT-PCR was used to detect mRNA levels of (A) CCL2 and (B) CCL5 in ischaemic hindlimb 
tissue from PBS, AdGFP, or Ad35K injected mice. ELISAs were used to determine protein 
levels of (C) CCL2 and (D) CCL5 in hindlimb tissue. Data is expressed as meanSEM. 
Statistical analysis was performed using a One-way ANOVA with Tukey’s post hoc 
analysis. ***p<0.001 compared to PBS. ^^^p<0.001 compared to AdGFP. 
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5.8. Expression of angiogenic markers 
5.8.1. Gene expression of markers involved in inflammation 
Inflammatory-driven angiogenesis is regulated primarily by the NF-κB signalling 
pathway which creates an inflammatory response that then promotes the recruitment of 
monocytes/macrophages to the inflamed sites. Tissue gene expression of the active NF-B 
subunit, p65 (Figure 5.14A) and CD68 (Error! Reference source not found.B) showed 
no significant differences across all three groups.  
 
 
Figure 5.14. Gene expression of inflammatory markers in the peri-arterial cuff model. 
RT-PCR was used to determine mRNA levels of (A) p65 and (B) CD68 in peri-arterial cuff 
tissue of PBS, AdGFP, or Ad35K injected mice. Data is expressed as meanSEM. 
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5.8.2. Gene expression of markers involved in hypoxia 
Hypoxia-mediated angiogenesis is driven by the key transcription factor HIF-1α, 
which is post-translationally modulated by the E3 ubiquitin ligases Siah1 and Siah2 and 
the prolyl hydroxylase family (PHD1-3). The expression of these angiogenic hypoxic 
markers were determined in hindlimb tissue following femoral artery ligation. 
Overall, the majority of markers involved in the post-translational modulation of 
HIF-1α saw little to no inhibition in mice injected with Ad35K when compared to the PBS 
and AdGFP control mice. No significant differences were seen in the mRNA levels of 
Siah1 (Figure 5.15A) and Siah2 (Figure 5.15B) across all three groups. Interestingly, 
PHD1 mRNA levels were significantly increased with Ad35K, compared to PBS (200.4%, 
p<0.001) and AdGFP (78.4%, p<0.05) (Figure 5.15C). These changes were not reflected in 
the other two members of the prolyl hydroxylase family, with no differences detected in 
the mRNA levels of PHD2 (Figure 5.15D) and PHD3 (Figure 5.15E). Additionally, protein 
expression of PHD1 (Figure 5.16A), PHD2 (Figure 5.16B), and PHD3 (Figure 5.16C) 
were not changed in ischaemic tissue of mice injected with Ad35K compared to PBS and 
AdGFP injected mice. 
 
 
Page | 142  
 
 
Figure 5.15. Gene expression of hypoxic markers in the hindlimb ischaemia model. 
RT-PCR was used to determine mRNA levels of (A) Siah1, (B) Siah2, (C) PHD1, (D) 
PHD2, and (E) PHD3 in the ischaemic hindlimb tissue from PBS, AdGFP, or Ad35K 
injected mice. Data is expressed as meanSEM. Statistical analysis was performed using a 
One-way ANOVA with Tukey’s post hoc analysis. ***p<0.001 compared to PBS. ^p<0.05 
compared to AdGFP. 
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Figure 5.16. Protein expression of hypoxic markers in the hindlimb ischaemia model. 
Western blot was used to determine protein levels of (A) PHD1, (B) PHD2, and (C) PHD3 
in the ischaemic hindlimb tissue from PBS, AdGFP, or Ad35K injected mice. Data is 
expressed as meanSEM. 
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5.8.3. Gene expression of key angiogenic markers 
The expression of key angiogenic markers involved in both inflammatory- and 
hypoxia-driven angiogenesis (HIF-1α, VEGF, CXCL12, and MIF) were determined for 
both models.  
We observed interesting trends in gene expression of the angiogenic markers in the 
peri-arterial cuff model. Firstly, HIF-1α mRNA levels were not significantly different 
across all three groups, although there was a trend towards an increase in both adenoviral 
groups above the vehicle PBS group (Figure 5.17A). While there was no significant 
differences in VEGF gene expression between PBS and AdGFP groups, there was a 
significant 47.2% (p<0.05) decrease in Ad35K mice when compared to PBS and a non-
significant 22.9% decrease (p=0.053) when compared to AdGFP (Figure 5.17B). Overall, 
CXCL12 levels appeared lower in the Ad35K group while the expression levels were more 
variable in the PBS and AdGFP groups, with a 66.1% and 51.3% non-significant reduction 
seen when compared to PBS and AdGFP respectively (Figure 5.17C). Finally, 35K 
increased MIF expression by 94.5% (p<0.05) compared to AdGFP while there was a trend 
to increased levels when compared to PBS (Figure 5.17D).  
In contrast, HIF-1α (Figure 5.17B), VEGF (Figure 5.17D), CXCL12 (Figure 
5.17F), and MIF (Figure 5.17H) mRNA levels were not significantly different across all 
three treatment groups in the hindlimb ischaemia model. Furthermore, no significant 
differences in HIF-1α (Error! Reference source not found.A), VEGF (Figure 5.18B) and 
MIF (Figure 5.18C) protein levels were observed. 
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Figure 5.17. Gene expression of angiogenic markers in the peri-arterial cuff and hindlimb 
ischaemia models. 
RT-PCR was used to determine gene expression of (A, B) HIF-1α, (C, D) VEGF, (E, F) 
CXCL12, and (G, H) MIF in the peri-arterial cuff and hindlimb ischaemia models. Data is 
expressed as meanSEM. Statistical analysis was performed using a One-way ANOVA 
with Tukey’s post hoc analysis. *p<0.05 compared to PBS. ^p<0.05 compared to AdGFP. 
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Figure 5.18. Protein expression of angiogenic markers in the hindlimb ischaemia model. 
Ischaemic hindlimb tissue was homogenised and assessed by Western blot to determine (A) 
HIF-1α, and ELISAs used to determine (B) VEGF, and (C) MIF protein. Data is expressed 
as meanSEM.  
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5.9. Discussion 
The present study sought to determine whether the in vitro effects of 35K observed 
in Chapters 3 and 4 could be translated to in vivo murine models of angiogenesis. In 
contrast to the in vitro studies, we used an adenoviral gene transfer approach for these 
studies to overexpress soluble 35K systemically. We found that broad-spectrum inhibition 
of CC-chemokines by 35K inhibited inflammatory-driven neovascularisation in the peri-
arterial cuff model as noted by reduced capillaries and arterioles. Conversely, 35K did not 
affect recovery of blood perfusion following induction of ischaemia in the hindlimb 
ischaemia model. Furthermore in ischaemia, capillary and arteriole density were not 
attenuated by broad-spectrum CC-chemokine inhibition, indicating that ischaemia-induced 
angiogenesis was preserved in vivo.  
The peri-arterial cuff model was used to stimulate inflammatory-driven 
angiogenesis. This model involved the placement of a cuff around the vessel. The cuff is 
larger than the vessel allowing unrestricted blood flow through the vessel. Placement of the 
cuff around the femoral artery initiates a localised inflammatory response which triggers 
the recruitment of macrophages and the release of pro-inflammatory cytokines and growth 
factors that drive increased neovessel formation at the site of injury (Bhardwaj et al. 2011). 
New vessel formation was assessed in the adventitia of the femoral artery by histological 
staining for CD31
+
 endothelial cells (neovessels) and α-actin+ for smooth muscle cells 
(arterioles), which represent early and late neovessels. A significant inhibition in the 
number of neovessels and arterioles were seen in the mice injected with Ad35K when 
compared to the controls. We hypothesise that the initial suppression in the formation of 
neovessels by 35K then results in the subsequent reduction in the number of arterioles that 
were able to mature. It is also possible that broad-spectrum CC-chemokine inhibition has 
direct effects on smooth muscle cells and the maturation of neovessels into arterioles, as 
the inhibitory effect of 35K on arterioles was more striking than on neovessel formation. 
Macrophages also play an important role in modulating inflammatory-driven 
angiogenesis by secreting pro-angiogenic cytokines and growth factors. Our in vivo model 
of inflammation-induced adventitial neovascularisation found that, whilst there was a trend 
for a reduction in adventitial macrophages and CD68 mRNA levels, 35K did not have a 
significant inhibitory effect on macrophage recruitment. This suggests that the inhibitory 
effect of 35K on neovascularisation in inflammation is via 35K suppressing the direct 
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effect of CC-chemokine activity on endothelial cells and angiogenesis rather than the 
indirect effect via the initial recruitment of macrophages. Additionally, 35K has high 
specificity binding to CC-chemokines only, and does not bind to other chemokine classes. 
Therefore the lack of significant reduction of macrophages in the tissue may be due to 
reduced chemokine activation of monocytes which are Ly6C
high
 or Ly6C
low
. Ly6C
high
 
monocytes have surface markers which are CCR2
high
 and CX3CR1
low
, thus 35K is more 
likely to prevent activation of these monocytes by binding to CCL2. However, Ly6C
low
 
monocytes have surface markers which are CCR2
low
 and CX3CR1
high
, these are patrolling 
monocytes, which are not affected by CCL2/35K binding as they primarily bind to 
CX3CL1 ligands (Burns et al. 2002). 
The intima:media ratio is a determination of the extent of neointimal hyperplasia in 
the artery.  Angiogenesis in the adventitia can drive this response (Khurana et al. 2004). 
However, no differences were seen in the intima:media ratio across all three groups. This 
suggests that inhibition of adventitial neovascularisation with broad-spectrum CC-
chemokine inhibition occurs independently of changes in the neointimal area  
In contrast to the inhibitory effects that CC-chemokine inhibition had on 
inflammatory-driven angiogenesis in vivo, 35K had no effect on angiogenesis in ischaemia. 
In fact, there was an increase in arterioles. The hindlimb ischaemia model employed in this 
chapter is a well-established model of ischaemia-driven neovascularisation in vivo 
(Bonauer et al. 2009), where both angiogenesis and arteriogenesis can be investigated 
depending upon where the placement of the ligature, and whether the femoral vessels are 
completely excised. The current study ligated the femoral artery above both the epigastrica 
and profunda femoris before severing them distal to the ligation. The femoral artery and 
vein were also completely excised as distal as the popliteal. This method ensures that 
angiogenesis occurs rather than arteriogenesis and has been utilised by multiple research 
groups worldwide for this purpose; and was recently characterised in detail (Limbourg et 
al. (2009). Furthermore, the gastrocnemius muscle which is distal to the ligation and rich in 
neovessels was analysed, rather than the adductor muscle where arteriogenesis may occur. 
Therefore, the arterioles detected in the gastrocnemius muscle, of which there are few, 
have developed directly from neovessels. 
Blood flow perfusion, as a marker of neovascularisation was not different between 
the Ad35K group and control cohorts. This suggests that broad-spectrum CC-chemokine 
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inhibition does not impact ischaemia-driven blood flow recovery. Furthermore, there were 
no differences in the number of neovessels in the hindlimb of the Ad35K injected mice 
compared to the controls. Interestingly, we observed a significant increase in the number of 
arterioles with the Ad35K group. Taken together, our two in vivo angiogenesis models 
showed that 35K specifically inhibits inflammatory-driven angiogenesis, but yet, has no 
effect on and is preserved in hypoxia. 
The expression of two CC-chemokines, CCL2 and CCL5, were measured in the 
plasma as well as the tissues of these mice. We found that Ad35K injected mice had 
significantly higher circulating CC-chemokine levels when compared to both the PBS 
vehicle control and the AdGFP adenoviral control in both in vivo models. While 
intuitively, this might seem unexpected, previous studies have also reported similar 
observations (Bursill et al. 2003; Bursill et al. 2004). We then sought to determine if the 
chemokine activity in the plasma samples of these mice was inhibited using a monocyte 
migration assay. Interestingly we found that, despite the increased levels of circulating CC-
chemokines in the plasma of the Ad35K mice, plasma CC-chemokine activity was 
reduced, as indicated by the reduced number of monocytes that migrate towards the 
Ad35K mouse plasma when compared to plasma from either PBS or AdGFP mice. Taken 
together, this suggests that 35K is bound to the CC-chemokines, thereby blocking the 
binding area of receptors on the surface of monocytes. Furthermore, when CC-chemokine 
levels were measured in the tissues, the reduction of CC-chemokines becomes evident. 
Given these observations, we propose that 35K protein is able to bind to CC-chemokines in 
the tissue and sequester them into the circulation resulting in an increase of circulating CC-
chemokine levels. Alternatively, circulating CC-chemokine levels increase to compensate 
for the reduced activity, however 35K continues to bind to new CC-chemokines preventing 
increase in activity leading to elevated levels of circulating (but inactive) CC-chemokines 
which is still detectable by ELISAs. With the reduction of CC-chemokine activity, the 
monocytes are unable to migrate and differentiate into macrophages. This reduces the 
inflammatory response in the tissue, consequently reducing inflammatory-driven 
angiogenesis. We see this with a trend towards reduced expression of two inflammatory 
angiogenic markers, the active NF-B subunit, p65, and macrophage marker CD68 in the 
Ad35K injected mice of the inflammatory in vivo model. However, given that 
inflammation occurs at the early stages of this model, the lack of change in mRNA levels 
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may not necessarily reflect the true action of 35K on inflammation and perhaps an earlier 
timepoint would be better suited to observe these effects in vivo.  
Post-translational modulation of HIF-1α is important in hypoxic cellular responses 
where under normoxic conditions, the prolyl hydroxylases (PHD1-3) function to 
hydroxylate HIF-1α, targeting it for ubiquitination and degradation. However, upon 
hypoxic stimulation, the E3 ubiquitin ligases Siah1 and Siah2 are upregulated, causing the 
inhibition of PHD1, PHD2, and PHD3. This prevents the degradation of HIF-1α allowing 
it to accumulate and translocate to the nucleus to drive hypoxia-responsive genes such as 
CXCL12 and VEGF to help mediate the cellular angiogenic response. There were no 
differences in Siah1, Siah2, PHD2 and PHD3 mRNA levels across all three treatment 
groups. Interestingly, while there was a significant increase in PHD1 mRNA levels in the 
Ad35K group, there were no differences in the protein levels of the PHD family suggesting 
that broad-spectrum CC-chemokine inhibition does not have any significant impact on the 
hypoxia-mediated angiogenic pathway.  
The expression of key pro-angiogenic mediators HIF-1α and VEGF were also 
determined in the tissue of both inflammation and ischaemia models. VEGF is essential in 
angiogenesis under both conditions as it contains both hypoxia (HIF) and inflammatory 
(NF-B) response elements in its promoter region (Ema et al. 1997; Forsythe et al. 1996; 
Levy et al. 1995; Shi et al. 2001). Additionally, HIF-1α has the NF-B response element in 
its promoter region. Similar to the in vitro studies, VEGF mRNA levels was found to be 
inhibited in inflammation but remain unchanged under hypoxia. In contrast to our in vitro 
observations where 35K suppressed HIF-1α levels, overall there was no significant 
differences in HIF-1α in vivo. Given that mRNA levels were detected at the conclusion of 
the study and that HIF-1α is usually triggered at the early stage of inflammatory/ischaemic 
response, perhaps any effect of 35K on HIF-1α may be lost and an earlier time point may 
provide more information. Similar to our in vitro mechanism findings, 35K had no effect 
on the post-translational HIF-1α mediators, Siahs and PHDs in vivo. Although there is only 
a slight non-significant reduction of NF-B this may be enough to affect HIF-1α and 
VEGF. VEGF is particularly affected by any changes to NF-B as it has two response 
elements for NF-B in its promoter region but only one hypoxic response element 
(Ramanathan et al. 2007). Furthermore, 35K may be conditionally regulating VEGF 
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through NF-B in inflammation, whilst having no effects on the hypoxic response element 
in hypoxia. 
Further analysis of macrophage migration inhibitory factor (MIF), a CXC 
chemokine that plays a role in angiogenesis in hypoxia, found it was unchanged in the 
hypoxic tissue. This would be expected as 35K specifically inhibits the CC-chemokine 
class. Interestingly, MIF was increased in our inflammatory-driven peri-arterial cuff 
model. MIF is also known to regulate the expression of macrophages in inflammatory 
conditions and this involves CCL2/CCR2 and CCL5/CCR5 CC-chemokine/receptor 
interactions (Gregory et al. 2006). Through inhibition of CC-chemokine activity by 35K, a 
compensatory elevation in MIF expression may therefore be occurring in our inflammatory 
model. 
In conclusion, the inhibition of CC-chemokine class by 35K suppresses 
inflammatory-driven angiogenesis, but yet preserves hypoxia-mediated angiogenesis in 
vivo. Broad-spectrum inhibition of the CC-chemokine class may present as a therapeutic 
strategy to specifically target diseases associated with inflammatory-driven angiogenesis 
such as atherosclerosis and cancer, without causing the adverse side effects that occur with 
complete inhibition of angiogenesis across all pathophysiological contexts. However, the 
effects of broad-spectrum CC-chemokine inhibition in a system where angiogenesis is 
driven by both inflammation and hypoxia, such as that seen in cancer progression remains 
to be elucidated. 
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CHAPTER 6.                   
THE EFFECT OF   
BROAD-SPECTRUM                     
CC-CHEMOKINE 
INHIBITION IN A MODEL 
OF TUMOUR 
NEOVASCULARISATION  
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6.1. Introduction 
In cancer, tumour development is caused by a defect in the homeostatic 
environment of the cell, leading to abnormal proliferation (Cooper 2000). As the tumour 
cells become distant from nearby vessels, neovascularisation is critical for the development 
of new blood vessels to supply growth factors and oxygen allowing for tumour growth and 
expansion (Carmeliet & Jain 2000a). For this reason, angiogenesis is critical to the tumour 
environment. An imbalance between pro- and anti-angiogenic stimulators is compromised 
leading to excessive angiogenesis and exacerbation of tumour growth. Changes which are 
triggered by the imbalance include increased inflammation, increased cell proliferation, 
increased cell invasion, and decreased apoptosis, which ultimately leads to tumour growth 
and progression/development. Various signals which trigger this imbalance include low 
oxygen, increased inflammatory response and genetic mutations (Carmeliet & Jain 2000a). 
Hypoxia is a common characteristic of locally advanced solid tumours and has been linked 
to diminished therapeutic response and progression of malignant tumours (Vaupel & 
Harrison 2004).  
As tumours are reliant on new blood vessel formation, angiogenesis is thought to be 
a good target for anti-tumour therapy. Current anti-angiogenic therapies available such as 
bevacizumab or TNP-470 inhibit VEGF or the endothelial cell cycle respectively (Ferrara, 
Hillan & Novotny 2005; Masiero, Figg & Kohn 1997; Teicher et al. 1994). However, the 
overall and complete inhibition of angiogenesis by these therapies causes a number of side 
effects including hypertension, haemorrhaging, vomiting, nausea, gastrointestinal 
perforations and reduced wound healing (Cabebe & Wakelee 2007; Mourad et al. 2008; 
Satchi-Fainaro et al. 2004). Thus an agent which inhibits pathological angiogenesis whilst 
preserving physiological angiogenesis is needed as an alternate therapeutic strategy. In 
cancer CC-chemokines regulate the migration of inflammatory cells to the tumour 
microenvironment. They are especially involved in the migration of tumour associated 
macrophages (TAM) to promote tumour neovascularisation (Mantovani et al. 2004; Okada 
et al. 2009; Rivas-Fuentes et al. 2015; Zhang, Lu & Pienta 2010a). Our findings from 
Chapter 5 show that broad-spectrum CC-chemokine inhibition by 35K reduced 
angiogenesis in the context of inflammation, whilst having no effects on angiogenesis in 
the context of hypoxia. In this study we seek to determine the effect of 35K in a disease 
pathology that involves neovascularisation in response to both inflammation and hypoxia, 
as seen in the context of cancer.  
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6.2. Method 
6.2.1. Preparation of Lewis lung carcinoma cells 
Lewis lung carcinoma (LLC) cells were grown to 70% confluency in Lewis lung 
carcinoma cell media (0.35% [w/v] D-glucose, 10% [v/v] foetal calf serum, in DMEM). 
The cells were trypsinised and resuspended in Hank‟s Buffered Salt Solution (HBSS, 
H1387, Sigma Aldrich) and kept in a 37
o
C water bath until needed. 
 
6.2.2. Tumour neovascularisation model procedure 
As with the previous models, 6 – 8 week old male C57Bl/6J mice were injected via 
tail vein, with either PBS, 1 x 10
11
 vp AdGFP, or 1 x 10
11
 vp Ad35K, 3 days prior to 
procedure (n = 10 per treatment group). Mice were anaesthetised by inhalation of 
methoxyflurane. A 1 mL insulin syringe was used to inject 200 L of a 1x106 LLC 
suspension into the subcutaneous layer of the right flank of the mice. After injection, mice 
were monitored for signs of discomfort, and fed on standard diet and water. 
 
6.2.3. LLC model sacrifice and tissue collection 
Mice were sacrificed 12 days after injection of the LLC. Mice were sacrificed by 
overdose of methoxyflurane followed by cardiac puncture. Samples collected include the 
blood plasma, liver and tumour. Blood plasma and liver processing were completed as in 
previous chapters (Chapter 5, 5.5). A visible tumour was seen in the subcutaneous layer of 
the right flank of the mice. As it is highly vascularised, care was taken to excise the whole 
tumour by first removing tissue around the tumour. The tumour was then weighed and cut  
to be processed for histology and gene analyses. 
 
6.2.4. Histology 
For this study the tissue was placed in OCT and snap frozen at -80
o
C. Using the 
cryostat, 7 m sections were taken from the tissue. Each slide had 3 sections per sample, 
cut slides were stored at -20
o
C until use. 
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Initial fixing of slides was performed in 4% (v/v) paraformaldehyde in PBS for 10 
minutes, however we found that the sections did not remain adhered to the slide. To 
resolve this, StarFrost
®
 hydrophilic slides (G311SF, ProSciTech) were used, however the 
sections continued to wash off the slide during fixing. Samples were instead fixed with 
methanol for 10 minutes. This method allowed the sample to remain attached for longer, 
however excessive washing during staining resulted in folding of the edges of samples. To 
obtain the best results, washing was kept to a minimum, any liquids were gently placed on 
to the sample, and liquid was removed by drawing up with a pipette rather than tipping off 
the slide. 
To stain the slides after fixing, the samples were washed twice in PBS for 5 
minutes each. Sections were incubated with the primary antibodies smooth muscle -actin 
(1:1000, F3777, Sigma-Aldrich) and laminin (1:300, AB79057, Abcam), in antibody 
diluent with background reducing agent (S080983-2, Dako) in the dark at room 
temperature. Following incubation with primary antibody, the slides were washed twice in 
PBS for 5 minutes each, before 1 hour incubation with Alexa Fluor 350 secondary 
antibody (1:500, A21093, Invitrogen, California, USA) in antibody diluent. Coverslips 
were mounted onto stained slides in fluorescent mounting media. Slides were allowed to 
dry for 24 hours and kept in the dark before imaging. Samples were imaged at 10X 
magnification with 3 fields of view per section. 
 
6.2.5. Gene expression 
RNA from tumour samples were extracted using the Qiagen RNeasy Mini kit 
(74104, QIAGEN, Venlo, Netherlands). 400 ng of total RNA was reverse transcribed and 
real-time PCR was conducted as described in Methods (Chapter 2, Section 2.3.7).  
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6.3. Results 
6.3.1. Confirmation of Ad35K gene transfer 
As with the previous studies, Western blotting was used to confirm the expression 
and delivery of 35K by adenovirus in the plasma of mice from each group. 
Immunoprecipitation with anti-HA agarose was used to pull circulating 35K protein from 
the plasma. Figure 6.1A shows the detection of 35K protein in the plasma of the mice 
injected with Ad35K only, whilst no 35K bands were seen in the plasma from the PBS and 
AdGFP mice. Viral gene transfer was further confirmed by the presence of green 
fluorescence seen only in the livers of AdGFP mice (Figure 6.1B). 
 
 
Figure 6.1. Confirmation of Adenoviral gene transfer 
(A) Western immunoblotting was used to detect the presence of circulating 35K protein in 
plasma samples from mice injected with PBS, AdGFP or Ad35K in the tumour 
neovascularisation model. (B) Green fluorescence protein was detected in livers of mice 
injected with PBS, AdGFP or Ad35K to confirm the viral gene transfer of AdGFP. Scale 
bars represent 100 m. 
Page | 157  
 
6.3.2. Tumour weights 
Analysis of tumour weights (Figure 6.2) found no significant differences between 
the three groups. However, tumours from the Ad35K infused mice showed a trend for 
reduction in tumour weights when compared to PBS (11.5%) and AdGFP (13.0%). 
 
Figure 6.2.Comparison of tumour weights. 
Tumour weights from PBS, AdGFP and Ad35K injected mice were determined and 
compared. Data is expressed as meanSEM.  
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6.3.3. Neovascularisation 
Smooth muscle -actin was detected by immunohistochemistry in the tumour 
samples to assess mature blood vessels in the tumour. Staining and analysis of smooth 
muscle α-actin (Figure 6.3Error! Reference source not found.) found no significant 
differences between PBS, AdGFP and Ad35K. However there was a 14.5% reduction in 
the Ad35K group when compared to AdGFP. Additionally, mice injected with AdGFP had 
increased smooth muscle -actin staining (17.9%) compared to PBS injected mice.  
 
 
Figure 6.3.Smooth muscle α-actin in Lewis lung carcinoma cell tumours 
Immunofluorescence staining of smooth muscle -actin (green) and laminin (blue) to 
indicate arterioles in the tumour tissue. The percentage of -actin positive cells/tumour 
area was determined for PBS, AdGFP and Ad35K mouse tumours. Scale bars represent 
200 m. Data is expressed as meanSEM. 
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6.3.4. Gene expression in tumour tissue 
As tumour development and progression involves several key cellular processes 
including inflammation, proliferation, invasion and apoptosis, real-time PCR was used to 
measure markers of inflammation (p65, CCL2, VEGF, Bcl-2), cell proliferation (Ki-67, c-
Jun), cell invasion (MMP2, MMP9) , and cell apoptosis (p53, caspase 9, caspase 8, caspase 
3). These will be described in further detail below. 
6.3.4.1 Markers of inflammation 
When inflammation is stimulated, the PI3K/Akt pathway is activated (Figure 6.4). 
This causes the increase of IKK to phosphorylate IB, allowing the translocation of the 
transcription factor NF-B to the nucleus.  NF-B then activates the expression of pro-
inflammatory factors such CC-chemokines and VEGF to enhance the inflammatory 
response. NF-B is also able to activate Bcl-2, an anti-apoptotic (cell survival) gene. 
Excess inflammation in a tumour is a contributing factor that promotes tumour growth. In 
this model, to assess the effect of Ad35K on inflammation we determined the gene 
expression of p65, CCL2, VEGF and Bcl-2. 
The expression levels of p65, CCL2, VEGF and Bcl-2 were not significantly 
different between the three treatment groups. Although not significant a number of trends 
were observed and are highlighted in Table 6.1. Unexpectedly 35K had no effect on the 
expression of CCL2. There was also no difference in the expression levels of p65, the 
active subunit of NF-B (Table 6.1). While there was no inhibition of inflammation in the 
Ad35K mice, a non-significant increase in VEGF expression was observed, with a 34.3% 
and 130.0% increase seen when compared to PBS and AdGFP respectively. Interestingly, 
Bcl-2 expression increased by 95.7% and 71.2% in the Ad35K mice compared to PBS and 
AdGFP respectively. Furthermore, the adenoviral AdGFP control tumours exhibited a non-
significant decrease (41.6%) in VEGF expression when compared to PBS. 
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Figure 6.4. Inflammation pathway 
Inflammation activates the PI3K/Akt pathway to increase production of NF-B, leading to 
the release of pro-inflammatory factors to exacerbate inflammation. NF-B also increases 
the production of Bcl-2, responsible for cell survival. 
 
Table 6.1. Gene expression of inflammatory markers in tumour tissue 
Inflammatory Markers 
Gene 
PBS AdGFP Ad35K 
value value trend (vs. PBS) value trend (vs. AdGFP) 
p65 100.0 ± 8.1 89.1 ± 40.8 - 96.8 ± 25.1 - 
CCL2 100.0 ± 10.6 89.8 ± 35.7 - 93.7 ± 27.9 - 
VEGF 100.0 ± 17.0 58.4 ± 32.1  134.3 ± 43.5  
Bcl-2 100.0 ± 10.3 114.3 ± 25.7 - 195.7 ± 64.9  
Data is expressed as meanSEM.  
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6.3.4.2 Markers of proliferation and invasion 
Cell proliferation and cell invasion are essential in tumour growth and metastasis. 
Figure 6.5 illustrates one pathway involved in regulation of proliferation and invasion, 
which involves both the ERK and JNK signalling pathways. To assess the effect of CC-
chemokine inhibition on tumour cell proliferation and invasion, the expression levels of 
Ki-67 (a marker of cell proliferation), c-Jun, matrix metalloproteinase-2 (MMP2) and 
matrix metalloproteinase-9 (MMP9) were determined. 
In this study, there was a non-significant increase in Ki-67 expression levels in the 
tumours of the Ad35K mice, with a 25.8% and 64.0% increase seen when compared to 
PBS and AdGFP respectively (Table 6.2). Similarly, the expression levels of c-Jun, which 
dimerises with c-Fos to activate transcription factor AP-1 and in turn increase proliferation, 
was increased in the Ad35K tumours (100.1% when compared to PBS and 84.8% 
compared to AdGFP). Interestingly, in the AdGFP tumours, the expression of Ki-67 
decreased by 23.3%, whilst no changes were detected in c-Jun expression levels. 
Other than proliferation, AP-1 is also responsible for the regulation of extracellular 
matrix degradation by MMP2 and MMP9. In the Ad35K tumours, MMP2 decreased by 
39.4% when compared to the adenoviral AdGFP control group. However, in the Ad35K 
tumours, MMP9 levels increased by 104.8% and 89.4% when compared to PBS and 
AdGFP respectively. In addition, the expression levels of MMP2 was higher (64.1%) in the 
AdGFP tumours compared to PBS. 
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Figure 6.5. Proliferation and invasion pathway in tumours 
MAPK pathways, ERK and JNK activate c-Jun and c-Fos respectively. Together they 
activate the AP-1 transcription factor to promote cell proliferation, and the expression of 
matrix metalloproteinases MMP2 and MMP9 which are responsible for extracellular 
matrix degradation. 
 
Table 6.2. Gene expression of cell proliferation and cell invasion markers in tumour tissue 
Cell Proliferation and Cell Invasion Markers 
Gene 
PBS AdGFP Ad35K 
value value trend (vs. PBS) value trend (vs. AdGFP) 
Ki-67 100.0 ± 8.5 76.7 ± 29.8  125.8 ± 25.4  
c-Jun 100.0 ± 7.9 108.3 ± 41.6 - 200.1 ± 63.0  
MMP2 100.0 ± 22.1 164.1 ± 82.1  99.4 ± 73.3  
MMP9 100.0 ± 9.6 108.1 ± 34.7 - 204.8 ± 50.9  
Data is expressed as meanSEM.  
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6.3.4.3 Markers of apoptosis 
To determine the effect of Ad35K on apoptosis, gene expression of p53, caspase 9, 
caspase 8, and caspase 3 were determined. Apoptosis is initiated by the tumour suppressor 
gene p53 (Figure 6.6Error! Reference source not found.) that then leads to caspase 
activation. Ad35K had no effect on the apoptosis-related genes that were tested in the 
tumours, compared to AdGFP infused mice. However, in the Ad35K mice, there was a 
non-significant trend for an increase in p53 expression (61.0%) compared to PBS and by 
175.7% compared to AdGFP (Table 6.3). Downstream from p53, expression of caspase 9 
was not significantly different across all three groups. However, caspase 8 levels 
significantly increased by 148.3% (p<0.05) in Ad35K tumours compared to PBS, whilst a 
non-significant increase of 113.9% was seen when compared to AdGFP. Furthermore, 
caspase 3 expression in the Ad35K tumours was non-significantly elevated by 26.8% when 
compared to PBS and by 38.7% relative to AdGFP controls. 
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Figure 6.6. Apoptosis Pathway 
Tumour suppressor gene, p53 is activated in apoptosis. This leads to the increase of pro-
apoptotic gene, Bax, to suppress Bcl-2 production. Bax also causes the release of 
cytochrome C from the mitochondria to promote the release of caspase 9 leading to 
caspase 3 accumulation for apoptosis. Similarly, the increase of caspase 8 leads to 
elevated caspase 3 levels, ultimately driving apoptosis. 
 
Table 6.3.Gene expression of apoptosis markers in tumour tissue  
Apoptosis Markers 
Gene 
PBS AdGFP Ad35K 
value value trend (vs. PBS) value trend (vs. AdGFP) 
p53 100.0 ± 11.1 58.4 ± 19.9  161.0 ± 38.7  
Caspase 9 100.0 ± 8.1 117.1 ± 58.0 - 105.0 ± 41.0 - 
Caspase 8 100.0 ± 5.6 116.1 ± 29.7 - 248.3 ± 59.3  * 
Caspase 3 100.0 ± 7.4 91.4 ± 31.7 - 126.8 ± 29.8  
Data is expressed as meanSEM. Statistical analysis was performed using a One-way 
ANOVA with Tukey’s post hoc analysis. *p<0.05 compared to PBS.  
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6.4. Discussion 
The present study sought to determine whether the in vivo inhibition of 
inflammatory-driven angiogenesis by 35K, as seen in Chapter 5, was also effective in a 
tumour context where neovascularisation is driven by both inflammation and hypoxia. 35K 
was delivered systemically by adenoviral overexpression of 35K. Overall, the effects of 
35K were not striking and we only observed a trend towards a reduction in tumour size, 
which could be attributed to increases in the expression of apoptosis genes. The Lewis lung 
cancer model is an aggressive model of tumour formation, which may explain the lack of 
change in tumour formation; therefore our observations provide the impetus to perform 
future studies in alternate models of cancer. 
The Lewis lung carcinoma model was used to assess tumour neovascularisation as 
the tumour that develops is highly vascularised and therefore relevant to the focus of this 
thesis on angiogenesis. Following the infusion of Lewis lung carcinoma cells 
subcutaneously into mice, the tumour is not visible for the first 8 – 9 days. The tumour 
then very suddenly grows visibly large over the next 1 – 2 days. This rapid tumour growth 
over the short time frame of just 1 – 2 days makes the optimisation of experiments to 
determine treatment effects very challenging. Despite this, trends for a reduction in tumour 
weight by broad-spectrum CC-chemokine inhibition using 35K were observed. This 
indicates that suppression of CC-chemokine activity has some tumour suppressive effects. 
Histological assessment of smooth muscle cell α-actin positive arterioles also supported 
this trend for a reduction in tumour weights. There was a trend for a reduction in arterioles 
in the Ad35K mice when compared to adenoviral AdGFP controls. Overall, however, 35K 
had no real effects on tumour development. This was unexpected, given the striking effects 
seen with 35K in reducing inflammatory-driven angiogenesis both in vivo (Chapter 5) and 
in vitro (Chapter 3). However, tumour development and progression also involves 
additional cellular processes including cellular invasion and apoptosis as well as hypoxia-
driven angiogenesis, therefore 35K may not be able to modulate multiple cellular processes 
in such a way as to suppress tumour growth significantly. 
Previous studies have reported the presence of CC-chemokines in various 
malignancies, including breast cancer (CCL2, CCL5), prostate cancer (CCL2) and 
leukaemia (CCL1, CCL3) (Lu & Kang 2009; Soria & Ben-Baruch 2008; Tanaka et al. 
2005; Zhang, Lu & Pienta 2010a). These chemokines promote angiogenesis in the tumour. 
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In contrast to the suppression of tissue CC-chemokines by 35K in the models used in 
Chapter 5, we found that CCL2 was unchanged in the Ad35K treated mouse tumours, 
compared to controls. This is supported by a lack of change in tumour p65, indicating no 
reduction of inflammation. We propose that this inconsistency may be due to dysregulation 
of the tumour environment. Additionally 35K may not be having a strong inhibitory effect 
on CC-chemokines in the tumour environment due to the speed at which the model grows. 
Furthermore several CC-chemokine receptors are expressed on tumour cells (Balkwill 
2004; Muller et al. 2001; Murphy 2001) with comparatively more chemokines in the 
tumour compared to other pathologies, thus making it more difficult for 35K to prevent 
CC-chemokine ligand and receptor binding. Without a decrease in tumour CCL2 levels by 
35K, inflammatory cell recruitment would also not have been suppressed, as we would 
have hypothesised with 35K.  Macrophages express VEGF and contribute to tumour 
neovascularisation, thereby a lack of change in inflammatory recruitment can also account 
for a lack of significant change in tumour weight by 35K. Interestingly, we also found that 
levels of the anti-apoptotic gene Bcl-2 were trending towards an increase in the Ad35K 
tumours, which would have been an additional factor in preventing the suppression in 
tumour weight.  
Tumour progression involves cell proliferation and cell invasion. In Ad35K mice 
there was a trend for an increase in tumour Ki-67 expression, a known marker of cellular 
proliferation. Similarly c-Jun, associated with regulation of proliferation through AP-1 
(Shaulian & Karin 2002), was higher, although not significantly, in the Ad35K mice 
compared to controls. An increase in c-Jun, will lead to an increase in the expression of the 
transcription factor AP-1 which in turn promotes extracellular matrix degradation by 
MMP2 and MMP9. Ad35K lead to a doubling of MMP9 expression in the tumours, which 
function to degrade the cellular “barriers” allowing for tumour cell invasion and 
metastasis. Aided by the increase in c-Jun and MMP9, proliferation and cell invasion may 
have been promoted in the Ad35K mice. As tumour weights were slightly lower in Ad35K 
mice it raises doubts as to whether this was occurring. 
An imbalance between cell proliferation and cell death is characteristic of the 
tumour environment. Cell death by apoptosis is triggered in order to counteract the over 
growth of cells to rectify this imbalance. Upon further investigation of the tumours in this 
model, 35K was able to increase the expression of p53, the tumour suppressor gene. This 
leads to increase in Bax (pro-apoptosis) and the release of cytochrome C from the 
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mitochondria. This causes the increase of caspase 9, leading to increase of caspase 3 to 
increased apoptosis. Caspase 8 was also seen to increase. While no differences were seen 
in caspase 9 levels, Ad35K tumours had significantly higher levels of caspase 8 and a 
slight increase in caspase 3. The strong trends seen with the apoptosis markers could 
account for the slight reduction in tumour size. These results also suggest that 35K may be 
able to promote apoptosis in the tumours despite showing no signs of reducing 
inflammation or CCL2 expression.  
As the Lewis lung cell model is a rapidly growing vascularised tumour model, 
perhaps this model was not the most appropriate to explore the effects of 35K and while 
the changes we see are minimal, and although not significant, the trends observed are 
promising as there is a possibility for these small changes to be enhanced through other 
modes of expression or delivery. Future studies could include the use with a membrane 
bound 35K as used in previous studies (Bursill et al. 2006) to induce localised expression 
of 35K on the Lewis lung carcinoma cells. This would allow for greater specificity and 
targeted expression of 35K within the tumour tissues. Alternatively, a less aggressive 
model of tumour neovascularisation may allow for better elucidation of the effects of 35K 
in the context of cancer. 
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CHAPTER 7.                   
THE EFFECT OF   
BROAD-SPECTRUM      
CC-CHEMOKINE 
INHIBITION IN A MODEL 
OF WOUND HEALING 
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7.1. Introduction 
Wound healing is an intricate process requiring strict coordination between 
inflammation and cell growth in the wound. A balance must be maintained to prevent 
impaired wound healing. The in vivo studies in Chapter 5 have shown that broad-spectrum 
CC-chemokine inhibition can suppress pathological inflammatory-driven angiogenesis 
while having no effect on physiological hypoxia-mediated angiogenesis. However, it 
appeared that 35K had no effect in the tumour neovascularisation model (Chapter 6), 
although this could be attributed, at least in part, to the aggressiveness of the Lewis Lung 
cancer model. We now seek to determine the effects of broad-spectrum CC-chemokine 
inhibition in the murine wound healing model, which involves an initial inflammatory 
response coupled with physiological-mediated angiogenesis.  
Wound healing is a multistep process composed of 3 distinct but overlapping 
stages: inflammation, proliferation, and remodelling. The first stage is the inflammatory 
phase, where neutrophils and macrophages are recruited to remove debris and begin the 
wound healing process. Clot formation, through platelet activation, occurs to prevent 
further blood loss. This is followed by the proliferation stage, where re-epithelialisation 
and the formation of granulation tissue begin to close the wound. During this stage 
angiogenesis is essential to bring inflammatory cells to the wound for debris removal and 
to provide support for proliferating and migrating cells, and the formation of granulation 
tissue (Gillitzer & Goebeler 2001). Finally, during the remodelling phase, fibroblasts 
reorganise the collagen matrix, forming a closed wound (Gurtner et al. 2008). 
Inflammation is critical in the initial stages of wound healing, as it promotes fast 
healing without infection. However, when the inflammatory phase is prolonged, a distinct 
disadvantage is the increased scar formation that can occur. Excessive scar formation is 
due to an increased accumulation of macrophages due to the inflammatory response. 
Prolonged inflammation also delays wound healing times, which in turn increases the risk 
of infection. Wounds that exhibit impaired healing frequently enter a state of pathological 
inflammation, with most chronic wounds developing into ulcers linked to ischaemia, 
diabetes mellitus, venous stasis disease or pressure (Guo & DiPietro 2010). Chronic, non-
healing wounds greatly impact a person‟s quality of life and when left untreated sometimes 
lead to amputation resulting in enormous health care burden (Mathieu, Linke & Wattel 
2006; Menke et al. 2007).  
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CC-chemokines regulate key processes involved in angiogenesis. They have been 
found to have direct effects on angiogenesis by stimulating tubulogenesis, and promoting 
endothelial cell migration (Galvez et al. 2005; Salcedo et al. 2001; Stamatovic et al. 2006; 
Strasly et al. 2004). Given the established role of CC-chemokines in inflammation and our 
recent observations of CC-chemokines in angiogenesis, manipulation of the CC-chemokine 
family could modulate either of these processes, which may in turn confer beneficial 
effects on wound healing. In human wounds, CC-chemokines CCL1, CCL2, CCL3, CCL4, 
CCL5 and CCL7 are expressed in the wound during the first week after injury and high 
levels of CCL2 have been found in human burns (Engelhardt et al. 1998; Gibran et al. 
1997). Additionally studies in excisional wounds show localised expression of CCL2 and 
CCL3 in the epidermis, while CCL3 was also expressed in follicular epithelium, and 
sebaceous glands (Jackman et al. 2000). To date, current studies have focussed on the 
effect of a single CC-chemokine intervention, often with varying results. For example, 
CCL2 knockout mice have delayed re-epithelialisation and reduced angiogenesis in early 
stages, whilst CCL3 knockout mice followed relatively normal wound healing (Low et al. 
2001). Similarly CCR1 knockout models showed no impairment despite CCR1 chemokine 
ligands being strongly upregulated in wounds (Kaesler et al. 2004).  
These minimal changes are likely due to the redundancy in CC-chemokine 
signalling, where when a single CC-chemokine is inhibited another CC-chemokine can 
replace its function. Currently there has been no investigation on the effect of broad-
spectrum CC-chemokine inhibition on wound healing. Therefore this study sought to 
determine the effect of broad-spectrum CC-chemokine inhibition by 35K on cutaneous 
wounds in a murine model that mimics human wound healing. For this study, the effect of 
topical application of isolated 35K protein was explored at two time points: (1) Day 4, 
which encompasses the early stages of wound healing including inflammation and 
angiogenesis, and (2) Day 10, the late stage of wound healing where 
inflammation/angiogenesis ceases and remodelling ensues. 
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7.2. Method 
7.2.1. Isolation of 35K protein 
35K protein was isolated from produced Ad35K viral media as outlined in Chapter 
2, Section 2.2.5. Isolated 35K was dialysed into sterile PBS and filtered through 0.45 m 
low protein binding syringe filter (Pall Corporation, NY, USA), then aliquoted to 200 nM 
and stored at -80
o
C until use. 
 
7.2.2. Mouse model of wound healing 
To explore the effect of broad-spectrum CC-chemokine inhibition, a murine model 
that closely mimics the human wound healing process was used (Dunn et al. 2013). This 
model was chosen to overcome the differences between the murine and human wound 
healing process. In the mouse, dermal wound healing occurs via contraction, while human 
wound healing occurs through re-epithelialisation. The introduction of splints in this 
murine model forces wound healing to occur via re-epithelialisation. 
Before surgery, silicone splints and occlusive dressing were prepared. To prepare 
the silicone splint 10 mm diameter circles were cut from the 0.5 mm thick silicone sheet 
(P18178, Life Technologies, CA, USA). A biopsy punch (BIOPUNCH04, Livingstone 
international PTY, LTD, NSW, Australia) was used to create a hole in the centre of the 
circles to create an “O” shape. To prepare the occlusive dressings 10 mm diameter circles 
were created from OPSITE™ FLEXIFIX™ Transparent Film (66000041, Smith & 
Nephew, London, UK). 
To perform the wound healing model, mice were anaesthetised by inhalation of 
methoxyflurane, pedal reflex were tested to confirm adequate analgesia before placing 
mice in the prone position. Using a biopsy punch to create a circle on the skin as a guide, 
two full thickness wounds including the panniculus carnosus, were excised on the dorsum 
of the mice, below the forelimbs, one on each side of the midline using surgical scissors. 
Backing from the silicone splint was removed, before the splint was secured around the 
wound with adhesive (super glue) and interrupted sutures, using 6-0 PROLENE™ sutures 
(8805H, ETHICON LLC, San Lorenzo, Puerto Rico). Wound diameter measurements were 
taken on the x-axis, y-axis and z-axis of the wounds using micro-callipers, before topical 
Page | 172  
 
application of either sterile PBS (vehicle control) or 200 nM 35K protein (n = 12 mice per 
time point). The clear dressing was applied on top of each wound. Following surgery, mice 
were injected subcutaneously with carprofen for pain relief, and mice were monitored for 
signs of discomfort. Wound measurement and application of treatment was conducted 
daily for the duration of the study. Blood perfusion was also measured by laser Doppler 
imaging (moorLDI2-IR, Moor Instruments, Devon, UK) throughout the study. Two 
cohorts were completed to determine changes at both the early-mid (Day 4) and late (Day 
10) stages of wound healing. 
 
7.2.3. Sacrifice  
Mice were sacrificed 4 or 10 days following wounding by overdose of anaesthesia 
of methoxyflurane followed by right ventricular puncture. The wounds were excised and 
prepared for histological, protein or gene analyses. 
For histology, wounds were cut in half directly through the middle of the wound. 
The sample was placed between two biopsy pads and into an embedding cassette, then 
fixed in 4% (v/v) paraformaldehyde overnight at 4
o
C before transferring to 70% ethanol 
prior to processing in graded ethanol concentrations before xylene and paraffin embedding. 
5 μm sections were taken and stained for neovessels (CD31), arterioles (α-actin), 
macrophages (CD68) and collagen using Millligan‟s trichrome according to techniques 
outlined in Chapter 2, Section 2.3.6.3.  
For protein and gene analysis the remaining wound tissue was halved and stored in 
Eppendorf tubes at -80
o
C. Protein and gene levels of CC-chemokines and key angiogenic 
(HIF-1α, VEGF and CXCL12) and inflammatory (active p65 subunit of NF-κB and CD68) 
markers were detected using Western blot, ELISAs or quantitative real-time PCR as 
outlined in Chapter 2, Sections 2.3.7 – 2.3.8. 
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7.3. Results 
7.3.1. Laser Doppler imaging and macroscopic measurement of wounds 
Laser Doppler imaging (LDI) was used to determine blood flow perfusion in the 
wounds over the study period. For early-mid (Day 4) stage wounds, LDI was performed 
daily, whilst LDI for the late (Day 10) stage wounds was performed on Days 2, 4, 7 and 
10. LDI was assessed by determining the ratio of 35K:PBS blood perfusions, where values 
over 100% indicate improved perfusion by the treatment (35K) compared to PBS controls. 
In Figure 7.1A, there was an increase in blood flow perfusion to the 35K wounds during 
the early-mid stage (Days 2 – 4), where angiogenesis is most important in the wound 
healing process. By Day 7 a decline in LDI perfusion was seen in the 35K wounds, 
however blood perfusion then increased by 19.8% (p<0.05) at Day 10 in the 35K treated 
wounds.  
Wound closure measurements were taken daily to determine the difference in 
wound area over time for PBS and 35K treated wounds. Topical application of 35K protein 
promoted wound closure, particularly at Days 4 – 6 (p<0.05) compared to PBS as seen in 
Figure 7.1B.  
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Figure 7.1. Improved blood flow perfusion early post-wounding correlates with faster 
wound closure in 35K treated wounds. 
(A) Laser Doppler imaging (LDI) was used to determine blood flow perfusion of the 
wounds. Measurements above 100% represent increased blood perfusion with the 35K 
treatment. (B) Wound closure measurements were taken daily to compare PBS and 35K 
treated wound areas. Data is expressed as meanSEM. Statistical analysis was performed 
using an unpaired two tailed t-test. *p<0.05 compared to relevant PBS treatment. 
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7.3.2. Histology 
7.3.2.1 Neovascularisation 
To demonstrate angiogenesis in the wounds, neovessels and arterioles were 
assessed by detecting the presence of endothelial cells (CD31
+
) and smooth muscle cells 
(-actin+). Typically, angiogenesis increases in the early-mid stage producing a rich and 
complex neovasculature allowing for increased infiltration of inflammatory cells for debris 
removal. However, at the late stage of wound healing, angiogenesis has ceased and the 
newly formed vessels disintegrate, leaving a collagen rich scar. Consistent with this, 35K 
increased neovessels by 81.6% (p<0.05) compared to PBS in the Day 4 wounds, where 
angiogenesis is essential to wound healing (Figure 7.2). However, at Day 10 there was a 
39.1% (p<0.05) decrease of neovessels in the 35K treated wounds compared to PBS, where 
angiogenesis has ceased. Furthermore, the arterioles detected in the wounds indicated a 
similar pattern as seen in the neovessels (Figure 7.3), where in the Day 4 wounds, there 
was a non-significant 34.2% increase in the number of arterioles in the 35K treated 
wounds, whilst by Day 10 35K treated wounds had 47.6% (p<0.05) less arterioles. 
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Figure 7.2. 35K treatment increases neovessels in the early stage wounds, but decreases 
neovessel content in late stage wounds. 
Photomicrographs represent neovessels detected by staining for CD31
+
 (brown) in PBS 
and 35K treated wounds at Day 4 and Day 10. Scale bars represent 50 m. Data is 
expressed as meanSEM. Statistical analysis was performed using an unpaired two tailed 
t-test. *p<0.05 compared to relevant PBS treatment. 
 
  
Page | 177  
 
 
Figure 7.3. 35K treatment decreases arterioles in late stage wounds. 
Photomicrographs represent arterioles detected by staining for smooth muscle -actin+ 
(pink) in PBS and 35K treated wounds at Day 4 and Day 10. Scale bars represent 50 m. 
Data is expressed as meanSEM. Statistical analysis was performed using an unpaired 
two tailed t-test. *p<0.05 compared to relevant PBS treatment. 
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7.3.2.2 Macrophage Infiltration 
Macrophages play an important role in mediating inflammation in the wound 
healing process and have indirect effects on angiogenesis via their expression of VEGF. 
Histological analysis of macrophages revealed that at the early stage of wound healing, 
there were no differences in macrophage infiltration in wounds treated with 35K compared 
to PBS (Figure 7.4). There was, however a non-significant trend for a decrease (24.8%) in 
wound macrophage content in the late stage (Day 10 post-wounding) cohort of 35K-treated 
wounds. 
 
 
Figure 7.4. Macrophage infilration is unchanged in wounds treated with 35K. 
Photomicrographs represent macrophages detected by staining for CD68
+
 (brown) in PBS 
and 35K treated wounds at Day 4 and Day 10. Scale bars represent 50 m. Data is 
expressed as meanSEM. 
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7.3.2.3 Collagen 
In wound healing, collagen formation is the pre-requisite to scar formation. 
Collagen begins to form during the proliferation stage of wound healing to help fill the 
wound area. Typically, during this stage the wound is dominated by inflammatory cells 
indicated by the purple nuclear staining, which is depicted in the Day 4 wounds (Figure 
7.5We found no differences in the amount of collagen deposition at Day 4 in the PBS and 
35K wounds. However in the Day 10 wounds, 35K significantly reduced the amount of 
collagen by 25.3% (p<0.05) compared to PBS. 
 
 
Figure 7.5. 35K decreases collagen formation in late stage wounds. 
Collagen (green) was detected by Milligan’s trichrome staining in PBS and 35K treated 
wounds at Day 4 and Day 10. Scale bars represent 50 m. Data is expressed as 
meanSEM. Statistical analysis was performed using an unpaired two tailed t-test. 
*p<0.05 compared to relevant PBS treatment. 
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7.3.3. CC-chemokine expression 
CC-chemokine expression during wound healing was determined through gene and 
protein analysis. Overall there was a decrease of CCL2 and CCL5 gene and protein 
expression with topical application of 35K protein to the wounds.  
Gene expression of CCL2 at the early (Day 4) time point, decreased by 36.0% 
(p<0.05, Figure 7.6A), which subsequently translated to a 40.8% (p<0.05) decrease in 
protein expression in the 35K treated wounds (Figure 7.6C). Additionally, at the Day 10 
time point, despite a non-significant 21.5% increase in CCL2 gene expression, protein 
expression decreased by 22.2% (ns) with topical 35K treatment compared to PBS treated 
wounds. 
 Similarly, at the Day 4 time point, while a non-significant decrease of 31.7% in 
CCL5 mRNA levels was seen in the 35K treated wounds (Figure 7.6B), CCL5 protein 
levels were significantly lower (36.5%, p<0.05, Figure 7.6Error! Reference source not 
found.D) compared to PBS treated wounds. However, 35K decreased both CCL5 gene 
(62.1%, p<0.05, Figure 7.6B) and protein (65.8%, p<0.01, Figure 7.6D) expression at Day 
10. 
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Figure 7.6. CC-chemokine expression in the wounds. 
Real-time PCR was used to measure gene expression of (A) CCL2 and (B) CCL5 in PBS 
and 35K treated wounds at Day 4 and Day 10. ELISAs were used to detect protein 
expression of (C) CCL2 and (D) CCL5 in PBS and 35K treated wounds at Day 4 and Day 
10. Data is expressed as meanSEM. Statistical analysis was performed using an unpaired 
two tailed t-test. *p<0.05, **p<0.01 compared to relevant PBS treatment. 
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7.3.4. Markers of angiogenesis and inflammation 
Wound angiogenesis is primarily driven by the inflammatory response, but hypoxia 
also plays a role in promoting neovascularisation of the wound. To further elucidate the 
mechanistic effects of 35K on the wound healing process, the expression of key angiogenic 
markers (HIF-1α, VEGF and CXCL12) and inflammatory markers (p65 and CD68) were 
determined. 
The mRNA levels of HIF-1α were not changed in the wounds of 35K treated mice 
although it was noted that there was a non-significant reduction (27.4%) in the Day 4 
cohort (Figure 7.7A). Similarly, protein expression of HIF-1α was not changed at any time 
point (Figure 7.7B). Despite trends for a reduction, there were no changes in VEGF mRNA 
(Figure 7.7C) or protein (Figure 7.7D) levels. There was, however, a significant reduction 
in CXCL12 mRNA levels (55.6%, p<0.05) in Day 10 wounds treated with 35K, compared 
to PBS control wounds (Figure 7.7E). 
Gene expression of the active subunit of NF-B, p65, was shown to significantly 
decrease by 33.8% (p<0.05) at Day 4 and by 62.3% (p<0.05) at Day 10 compared to PBS 
treated wounds (Figure 7.8A). This correlated with the reduction in CC-chemokine 
expression that we see in these wounds (Section 7.3.3). No changes were seen in the levels 
of CD68 (Figure 7.8B), which correlated with the lack of differences seen in the 
macrophage histological observations in Section 7.3.2.2. 
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Figure 7.7. Expression of angiogenic markers in wounds. 
Real-time PCR was used to measure gene expression of (A) HIF-1α, (C) VEGF, and (E) 
CXCL12, and protein expression was determined by (B) Western blot for HIF-1α and (D) 
ELISA for VEGF in PBS and 35K treated wounds at Day 4 and Day 10. Data is expressed 
as meanSEM. Statistical analysis was performed using an unpaired two tailed t-test. 
*p<0.05 compared to relevant PBS treatment.  
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Figure 7.8.Gene expression of inflammatory markers in wounds. 
Real-time PCR was used to measure gene expression of (A) active p65 subunit of NF-κB 
and (B) CD68 in PBS and 35K treated wounds at Day 4 and Day 10. Data is expressed as 
meanSEM. Statistical analysis was performed using an unpaired two tailed t-test. 
*p<0.05 compared to relevant PBS treatment. 
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7.4. Discussion 
The stages of the wound healing process are highly regulated and encompass the 
most complex biological processes that occur in human life. An imbalance or change to the 
process can greatly affect the outcome of wound healing, resulting in impaired wound 
healing which can often lead to severe unfavourable outcomes such as amputation; 
therefore highlighting the need to develop novel agents that promote wound repair. This 
study used a murine wound healing model that mimics the human wound healing process 
to explore the effect of topical application of 35K protein to treat cutaneous wounds. We 
found that broad-spectrum CC-chemokine inhibition by 35K promoted the rate of wound 
closure during the early stage (Day 4) and improved the state of the healed wound, 
producing less collagen and less neovessels compared to PBS control treatments, by the 
late stage (Day 10). Additionally, there was an overall reduction in the inflammatory state 
of the 35K treated wounds, which is accompanied by reduced CC-chemokines at the 
wound site. 
Topical application of the broad-spectrum CC-chemokine inhibitor 35K promoted 
blood flow perfusion at the early stages of wound healing (Days 2 – 4). This was 
complemented by an increase in wound closure during the early-mid stage of healing 
(Days 4 – 6). At this stage blood flow perfusion is critical to wound healing to bring 
inflammatory cells to the wound site, changing the leukocyte subset from dominantly 
neutrophils to macrophages (Gurtner et al. 2008; Sunderkotter et al. 1994). This change is 
essential to accelerate debris removal and to promote wound healing. Macrophages release 
a host of growth factors and cytokines including in particular VEGF as well as TGF-, 
TGF-, bFGF, PDGF. Some of these stimulate collagen (Eming, Krieg & Davidson 2007). 
Consistent with previous studies in CCL2 and CCL3 knockout mice (Low et al. 2001), 
macrophage recruitment was maintained and collagen deposition reduced despite a 
reduction in neovessels in the Day 10 cohort of the present study. Additionally, increased 
perfusion increases oxygenation to help maintain the formation of the healed tissue 
(Jonsson et al. 1991). Typical at this early stage of wound healing, there was an increase of 
neovessels and arterioles in the 35K wounds, which in turn facilitated the increased 
perfusion detected by Laser Doppler imaging.  
In contrast to the early stage of wound healing, the late stage (Day 10) wounds had 
reduced neovessels and arterioles with 35K treatment. At this stage, wounds have healed, 
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re-epithelialisation has occurred, inflammation has ceased, a scar has formed, and collagen 
remodelling from type III to type I collagen can begin (Lovvorn et al. 1999). Importantly 
as the wound healing process is near completion, angiogenesis ceases and neovessels 
disintegrate to allow for continued remodelling (Gillitzer & Goebeler 2001; Ilan, Mahooti 
& Madri 1998; Singer & Clark 1999). The pronounced reduction of neovessels and 
arterioles in our 35K treated wounds suggest that these wounds are at a more advanced 
stage where wounds have healed faster by Day 10 compared to PBS treatment. Consistent 
with this, the 35K wounds exhibited less collagen formation, filling the wound quickly and 
helping to close the wound to allow for reduced scar formation in the wounds. These 
findings are similar to previous studies in which reduced fibrosis was detected in kidneys 
and lungs of mice when CCR1 or CCR5 were knocked down or their signalling inhibited 
(Anders et al. 2002; Schuh, Blease & Hogaboam 2002).  
Unexpectedly in the Day 10 wounds, 35K treatment caused an improvement in 
blood flow perfusion compared to PBS. This increase could be due to several factors. At 
this stage, remodelling is in its early phase, where the granulation tissue is disorganised 
and neovessels are still present but not as prominent as in the earlier stages. The increased 
perfusion in 35K treated wounds may be a factor of the less densely packed collagen, 
allowing more space for neovessels to increase the perfusion detected at the surface; 
whereas in the PBS wounds, a more tightly packed collagen was present preventing the 
detection of perfusion at the surface of the wound area. Additionally, the wound area 
measurement by Laser Doppler assesses the entire area with the circular splint, rather than 
only the healing wound area, which could result in the detection of residual perfusion 
around the wound.  
Previous studies have shown an increase in the expression of CC-chemokines 
including CCL1, CCL2, CCL3, CCL4, and CCL5 in normal wounds, and particularly high 
expression of CCL2 one day after wounding (DiPietro et al. 1995; Engelhardt et al. 1998; 
Gillitzer & Goebeler 2001; Jackman et al. 2000), with more than 20% of total cells in the 
wound expressing CCL2 and by Day 2 hyperproliferating keratinocytes also express CCL2 
(Gillitzer & Goebeler 2001). Increased expression of CCL2 was reported 6 hours after 
wounding compared to control, with persistent levels maintained during the early stages of 
healing (Jackman et al. 2000). In our study, the Day 4 and Day 10 wounds treated with 
35K showed an expected overall decrease in the expression of CCL2 and CCL5. This is 
typically associated with decreased macrophages to the site of injury, however no 
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significant reductions in macrophages were observed. It has been previously reported that 
despite dominant expression of CCL2, these levels are considered relatively low and 
correlate with the observation of optimal monocyte accumulation with low levels of CCL2 
(Gu et al. 1997), indicating that, a reduction but not complete ablation of CCL2 and 
consequently other CC-chemokine expression, may be beneficial in the recruitment of 
optimal levels of macrophages in the early stage. However, at the later stage (i.e. Day 10), 
the wound is preparing to enter remodelling so macrophages then undergo apoptosis and 
chemokine upregulation and angiogenesis are reduced. This may explain the consistent 
macrophage levels between PBS and 35K wounds despite the reduction in CC-chemokine 
levels. Even without significant reductions to macrophages in the wound, there was an 
overall reduction of inflammation in the 35K treated wounds as shown by reduction in p65 
expression.  
Consistent with the observations seen with macrophage infiltration, there was no 
change in VEGF expression in wounds treated with 35K compared to PBS. VEGF is 
involved in angiogenesis and the synthesis of collagen in the wound (Bao et al. 2009; 
Eming, Krieg & Davidson 2007). It is produced by wound fibroblasts, keratinocytes and 
macrophages (Eming, Krieg & Davidson 2007; Martin 1997; Singer & Clark 1999). As 
VEGF is not solely regulated through CC-chemokine activity, the reduced CC-chemokine 
expression in 35K wounds had minimal effects on VEGF, and therefore sufficient VEGF 
expression can be produced through other avenues. We also found no inhibition of HIF-1α 
gene and protein expression in the wounds, suggesting that there was sufficient 
oxygenation to the wounds to aid in the healing process. Despite no significant changes in 
HIF-1α, there was a surprising reduction of CXCL12 in the late stage of wound healing of 
our 35K treated wounds. At this point wounds have healed, thus the levels of CXCL12 
may have declined as it is no longer needed at this point, particularly as the 35K treated 
wounds healed faster.  
The present study found a significant decrease in mRNA levels of the active NF-κB 
subunit p65 at both time points. As NF-κB also drives other inflammation-responsive 
genes that may mediate macrophage recruitment, this suggests that the macrophages we 
have detected may be recruited by means other than solely through CC-chemokines and 
other NF-κB-driven genes. For example macrophages may be recruited by other 
chemokine classes as they can also express CXCR1 and CXCR2 receptors which bind 
CXCL8 (Patel et al. 2001). Additionally, macrophages can be divided into pro- and anti-
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inflammatory phenotypes and both are involved in different stages of wound healing 
(Daley et al. 2010). With this in mind, there could be a possible shift in macrophage 
phenotype from pro-inflammatory to a more anti-inflammatory phenotype which is 
important in wound regulation (Daley et al. 2010). 
In conclusion, this study shows that broad-spectrum CC-chemokine inhibition by 
topical application of 35K enhances wound closure through early promotion of 
neovascularisation. There were also reductions in the key inflammatory transcription factor 
NF-κB. Additionally, reduced collagen deposition in the Day 10 35K treated wound was 
indicative of reduced scar formation. Taken together, our findings showed that broad-
spectrum inhibition of CC-chemokines may be beneficial in chronic wounds where 
inflammation is in excess, in order to promote wound healing and neovascularisation and 
reduce scar formation. 
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CHAPTER 8.   
DISCUSSION 
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8.1. Introduction 
Angiogenesis can have both beneficial and detrimental effects depending on the 
pathophysiological context. Current anti-angiogenic therapies are successful in suppressing 
the inflammatory-driven angiogenesis seen in pathological diseases such as atherosclerosis 
and cancer. However, physiological ischaemia-mediated angiogenesis that is essential for 
growth and regeneration, is also inhibited resulting in severe side effects including 
hypertension, haemorrhaging, vomiting, nausea, gastrointestinal perforations and reduced 
wound healing. This highlights the need for alternate anti-angiogenic therapies that can 
specifically target inflammatory-driven angiogenesis whilst having minimal effects on 
ischaemia-mediated angiogenesis. Increasing evidence has shown that CC-chemokines are 
implicated in inflammatory induced pathologies in which angiogenesis plays an important 
role. In contrast, the CC-chemokine class appear to have little to no role in ischaemia-
mediated angiogenesis. Specific inhibition of the CC-chemokine class may therefore 
inhibit pathological inflammatory-driven angiogenesis, while preserving physiological 
hypoxia-mediated angiogenesis. The broad-spectrum CC-chemokine inhibitor „35K‟ has 
already been shown to inhibit a host of inflammatory diseases including atherosclerosis, 
acute peritonitis and hepatitis, however a comparison of its role in both inflammatory and 
ischaemia-driven angiogenesis has not been tested.  
This thesis investigated the effect of broad-spectrum CC-chemokine inhibition on 
angiogenesis using 35K. Treatment with purified 35K protein in vitro significantly reduced 
key functional angiogenic assays when subjected to an inflammatory stimulus, but had 
more modest or no effects in response to hypoxia. Mechanistically, in vitro studies 
revealed that 35K conditionally regulates VEGF, such that it is inhibited under 
inflammatory conditions, but yet preserved in hypoxia. These in vitro observations were 
also translated in vivo. Using an adenoviral delivery approach to overexpress 35K in mice, 
we observed that 35K effectively reduced the number of adventitial neovessels and 
arterioles in the peri-arterial femoral cuff model of inflammatory-driven adventitial 
angiogenesis. In contrast, 35K had no inhibitory effect on ischaemia-mediated 
angiogenesis in the hindlimb ischaemia model. The effect of CC-chemokine inhibition was 
also explored on tumourigenesis, where angiogenesis is driven by both inflammation and 
hypoxia. We found that, despite a trend for a reduction in tumour size, 35K had no effect 
on tumourigenesis in the Lewis lung carcinoma model. However, this lack of effect is 
likely due to the aggressiveness of the model used. Finally, given angiogenesis is critical in 
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the early stages of wound healing, topical application of 35K protein was tested in a 
murine wound healing model that mimics human wound closure. 35K improved the rate of 
wound neovascularisation and wound closure. The wounds also contained less collagen, 
indicating that there would ultimately be less scar formation. 
 
8.2. Conditional regulation of angiogenesis by 35K in vitro 
Endothelial cells (ECs) are one of the major cell types involved in angiogenesis and 
as they are mainly quiescent, angiogenesis needs to be triggered by a stimulating cytokine, 
such as the pro-angiogenic mediator VEGF (Carmeliet 2000; Karamysheva 2008). 
Endothelial cell proliferation, migration and tubule formation are key processes for the 
formation of neovessels (Carmeliet 2000). Upon VEGF stimulation, endothelial cells 
proliferate and migrate to sites of injury. They then assemble into tubular structures to 
form new blood vessels at the injury site. To examine this process, the effect of 35K in 
three in vitro functional angiogenic assays was assessed in inflammatory and hypoxic 
conditions. These studies, highlighted in Chapter 3, found that 35K strikingly inhibits 
proliferation, migration and tubule formation under inflammatory conditions, but these 
effects were more modest in response to hypoxic stimulation. The observations in response 
to inflammation support previous studies where incubation with single CC-chemokines 
(such as CCL2, CCL11 and CCL16) directly promotes endothelial cell tubule formation, 
migration and neovascularisation (Galvez et al. 2005; Salcedo et al. 2001; Stamatovic et al. 
2006; Strasly et al. 2004). As expected, 35K has minimal or no effects under hypoxic 
stimulation as it inhibits CC-chemokines that have not been previously reported to have a 
role in ischaemia-mediated angiogenesis. Furthermore, the specificity of 35K to bind CC-
chemokines means that it does not interact with the CXC-chemokine class (Burns et al. 
2002). This is important as CXC-chemokines and, in particular, CXCL12 plays a key role 
in angiogenesis in response to hypoxia/ischaemia (Frangogiannis 2007).  
In this study we chose to examine all three endothelial angiogenic processes to 
allow for a more complete understanding of the effect of broad-spectrum CC-chemokine 
inhibition on angiogenesis. Firstly, proliferation, the initial phase of angiogenesis after 
endothelial cell activation, was determined by directly measuring DNA synthesis using the 
Click-It EdU assay. This assay has advantages over other protocols as it does not require 
denaturing. This is due to the small size of the azide dye of the assay, which can easily 
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access the EdU through detergent permeabilisation. Additionally, this assay is more 
specific than other proliferation assays which count the number of “living cells” either by 
crystal violet staining, trypan blue exclusion or the MTT assay (Staton, Reed & Brown 
2009), but rather assesses the transition from the G0-phase to S-phase of the cell cycle.  
Secondly, endothelial cell migration is crucial to angiogenesis to recruit new cells 
to the site of injury. The scratch assay with monitoring by live cell imaging was chosen 
over the more conventional chemotaxis assay as it measures the cell to cell interaction to 
stimulate migration instead of the interaction with a stimulus. Thus the scratch assay is a 
better method to determine the effect of CC-chemokine inhibition by 35K, as there is no 
interference from an angiogenic stimulus. The assay was performed in 4 well chamber 
slides, thereby limiting the number of concentrations tested to one per treatment. The 50 
nM concentration was chosen as higher concentrations showed complete inhibition of 
migration (data not shown). The benefit of choosing the chamber slide was the markings in 
the chamber slide allowed the scratches to be made at consistent intervals in each chamber 
and across all slides. Furthermore, as images were taken by the live cell imager over time, 
this allows for additional analysis such as the rate of migration or wound “closure” to be 
done. 
Thirdly, tubulogenesis is the final step to forming new blood vessels. At this point 
endothelial cells have proliferated and migrated to the site of injury and must now form the 
early blood vessel structures, the capillaries. The basic tubule formation assay involves 
plating endothelial cells onto or into a layer of gel matrix (commonly collagen, fibrin or 
matrigel), which stimulates the attachment, migration and differentiation of endothelial 
cells into tubule like structures in a manner that simulates the in vivo situation (Kanzawa, 
Endo & Shioya 1993; Lawley & Kubota 1989). For this assay, cells were plated onto 
growth factor reduced (GFR) matrigel as opposed to the basement membrane matrigel. 
While not completely depleted of growth factors, GFR matrigel contains the same 
extracellular proteins with decreased amounts of EGF, IGF-1, PDGF and TGF-, thus 
allowing for better testing of endothelial tubule formation without the strong interference 
of angiogenic growth factors that may be supplemented in the basement membrane 
matrigel (Taub et al. 1990). Endothelial tubule formation is observed for 4 hours, where 
cells will attach to the matrigel, migrate towards each other, align to the basement 
membrane (nucleus facing the basement membrane) and form tubules. This assay 
encompasses the key steps involved in angiogenesis, making the GFR matrigel 
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tubulogenesis assay a good in vitro test for angiogenesis in response to broad-spectrum 
inhibition of CC-chemokines by 35K.  
Alternate assays that could be used to assess angiogenesis include the 3D gel assay, 
the chick choriallantoic membrane assay and the matrigel plug assay. However, these 
assays focus on the end product of new blood vessel formation and do not assess the 
individual processes involved in angiogenesis. Additionally, certain alternate assays such 
as the corneal angiogenesis assay, and the sponge plug assay do not allow the control of 
the angiogenic environment (inflammation/hypoxia) tested, thus not enabling the 
differential comparison of the effects of 35K. Despite the range of in vitro assays, a „gold-
standard‟ angiogenesis assay has yet to be developed; therefore, a combination of assays 
are required to identify the full scope of effects of a test protein or to identify the molecular 
and/or cellular events in angiogenesis (Staton, Reed & Brown 2009). The three assays used 
in this study, allowed for a more thorough elucidation of the effects of broad-spectrum CC-
chemokine inhibition on angiogenesis in vitro in both inflammatory and hypoxic 
conditions. 
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8.3. 35K conditionally regulates key angiogenic marker VEGF in vitro  
Given the differential effects of 35K on in vitro functional angiogenic assays, the 
studies outlined in Chapter 4 sought to elucidate the mechanism of 35K action by 
measuring key angiogenic markers in vitro. We found that 35K treatment reduced the 
expression of HIF-1α and VEGF in inflammatory conditions, whilst in hypoxia 35K had 
more modest inhibitory effects on HIF-1α, and no effect on VEGF. Further elucidation of 
the HIF-1α post-translational modulation pathway also revealed that 35K had no effect on 
the prolyl hydroxylases (PHD1-3). These results suggest that 35K conditionally regulates 
VEGF. This is possible due to the presence of response elements for both NF-B and HIF 
in its promoter region. Similarly, HIF-1α also has NF-B and HIF response elements in its 
promoter region. Accordingly a similar response pattern as VEGF may be expected with 
35K. However, in response to hypoxia, HIF-1α is also post-translationally modulated by 
prolyl hydroxylases to promote HIF-1α degradation. It may be possible that 35K affects 
the post-translational modulation of HIF-1α under hypoxia. However, we found no effects 
on PHD1-3 with 35K under hypoxia. Therefore an alternate pathway in which VEGF is 
maintained in hypoxia despite reduced HIF-1α may be affected by 35K. Previous studies 
have found that while HIF-1α is the main transcription factor driving ischaemia-mediated 
angiogenesis, the NF-κB signalling pathway may also be activated in response to hypoxia. 
Under hypoxia, inhibition of PHDs increases NF-B activation through phosphorylation of 
its upstream enzyme IKK (Cummins et al. 2006). As HIF-1α also has an NF-B response 
element in its promoter region, it is proposed that 35K is most likely suppressing HIF-1α 
expression through its effects on NF-B and not via direct cellular responses to hypoxia. 
There may also be additional activation of NF-B in hypoxia that helps maintain VEGF 
levels following the suppression of HIF-1α by CC-chemokine inhibition. 
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8.4. 35K reduces inflammatory-driven adventitial neovascularisation whilst 
ischaemia-mediated neovascularisation is unaffected in vivo 
To determine whether the differential angiogenic effects of 35K in vitro were also 
observed in vivo, two murine models were used to examine inflammatory-driven 
angiogenesis (peri-arterial cuff model) and ischaemia-mediated angiogenesis (hindlimb 
ischaemia model). For the in vivo studies, an adenoviral approach was used to overexpress 
35K protein systemically. A single injection of Ad35K promoted persistent high-level 
expression of 35K avoiding the need for multiple dosing with recombinant protein. 
Previous studies report that the virus is expressed for at least 1 month in vivo post-injection 
(Ali et al. 2005). Our findings highlighted in Chapter 5, showed that broad-spectrum 
inhibition of CC-chemokines with 35K reduced inflammatory-driven adventitial 
neovascularisation but, in contrast, had no effect on ischaemia-mediated angiogenesis.  
The murine peri-arterial cuff model was first adapted from a similar model in 
rabbits (Moroi et al. 1998). In this model the non-constricting cuff triggers intimal 
hyperplasia, and promotes neo-adventitial formation that contains neovessels formed three 
weeks after cuff placement. This model was selected for our studies as it produces a rapid 
angiogenic effect that is solely induced by the inflammatory stimulation caused by the 
placement of the cuff, which in turn promotes the recruitment of macrophages that secrete 
pro-angiogenic cytokines and growth factors, and promote neovascularisation. 
Furthermore, as opposed to a stent or graft model, there is a minimal chance of the 
incidence of thrombosis which could impact on the experimental outcome (Carmeliet, 
Moons & Collen 1998). The aetiology of this model is such that it exhibits many similar 
features as those seen in atherosclerosis. 
The murine hindlimb ischaemia model is a well-established model of ischaemia-
mediated neovascularisation (Bonauer et al. 2009; Limbourg et al. 2009; Niiyama et al. 
2009). Both angiogenesis and arteriogenesis can be investigated using this murine model 
depending upon where the ligature is placed, and whether the femoral vessels are 
completely excised. Ligation of the femoral artery causes an ischaemic environment in the 
mouse hindlimb. To repair this arteriogenesis occurs in the femoral collaterals and 
angiogenesis occurs in the distal ischaemic muscles. The current study ligated the femoral 
artery above both the epigastrica and profunda femoris before severing them distal to the 
ligation. The femoral artery and vein were also completely excised as distal as the 
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popliteal. This method ensures that in the gastrocnemius muscle there is significant 
hypoxia and that angiogenesis occurs rather than arteriogenesis. This model with the exact 
same surgical procedure has been utilised by multiple research groups worldwide for this 
purpose and was recently characterised (Limbourg et al. 2009). Furthermore, only the 
gastrocnemius muscle was analysed, which is distal to the ligation and rich in neovessels, 
rather than the adductor muscle where arteriogenesis may occur.  
Increasing evidence suggests that CC-chemokines are important in inflammatory-
driven angiogenesis. Previous studies have examined the effect of single CC-chemokine or 
CC-chemokine receptor knockout studies in various inflammatory-driven angiogenic 
pathologies, however these studies have reported conflicting results. For example, in 2008, 
a study of CCL3
-/-
 and CCR5
-/-
 mice show reduced corneal neovascularisation, and reduced 
macrophages compared to wild type mice suggesting an importance of CCL3 and its 
receptor CCR5 in this inflammatory model of angiogenesis (Lu et al. 2008). Contradictory 
to this, in a study done the following year in the sponge-induced model of inflammatory-
driven angiogenesis, no changes in neovascularisation was seen in CCL3
-/-
 and CCL5
-/-
 
mice (Barcelos et al. 2009). Additionally, treatment with Met-RANTES (CCR1/CCR5 
antagonist) reduced neutrophil and macrophage influx in wild type mice, whilst improving 
vascularisation in a sponge-induced inflammatory angiogenesis model (Barcelos et al. 
2009). These conflicting results may be due to the redundancies seen in the chemokine 
family. Furthermore, the sponge model is not exclusively a model of inflammatory-driven 
angiogenesis.  
Chemokine ligands are able to bind to several chemokine receptors, and 
conversely, chemokine receptors are able to bind to several CC-chemokine ligands. 
However these interactions are restricted within each chemokine class, whereby 
chemokines and receptors will not bind to chemokines from different classes. Chemokine 
redundancy is essential for the chemokine network as it allows for the robust control of the 
inflammatory system, such that if one chemokine is inhibited another may replace its 
function. With this in mind, we used the broad-spectrum CC-chemokine inhibitor 35K to 
determine whether inhibition of the entire CC-chemokine class would be a better 
therapeutic approach for the inhibition of inflammatory-driven angiogenesis. Our findings 
suggest that by removing the influence of redundancies, inflammatory-driven angiogenesis 
can be better targeted and significantly suppressed. We propose that 35K mediates its 
actions via 3 ways: (1) binding CC-chemokines in the tissue and circulation, (2) causing 
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inactivation to prevent the recruitment of monocytes to the site of injury, and (3) removing 
bound CC-chemokines from the tissue to the circulation to reduce the expression of CC-
chemokines at the injury site. 
Broad-spectrum CC-chemokine inhibition has added advantages over current anti-
angiogenic therapies used in cancer as it had no effect on ischaemia-mediated 
angiogenesis. This is significant as physiological angiogenesis is critical for repair and 
regeneration following a myocardial infarction or in wound healing. If angiogenesis is 
completely ablated across all pathophysiological contexts, normal repair and growth 
processes are inhibited, leading to a wide variety of side effects such as severe bleeding, 
proteinuria, arterial and venous thromboembolisms, hypertension, and gastrointestinal 
perforations, as seen with current anti-angiogenic therapies (Elice & Rodeghiero 2012; 
Keefe et al. 2011). 
Taken together with our in vitro observations from Chapters 3 and 4, we find that 
broad-spectrum inhibition of the CC-chemokine class by 35K suppresses inflammatory-
driven angiogenesis yet preserves ischaemia-mediated angiogenesis. Mechanistically, this 
may be via the conditional regulation of the key pro-angiogenic mediator VEGF in 
inflammation and hypoxia. Global inhibition of the CC-chemokine class may therefore 
present as an alternate therapeutic strategy to specifically inhibit diseases associated with 
inflammatory-driven angiogenesis such as atherosclerosis and cancer, without causing the 
adverse side effects that occur with complete inhibition of angiogenesis in all 
pathophysiological contexts. 
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8.5. 35K has no effect on tumour formation in vivo 
Chapters 3 – 5 demonstrated that broad-spectrum CC-chemokine inhibition has 
differential effects on angiogenesis depending on the pathophysiological context. The 
studies conducted in Chapter 6 then sought to elucidate the effect of broad-spectrum CC-
chemokine inhibition on tumour formation in which angiogenesis is driven by both 
inflammation and hypoxia. The Lewis lung carcinoma (LLC) model was chosen for these 
studies as it is a highly vascularised tumour model. LLC is a cell line established from the 
lung of a C57Bl/6 mouse bearing a tumour resulting from the implantation of primary 
Lewis lung carcinoma (Kellar, Egan & Morris 2015). The cell line is highly tumourigenic 
and is primarily used to model metastasis as well as to evaluate the efficacy of 
chemotherapeutic agents in vivo (Fisher et al. 2001; Perez-Soler 2004; Politi et al. 2006). 
The LLC cell line is typically injected subcutaneously into the back flanks of C57Bl/6 
mice (1×10
7
 cells per mouse) and within two weeks of incubation, tumours reach 2.2±0.4 
mm (Fichtner et al. 2008; Politi et al. 2006). Overall, we found that the effects of broad-
spectrum CC-chemokine inhibition by 35K on tumour size were not striking. This may be 
attributed to the aggressiveness of the tumour model chosen. Interestingly, however, the 
tumours in the Ad35K infused mice were slightly smaller in size and there was an overall 
trend towards an increase in apoptotic markers which could have attributed to this.  
CC-chemokines regulate the infiltration of inflammatory cells in the tumour 
environment. Most notably, CC-chemokines are involved in the recruitment of tumour 
associated macrophages (TAM), especially CCL2 and CCL5 in breast cancer, prostate 
cancer lung cancer (Conti & Rollins 2004; Mantovani et al. 2004; Rivas-Fuentes et al. 
2015; Sawanobori et al. 2008; Soria & Ben-Baruch 2008; Zhang, Lu & Pienta 2010a), and 
CCL7 in gliomas (Okada et al. 2009). As with macrophages, in response to inflammation 
TAMs are associated with angiogenesis, however they are also involved in the inhibition of 
anti-tumour responses (Mantovani et al. 2006; Pollard 2004). CC-chemokine levels are 
also found to be elevated in melanoma, breast cancer, colon cancer, oesophageal cancer, 
pancreas cancer, and prostate cancer (Harlin et al. 2009; Loberg et al. 2007; Luboshits et 
al. 1999; Monti et al. 2003; Ohta et al. 2002; Ueno et al. 2000). In the tumour environment, 
CC-chemokines are produced by tumour and stromal cells (Karnoub et al. 2007). CC-
chemokines are increasingly linked with a range of tumours, with elevated CCL2, CCL5, 
CCL17, and CCL22 levels being associated with poor prognosis in human tumours (Lee et 
al. 2009; Luboshits et al. 1999; Niens et al. 2008; Ueno et al. 2000). Furthermore, 
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simultaneous expression of both CCL2 and CCL5 has been linked to advanced stages of 
breast cancer. With this in mind, it would have been anticipated that broad-spectrum CC-
chemokine inhibition would suppress tumour progression.  
In addition to increasing angiogenesis in the tumour environment, macrophages 
also release matrix metalloproteinases (MMPs). Previous studies show that CC-
chemokines, mainly CCL2, CCL4, and CCL5 induce the production/release of MMP9 in 
macrophages (Robinson, Scott & Balkwill 2002). MMPs such as MMP9 are involved in 
extracellular matrix degradation and remodelling which aid in tumour cell migration and 
invasion. Additionally, previous studies found the increase of MMP9 in pancreatic cancer 
is critical for angiogenesis by stimulating VEGF production (Nozawa, Chiu & Hanahan 
2006). Elevated levels of TAMs/macrophages in the tumour environment are greatly 
associated with poor prognosis in cancers/tumours (Bingle, Brown & Lewis 2002). Thus 
an agent that targets the regulators/recruitment of macrophages (such as CC-chemokines) 
in the tumour environment may result in a better prognosis and clinical outcome. Previous 
studies found there was a positive correlation between CCL2 and CCL5 levels, and 
macrophages in tumours This also correlated with a poor prognosis and increased cancer 
aggressiveness in human breast cancer (Azenshtein et al. 2002; Luboshits et al. 1999; Saji 
et al. 2001). In contrast, a previous study in the breast cancer cell line MCF-7, showed that 
activation of CCR5 receptor by CCL5 (Manes et al. 2003) resulted in the promotion of 
genes downstream of p53, a key apoptotic gene, suggesting that some CC-chemokines may 
also help to reduce tumour overexpression. Thus it may be possible that CC-chemokines 
are able to regulate pro- and anti-tumour processes in different tumours and in different 
conditions.  
As mentioned, the lack of change in tumour development by 35K may be due to the 
aggressive and fast growing nature of the LLC model. Furthermore, there are multiple 
contributory factors that are involved in tumour neovascularisation that may not be 
influenced by the inhibition of CC-chemokines. Additionally, CC-chemokines are 
expressed and produced by several cell types, including tumour and stromal cells in the 
tumour environment, which means there are more recruiters/stimulators for CC-
chemokines involved in the progression of tumour compared to other disease pathologies. 
In the Ad35K treated mice, there was little or no difference in inflammation, proliferation, 
and invasion markers, although slight increases were observed. This outcome could be 
attributed to the lack of CC-chemokine inhibition by 35K in the tumours. Surprisingly, we 
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observed a slight increase in key apoptotic markers including p53, caspase 8, and caspase 3 
in mice overexpressing 35K in this aggressive tumour model, which aligns with the trend 
for a reduction in tumour size. 
An alternate mode of delivery of 35K or a different tumour neovascularisation 
model may be needed to allow for a clearer elucidation of the effects of broad-spectrum 
CC-chemokine inhibition in tumour neovascularisation. For example, a local delivery 
approach of 35K could be used to direct 35K specifically to the tumour cells. This would 
ensure that there would be no competition of the circulating 35K with other circulating 
CC-chemokines. A membrane-bound 35K (mem35K) construct has been generated in 
which 35K is expressed on the cell whilst still being able to inhibit CC-chemokines in vivo 
and in vitro (Bursill et al. 2006). The use of mem35K in the LLC model would allow for 
the determination of the effects of localised 35K expression at the tumour site. We would 
hypothesise that localised 35K will bind to CC-chemokines produced by the tumour cells 
before they are able to express more CC-chemokines and subsequently recruit 
inflammatory cells to the growing tumour. Alternatively, pure 35K protein could be 
injected directly into the growing tumour. 
Additionally, alternate tumour models that may be better suited to deciphering the 
effect of 35K on tumourigenesis could be used. For example, CT26 cells used in models of 
colorectal cancer and 4T1 mammary cells used in breast cancer models may be superior 
options. When injected subcutaneously, both cell lines also produce highly vascularised 
tumours. After 15 days, the 4T1 tumours produce smaller tumours with low CCL2 and 
high VEGF levels, whilst the CT26 cells produce tumours with high CCL2 and low VEGF 
that are comparatively larger (Viana et al. 2013). Using the CT26 cell line for tumour 
induction may be a better option as 35K would be able to specifically target CCL2 in these 
tumours. The larger tumour size compared to the 4T1 tumours after 15 days, also means 
that the experiment does not have to be prolonged reducing the length of discomfort that 
may be caused by the tumour growth. 
Tumour growth stimulates the production of a wide variety of pro-angiogenic 
molecules, however, targeting a single angiogenic factor may cause a switch to increase 
the production of other factors. Current anti-angiogenic therapies inhibit the critical pro-
angiogenic mediator VEGF that is known to stimulate angiogenesis in both physiological 
and pathological environments. Inhibition of VEGF causes a number of side effects which 
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can become quite severe. Thus, it may be beneficial to inhibit a group of pro-angiogenic 
molecules, such as CC-chemokines in order to reduce tumour angiogenesis. Currently, 
clinical trials have begun with single CC-chemokine receptor inhibitors. For example, 
mogamulizumab which targets CCR4 has been successful in clinical trials of adult T-cell 
leukaemia-lymphoma (Subramaniam et al. 2012). CCR4 binds to several important CC-
chemokines including CCL2, CCL3, CCL5, CCL17, and CCL22, all of which are 
upregulated in cancer. Mogamulizumab treatment showed that inhibition of CCR4 and 
subsequently its interaction with several CC-chemokine targets had no adverse side effects, 
suggesting that inhibiting the whole CC-chemokine class may be a better approach in 
targeting tumour growth.  
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8.6. 35K improves wound healing and wound angiogenesis in vivo 
Wound healing is a multi-step process involving inflammation, proliferation, and 
remodelling. While current therapies provide some relief and facilitate wound healing, 
there is a need for the development of novel therapies that can further address the 
debilitating effects of impaired wound healing. CC-chemokines are particularly important 
during the inflammation and proliferation stages when there is an influx of inflammatory 
cells and increased angiogenesis. However, CC-chemokines are less important during the 
remodelling phase where inflammation has ceased and angiogenesis is no longer required. 
Angiogenesis plays a critical role in the early phases of wound healing, recruiting 
inflammatory cells to the wound and providing a microvascular network to maintain new 
tissue formation. Chapter 7 explored the effect of broad-spectrum CC-chemokine 
inhibition using a murine model that mimics the human wound healing process. For this 
study, daily topical application of 35K protein enhanced blood flow recovery and wound 
closure and reduced collagen content which is indicative of less scar formation. Therefore, 
broad-spectrum CC-chemokine inhibition may be an alternate therapeutic approach, 
particularly given the beneficial effects of 35K on inflammatory-mediated diseases (Ali et 
al. 2005; Bursill et al. 2003; Bursill et al. 2006; Bursill et al. 2004; Bursill et al. 2009; Seki 
et al. 2009) and that non-healing chronic wounds are largely attributed to pathological 
inflammation. Two time points were chosen for this study: an earlier time point (Day 4) to 
elucidate the effects of 35K on initial inflammatory response and angiogenesis, and a later 
time point (Day 10) to determine the effects of 35K on the remodelling phase.  
CC-chemokine receptors are expressed by endothelial cells, keratinocytes, 
fibroblasts, smooth muscle cells, epithelial cell and monocytes in the wound (DiPietro et 
al. 1995; Martins-Green, Petreaca & Wang 2013; Wetzler, Kampfer, Pfeilschifter, et al. 
2000). During the inflammatory phase, neutrophils are initially recruited by CXCL8, 
however they undergo spontaneous apoptosis with the absence of inflammatory mediators 
(Conus et al. 2008). Thus neutrophils are followed by monocyte influx. This is mediated 
through CC-chemokine signalling and release from endothelial cells. Additionally, 
neutrophils are able to release CCL2 to aid in monocyte recruitment (Gillitzer & Goebeler 
2001). The monocytes differentiate into macrophages that remove dead neutrophils, and 
release cytokines and growth factors to promote wound healing. Furthermore, 
macrophages release pro-angiogenic factors such as VEGF, to stimulate new blood vessel 
formation to the wound. Angiogenesis allows for the easy recruitment of cells and the 
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continued oxygenation of the wound preventing hypoxia. During the proliferation stage, 
granulation tissue begins to form, and re-epithelialisation occurs. CCL3, CCL4, CCL5 are 
produced by granulation tissue to recruit lymphocytes as a final defence against microbes 
and foreign bodies in the wound (Martins-Green, Petreaca & Wang 2013). The persistence 
of macrophages is important during the proliferation phase as it releases growth factors to 
stimulate keratinocyte production and migration at the wound edge. Finally during the 
remodelling phase, inflammation and angiogenesis has ceased, and fibroblasts re-organise 
collagen to create a scar. 
Given the importance of CC-chemokines in wound healing, previous studies have 
looked at the inhibition of individual CC-chemokines, however, in contrast to the studies in 
Chapter 7, no significant beneficial effects to wound healing were seen. For example, 
CCL2
-/-
 mice have delayed re-epithelialisation and reduced angiogenesis in early stages, 
whilst in CCL3
-/-
 mice wounds healed normally (Low et al. 2001). Similarly CCR1
-/-
 
models showed no impairment in wound healing despite a strong upregulation of CCR1 in 
wounds (Kaesler et al. 2004). These studies suggest that the inhibition of a single CC-
chemokine may not be as effective in wound healing due to the varied roles of CC-
chemokines and the specificity in expression within the wound. Furthermore, there is also 
redundancy in CC-chemokine class signalling (Devalaraja & Richmond 1999; Mantovani 
1999).  
Broad-spectrum inhibition of CC-chemokines by 35K promoted the formation of 
neovessels and arterioles early in wound healing, whilst neovascularisation was suppressed 
at the later stage of wound healing. The augmentation of wound neovascularisation 
correlated with faster wound healing rates. Furthermore, suppression of inflammation at 
the early stage of wound healing and reduced collagen content is indicative of a better 
healed wound. A previous study has found impaired wound healing in a diabetic mouse 
model that was due to sustained prolonged expression of CCL2 in keratinocytes at the 
wound edge. This prolonged expression was associated with increased presence of 
macrophages that contribute to impaired wound healing, especially in the late stages (Day 
13) (Wetzler, Kampfer, Stallmeyer, et al. 2000). Therefore a decrease/inhibition of CC-
chemokines in the late stage of healing may be beneficial in the diabetic wound as seen in 
our study. Additionally, a study analysing wound fluid from venous ulcers was associated 
with decreased CCL2, CCL4 and CCL5 as the wound healed (Fivenson et al. 1997). 
Conversely, the inhibition of CC-chemokines in wound healing during the early phase as 
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seen in our study may not be beneficial to impaired wound healing in diabetes. A recent 
study found that delayed recruitment of macrophages to the diabetic wounds caused 
impaired healing, but could be corrected by treatment with CCL2 (Wood et al. 2014). 
However, the mice used in the current study were not made diabetic and therefore, whether 
broad-spectrum CC-chemokine inhibition also has similar effects in a diabetic setting 
remains to be explored. 
Interestingly, no changes in macrophages were seen despite increased neovessels in 
the early stage and decreased neovessels in the late stage. This may be due to the need for 
an optimal level of macrophages for wound healing. Too many macrophages early in 
healing such as in diabetes result in prolonged inflammation and subsequently delayed 
healing. However, lower macrophage numbers will result in impairment of the healing 
process. This is because neutrophils have a finite life span in the circulation and tissue and 
are only involved in the initial immune response immediately following wounding. 
Following the initial immune response, macrophages replace neutrophils and are important 
for mediating the extended inflammatory response often seen with wound healing. 
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8.7. Future directions 
The work generated in this thesis has provided some interesting and novel findings. 
There are, however, several questions that remain incompletely answered. Our 
observations have highlighted a role for broad-spectrum CC-chemokine inhibition in a 
clinical context, particularly in diseases associated with inflammatory-driven angiogenesis 
such as atherosclerosis and cancer. Specifically targeting inflammatory-driven 
angiogenesis in these diseases may allow for an alternate therapy that does not cause 
detrimental side effects seen with current anti-angiogenic therapies. However as cancer 
varies in both type and severity and tumour neovascularisation involves a complex plethora 
of critical cellular processes including both inflammatory-driven and ischaemia-mediated 
angiogenesis, proliferation and apoptosis, further studies are still required to explore the 
effects of broad-spectrum CC-chemokine inhibition in the tumour environment. The most 
obvious experiments are to try a less aggressive tumour model and a different mode of 
expression of 35K in the tumour environment. Localised expression of 35K in the tumours 
is the next step to determine the efficacy of 35K in tumours. An alternate mode of directly 
injecting tumours with 35K protein or a 35K-Fc fusion protein may be a better approach 
clinically.  
Additionally, further investigation of broad-spectrum CC-chemokine inhibition in 
the context of wound healing could be explored. Wounds that exhibit impaired healing 
frequently enter a state of pathological inflammation, with most chronic wounds 
developing into ulcers and the incidence of these are associated with ischaemia, diabetes 
mellitus, venous stasis disease or pressure (Guo & DiPietro 2010). Chronic, non-healing 
wounds greatly impact a person‟s quality of life and when left untreated sometimes lead to 
amputation resulting in enormous health care burden as can be seen with an increasing rise 
in the diabetic and/or aged population (Mathieu, Linke & Wattel 2006; Menke et al. 2007). 
We have shown that 35K is beneficial in wounds of wild type mice, so it would be 
interesting to see if 35K had the same or better beneficial effects in a model of 
impaired/delayed wound healing such as with diabetic or aged mice.  
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8.8. Summary and conclusions 
In summary, the studies generated in this thesis demonstrate, for the first time, that 
broad-spectrum CC-chemokine inhibition by 35K could be an alternate therapeutic 
approach over current anti-angiogenic therapies. The novel findings generated both in vitro 
and in two in vivo models of angiogenesis showed that broad-spectrum CC-chemokine 
inhibition suppresses unwanted pathological inflammatory-driven angiogenesis whilst 
preserving desired physiological ischaemia-mediated angiogenesis. 35K may have 
significant advantages over current therapies as it inhibits only pathological angiogenesis 
leaving physiological angiogenesis unaffected and able to continue in healing and 
regeneration. 
While 35K also showed promising effects in the LLC tumour neovascularisation 
model representing the combined and exaggerated inflammatory and ischaemic 
environments, further work needs to be performed to elucidate the effects of broad-
spectrum CC-chemokine inhibition in the context of cancer. Finally, topical application of 
35K promoted wound healing and wound angiogenesis suggesting that broad-spectrum 
CC-chemokine inhibition may be beneficial in chronic wounds where inflammation is in 
excess, in order to promote wound healing and neovascularisation and reduce scar 
formation.  
Collectively, these findings highlight the potential therapeutic capacity for broad-
spectrum CC-chemokine inhibition in the treatment of inflammatory-driven angiogenesis-
associated diseases while preserving ischaemia-mediated angiogenesis that is critical for 
tissue neovascularisation such as in a myocardial infarction or promoting wound 
neovascularisation.  
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